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Chapter 1 
Introduction 
 
“That principles of research do in fact exist or that there are persons qualified to 
expound them are not self-evident propositions”. 
Jerome Cornfield (1912-79) 1 
 
 
oday’s clinicians are expected to practice evidence-based medicine, and to 
consult sources such as Clinical Evidence2 when deciding on treatment. Re-
sults from randomised controlled clinical trials (RCTs) have become an essential 
part of the ever evolving state of knowledge upon which Clinical Evidence is 
based. Current treatment of prevalent conditions such as hypertension, hyperlipi-
daemia, acute myocardial infarction and heart failure would be unthinkable without 
the numerous and often very large trials that have been done. The physician who 
prescribes a beta-blocker, a statin, a thrombolytic agent or an angiotensin-
converting enzyme inhibitor can be assured that these are beneficial because their 
“effectiveness has been demonstrated by clear evidence from RCTs”.2 
There is a large body of literature in textbooks and specialised journals on 
clinical trial methods, mostly statistical in nature. A useful overview may be found 
in Redmond and Colton.3 What is perhaps insufficiently realised is that the state-
ment ‘we did a randomised, placebo controlled, double blind trial’ defines a proce-
dural concept. Whether a “systematic tendency of any factors associated with the 
design, conduct, analysis and interpretation of the results … to make the estimate 
of treatment effect deviate from its true value”4 was avoided can never be shown 
from the data. Even the most sophisticated statistical methods cannot compensate 
for flawed trial conduct. 
In 1969, evidence from RCTs became mandatory for getting marketing ap-
proval from the US Food and Drug Administration (FDA).5 This has meant that 
most clinical trials are executed today within a polygon of forces and interests.6 
While there is a tendency to accept results of trials at face value, in particular when 
published in a major peer-reviewed medical journal, problems have arisen that can 
often be attributed to inappropriate interference with trial conduct.7 Trust in the 
results of a particular trial is therefore equivalent to trusting that its scientific integ-
rity was ensured by managing trial conduct without undue interference. 
The aim of this thesis is to show how clinical trial conduct can be managed 
while respecting the underlying scientific principles. Chapter 2 describes the main 
results of PICO (PImobendan in COngestive heart failure), a trial which investi-
gated a positive inotropic agent in patients with heart failure using exercise toler-
T
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ance as primary outcome. The results of this trial framed our thinking about how to 
analyse the balance between positive and untoward effects of treatment, thinking 
that is further elaborated in Chapter 3. This chapter also covers issues that relate to 
the use of so-called combined endpoints, a feature of many recent large trials fo-
cusing on clinical outcome. Several of the lessons learnt as described in Chapter 3 
were implemented while designing the ACTION (A Coronary disease Trial Investi-
gating Outcome with Nifedipine) trial as described in Chapter 4. In Chapter 5 base-
line data from the same trial are presented. At the time of writing, ACTION was 
still ongoing; results will be available in September 2004. In Chapter 6 we describe 
the database management system which was implemented to manage the ACTION 
study. In Chapter 7, the statistical analysis plan for this trial is reproduced. Finally, 
in a general discussion (Chapter 8) we focus on the trial management issues that 
arose during the conduct of the PICO and ACTION trials respectively. 
Major medical journals will publish trial results only when the “data have 
been gathered and are presented in an objective and dispassionate manner”.8 It fol-
lows that scientific integrity cannot be an afterthought when the trial is finished. 
Scientific integrity must be ensured by appropriate trial conduct from the begin-
ning. Otherwise, the results may never see the light of day. 
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Chapter 2 
Effect of pimobendan on exercise capacity in patients 
with heart failure: main results from the PImobendan in 
COngestive heart failure (PICO) trial 
 
 
 
 
 
 
 
 
 
ABSTRACT 
Primary objective: To determine the effects of pimobendan 2·5 and 5 mg daily on 
exercise capacity in patients with chronic heart failure. 
Design: A randomised, double blind, placebo controlled trial of the addition of pi-
mobendan to conventional treatment with a minimum follow up of 24 weeks. 
Setting: Outpatient cardiology clinics in six European countries. 
Patients: 317 patients with stable symptomatic heart failure, objectively impaired 
exercise capacity and an ejection fraction of 45% or lower who were treated with at 
least an angiotensin converting enzyme inhibitor and a diuretic and who tolerated a 
test dose of pimobendan. 
Results: Compared to placebo, both pimobendan 2·5 and 5 mg daily improved ex-
ercise duration (bicycle ergometry) by 6% (P = 0·03 and 0·05) after 24 weeks of 
treatment. At that time 63% of patients allocated to pimobendan and 59% of those 
allocated to placebo were alive and able to exercise to at least the same level as at 
entry (P = 0·5). No significant effects on oxygen consumption (assessed in a sub-
group of patients) and on quality of life (assessed by questionnaire) were observed. 
Pimobendan was well tolerated. Proarrhythmic effects (24-hour electrocardiogra-
phy) were not observed. In both pimobendan groups combined the hazard of death 
was 1·8 (95% confidence interval 0·9 to 3·5) times higher than in the placebo 
group. 
Conclusions: Pimobendan improves exercise capacity in patients with chronic 
heart failure who are also on conventional treatment. The balance between benefit 
and risk of treatment with this compound remains to be established however. 
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Despite optimal treatment with diuretics and angiotensin converting enzyme inhibi-
tors1 many patients with chronic heart failure suffer from persistent symptoms, lim-
ited exercise tolerance and impaired quality of life. Also the prognosis continues to 
be poor. Hence, the treatment of this condition remains a therapeutic challenge. 
Inotropic stimulation has met with little success. That digitalis glycosides im-
prove exercise performance and quality of life is generally accepted but their effect 
upon mortality remains to be established. More recently phosphodiesterase inhibi-
tors with both inotropic and vasodilating properties have been introduced.2,3 Much 
has been expected of this class of substances4 but long-term trials have shown that, 
although a moderate improvement in quality of life and exercise capacity can be 
achieved, mortality is increased.5-7 A novel approach to inotropic stimulation is the 
direct sensitisation of cardiac myofilaments to cytosolic calcium. Pimobendan 
(UDCG 115 BS) combines this effect with myocardial cyclic adenosine mono-
phosphate-dependent phosphodiesterase inhibition.8 It is rapidly absorbed, the peak 
plasma level is reached after 1·5 hours and the effect lasts eight to 10 hours. Its 
main metabolite, UDCG 212, has similar pharmacodynamic properties as the par-
ent compound. In patients with heart failure, oral or intravenous pimobendan pro-
duces lasting and dose dependent beneficial haemodymic effects. Myocardial ener-
getics seem to be favourably influenced because the ratio between cardiac work 
and oxygen consumption remains unchanged or is even improved.9 Systemic blood 
pressure is reduced slightly with higher doses of pimobendan. Although the phos-
phodiesterase inhibiting properties of pimobendan suggest arrhythmogenic poten-
tial, no important proarrhythmic effect has been observed in the clinical studies 
performed so far. 
Several earlier trials in chronic heart failure patients showed beneficial effects 
when pimobendan was added to an optimal basic regimen with or without digi-
talis.10-12 Also, a trial comparing pimobendan with the angiotensin converting en-
zyme inhibitor enalapril was performed.13 To confirm these earlier findings, an-
other placebo-controlled trial focusing on exercise capacity, oxygen consumption, 
and quality of life was undertaken with a longer (at least 24 weeks) treatment dura-
tion and in a larger group of patients than in previous trials. 
PATIENTS AND METHODS 
Patients 
In 30 centres (see Appendix) patients were recruited if they had chronic moderate 
(New York Heart Association class II-III) heart failure and had given written in-
formed consent. All patients were at least 18 years of age, had been clinically stable 
without important changes in background medication for at least 30 days, and had 
an ejection fraction of 45% or lower. At two maximal exercise tests at least two 
weeks apart, exercise times were within the age and sex-specific limits shown in 
table 1 and no more than one minute apart. 
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Table 1: Exercise protocol (maximal bicycle ergometry in sitting position) 
and limits of exercise time allowed at entry 
 Age (years) 
Men <65 65-69 70-74  >75   
Women  <50 50-59 60-64 65-69 70-74 >75 
Workload (Watts): 
1st minute 0 W 0 W 0 W 0 W 0 W 0 W 0 W 
2nd min-
ute 30 W 20 W 20 W 10 W 10 W 10 W 10 W 
Each 
next min-
ute 
+10 W +10 W +10 W +10 W +10 W +10 W +10 W 
Limits (minutes:seconds): 
At least 3:00 3:00 3:00 3:00 3:00 3:00 3:00 
Less than 10:00 10:00 10:00 10:00 9:00 8:00 7:00 
 
Exclusion criteria were: stenotic, obstructive or infectious cardiac disease; ex-
ercise capacity limited by angina; on waiting list for transplantation, suspicion of 
digitalis toxicity; acute myocardial infarction, coronary revascularisation, or epi-
sode of syncope or cardiac arrest during the last three months; automatic cardiac 
defibrillator implanted; primary renal or hepatic disease; haemodynamically sig-
nificant pulmonary embolism or severe pulmonary disease; any other still present 
life-threatening condition; previous participation in a trial with pimobendan; and 
anticipated problems with follow up or compliance. Women were excluded unless 
they had been sterilised or were at least two years post-menopausal. Baseline serum 
potassium had to be above 3·8 mmol/l, serum creatinine below 194 μmol/l and as-
partate aminotransferase below 100 U/l. 
The day before double blind medication was started, all patients were given a 
single test dose of pimobendan and were excluded if this dose produced significant 
symptoms or signs of intolerance. 
 
Medication regimen 
Background medication consisted of at least an angiotensin converting enzyme in-
hibitor and a diuretic. In addition, digitalis, nitrates and molsidomine were allowed. 
Other inotropic agents, phosphodiesterase inhibitors, ibopamine, β blockers, cal-
cium antagonists and other vasodilators could not be given. The only antiarrhyth-
mic agent allowed was amiodarone, which had to have been started at least three 
months before entry. In patients receiving amiodarone, the QT interval corrected 
for heart rate14 (QTc) was monitored and the dose of this compound was reduced if 
QTc exceeded 480 ms. 
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Double blind medication consisted of either placebo, or pimobendan 2·5 or 5 
mg daily, divided in two equal doses. Allocation was randomised and blocked by 
centre. Medication was also taken on the days of exercise testing. Investigators 
were instructed to halve the dose when serum creatinine rose to at least 2·5 mg/dl 
(220 μmol/l), or aspartate aminotransferase to at least 150 U/l; and to withdraw 
double blind medication if such elevation(s) persisted. Compliance was monitored 
by pill counts and was judged to have been good when at least 80% of the pre-
dicted number of double blind medication capsules had been used without interrup-
tion for more than 48 hours. 
 
Trial design 
The screening phase consisted of a minimum of two outpatient clinic visits at least 
two weeks apart and was followed by a 24-week efficacy phase on double blind 
medication consisting of clinic visits after 2, 4, 8, 12 and 24 weeks. Clinical status 
permitting, all planned follow up assessments (including exercise testing) were 
completed irrespective of deviations from the double blind medication regimen 
(intention-to-treat principle). After completion of the efficacy phase, patients who 
were still alive at that moment were followed for further clinical events until a 
common stopping date. Patients who consented continued to take double blind 
medication (extended follow up phase). 
The primary outcome was exercise time measured at least twice during screen-
ing, and 4, 12 and 24 weeks after start of double blind medication. The same age 
and sex specific maximal bicycle ergometry protocol in the sitting position (table 
1) was used in all centres. In a sub-study, gas exchange measurements were also 
performed. 
Baseline ejection fraction was assessed by the investigator from a two dimen-
sional echocardiogram, which was recorded on videotape and re-analysed later at 
the co-ordinating centre. If no analysable echocardiogram was available, a value 
obtained by another method was accepted. At each visit, the symptomatic state was 
assessed by the New York Heart Association classification.15 Quality of life was 
evaluated by the Minnesota Living with Heart Failure questionnaire16 administered 
twice during screening and after four, 12 and 24 weeks. Patient safety was assessed 
by monitoring vital signs (every visit), standard 12 lead electrocardiography pre-
ceding exercise testing, standard laboratory tests (screening, four, 12 and 24 weeks) 
and 24 hour electrocardiography (screening, four and 24 weeks). ECGs were ana-
lysed at the co-ordinating centre. Proarrhythmia was assessed by criteria described 
previously.17 
While the trial was ongoing, patients were withdrawn when a clinically rele-
vant violation of the selection criteria was detected at the co-ordinating centre. The 
decision to do so was taken by the steering committee before the medication code 
was broken. Cause of death was classified by the critical events committee, which 
had no access to the medication code. Sudden death was defined as witnessed death 
within one hour of onset of symptoms or unexpected, unwitnessed death.18,19 This 
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committee also assessed whether missed exercise tests were due to the patient’s 
cardiovascular condition. 
 
Ethics 
The trial was carried out in accordance with the Declaration of Helsinki,20 had been 
approved by the institutional review board of each centre and was monitored ac-
cording to European Union standards of Good Clinical Practice. For patient safety, 
episodes of ventricular tachycardia in excess of three consecutive beats observed in 
centrally analysed 24 hour electrocardiograms were reported to the investigator. 
Data on serious adverse events were regularly reviewed by an independent moni-
toring committee, which was in the possession of the treatment code from the start 
of the trial onwards. 
 
Statistical methods 
Sample size estimation was based on the results of an earlier trial with the same 
compound and the same primary outcome.11 For exercise time and for the physical 
dimension of the Minnesota Living with Heart Failure questionnaire, 70 patients 
per group were required for a power of 90% at a two-sided significance level of 5% 
(based on charts of the power function for analysis of variance tests21 and sums of 
squared treatment effects estimated from the earlier trial11). For peak oxygen con-
sumption 45 patients per group were required. No interim analyses for efficacy 
were performed. 
All patients who complied with the selection criteria and had started double 
blind medication were included in intention-to-treat analyses; no patient was ex-
cluded for protocol violations which had occurred during follow up. The primary 
pre-specified analysis of exercise time was limited to those patients who had at 
least the first follow up (four week) exercise test carried out and had shown good 
compliance (see medication regimen) up to the day of the test. If subsequent tests 
were not performed, whatever the reason, or were performed although compliance 
between tests had been poor, the last exercise time value obtained while compli-
ance was good was carried forward. Tests of significance were performed by fixed-
effects analysis of variance for repeated measurements.22 All P values quoted are 
two-sided. 
As a secondary analysis, changes in exercise time at 24 weeks were ranked 
and all patients assigned to placebo were compared by a standard non-parametric 
test with all patients assigned to pimobendan on an intention-to-treat basis. If the 
patient had died or if there had been a cardiovascular contraindication for exercise 
testing, the rank assigned was that below the patient with the lowest rank based on 
exercise time changes actually observed. If exercise time was missing for other rea-
sons, the last available value was carried forward in calculating the rank. 
Percentages were compared between groups by chi-square tests with one or 
two degrees of freedom for comparisons between two or three groups respectively. 
Hazards of all-cause mortality and of the combined event death or hospitalisation 
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for cardiovascular reasons were calculated by dividing the total number of events 
that had occurred by the number of person-years of follow up that patients had 
been at risk of the event considered. The time of first intake of double blind medi-
cation was regarded as the beginning of follow up, and the day the patient was last 
known to be alive, as the end. Medication groups were compared by hazard ratios 
and their 95% confidence intervals.23 To assess whether the hazard ratio estimates 
for the combined endpoint death or hospitalisation for cardiovascular reasons were 
distorted by imbalance between treatment groups for clinical predictors of this 
event at baseline, the same hazard ratios were also estimated by Cox multivariate 
proportional hazard analysis.24 
RESULTS 
Patients, conduct and compliance 
The trial was completed as planned. From March 1993 to June 1994, 333 patients 
completed the screening phase and had one test dose of pimobendan administered. 
None of these patients showed acute intolerance but two were subsequently ex-
cluded (one for hypokalaemia, one for worsening heart failure). Thus 331 patients 
were started on double blind medication. Before the medication code was broken 
14 of these were excluded for violations of the selection criteria (four placebo, six 
pimobendan 2·5 mg/day, four pimobendan 5 mg/day; one excluded patient assigned 
to placebo died nine months after randomisation). Hence, 317 patients (108 allo-
cated to placebo, 106 to pimobendan 2·5 mg/day, and 103 to 5 mg/day) are the ba-
sis of this report. All but one had been followed until November 1994 for clinical 
events. Selected entry characteristics are presented in table 2. Given the relatively 
small numbers in each treatment arm, randomisation resulted in well balanced 
groups. 
 
 
Table 2: Entry characteristics* 
  Pimobendan (daily dose)  
 Placebo 2·5 mg 5 mg Total 
Number of patients 108 (100%) 106 (100%) 103 (100%) 317 (100%) 
Age (years) 65·1 (10·3) 64·8 (9·1) 66·6 (9·1) 65·5 (9·5) 
Male 79% 78% 83% 80% 
History:     
Ischaemic aetiology 72% 67% 67% 69% 
Documented MI 65% 63% 57% 62% 
Coronary bypass graft-
ing 18% 26% 21% 22% 
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  Pimobendan (daily dose)  
 Placebo 2·5 mg 5 mg Total 
Treated for high blood 
pressure 23% 36% 20% 26% 
Diabetes 14% 15% 20% 16% 
Median (range) duration 
of HF (months) 34 (1–225) 35 (2–480) 35 (2–284) 35 (1–480) 
Hospitalised >24 hours 
for HF 73% 66% 70% 70% 
NYHA II / III 51% / 49% 56% / 44% 50% / 50% 52% / 48% 
Basic regimen:     
ACE-inhibitor and diu-
retic 100% 100% 100% 100% 
Digitalis glycosides 63% 55% 59% 59% 
Nitrates 43% 44% 46% 44% 
Molsidomine 7% 7% 5% 7% 
Amiodarone 9% 11% 17% 12% 
Anticoagulants 56% 46% 51% 51% 
Observations:     
Regular sinus rhythm 78% 74% 73% 75% 
Ejection fraction (%)† 28 (7) 26 (6) 28 (7) 27 (7) 
End-diastolic volume 
(ml)‡ 312 (104) 315 (95) 308 (113) 312 (104) 
Exercise time (seconds) 435 (97) 417 (100) 416 (110) 423 (102) 
Drop of SBP during ex-
ercise 3% 4% 7% 4% 
Total MLHF score§ 27·9 (18·4) 26·5 (16·8) 25·8 (19·1) 26·8 (18·1) 
QTc interval >480 msec 14% 18% 18% 17% 
* Data are given either as a percentage or as a mean (SD), unless indicated otherwise. ACE, angio-
tensin converting enzyme; HF, heart failure; MI, myocardial infarction; MLHF, Minnesota Living 
with Heart Failure questionnaire; NYHA, New York Heart Association classification; SBP, systolic 
blood pressure; QTc, QT-interval corrected for heart rate 
† No entry value was available for one patient assigned to pimobendan 5 mg/day (local values were ac-
cepted when central analysis was not possible). 
‡ No entry values were available for 11 patients assigned to placebo, 7 patients assigned to pimobendan 
2·5 mg/day and 10 patients assigned to pimobendan 5 mg/day 
§ No entry value was available for one patient assigned to pimobendan 2·5 mg/day. 
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Table 3: Exercise testing and medication compliance during efficacy phase 
  Pimobendan (daily 
dose) 
 
 Placebo 2·5 mg 5 mg Total 
Number of patients 108 106 103 317 
Exercise test done: 
4 weeks 103 99 98 300 
12 weeks 97 92 88 277 
24 weeks 94 86 88 268 
Exercise test done and good compliance: 
4 weeks 101 97 94 292 
4 and 12 weeks 93 82 82 257 
4, 12 and 24 weeks 88 73 79 240 
Exercise test not done due to death: 
4 weeks 2 3 3 8 
12 weeks 5 5 10 20 
24 weeks 6 13 11 30 
Exercise testing contra-indicated: 
4 weeks 1 3 2 6 
12 weeks 3 4 4 11 
24 weeks 4 2 3 9 
Exercise test not done for other reasons: 
4 weeks 2 1 0 3 
12 weeks 3 5 1 9 
24 weeks 4 5 1 10 
 
 
Table 3 summarises the extent to which exercise testing was performed in relation 
to compliance with the double blind medication regimen. For the primary analysis 
of exercise time 92% of patients (292/317) were available. In 76% (240/317) all 
three exercise tests were performed and compliance was good throughout the effi-
cacy phase. One or more exercise test results was carried forward in the primary 
analysis for 52 patients. In 10 patients there was a reason other than death or a con-
tra-indication for not performing the planned 24-week exercise test. For these the 
last exercise test result was carried forward in the ranked secondary analysis of 
change in exercise capacity at 24 weeks (see statistical methods). 
Based on the same criteria for inclusion as for the primary analysis of exercise 
time, 35 patients on placebo, 34 on pimobendan 2·5 mg/day and 34 on pimobendan 
5 mg/day respectively were available for analysis of gas exchange measurements. 
Similarly, 103 patients on placebo, 100 on pimobendan 2·5 mg/day and 94 on pi-
mobendan 5 mg/day were available for a per-protocol analysis of Minnesota Living 
with Heart Failure questionnaire scores. 
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Exercise capacity and peak oxygen consumption 
The mean changes in exercise time (relative to the last baseline test) for the patients 
included in the primary analysis are shown in figure 1. After four, 12 and 24 weeks 
respectively, the mean treatment effects of pimobendan 2·5 mg/day relative to pla-
cebo were 13, 27 and 29 seconds (P = 0·03); and of pimobendan 5 mg/day 19, 17 
and 28 seconds (P = 0·05). 
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Figure 1: Mean (SEM) of change in exercise time after four, 12 and 24 weeks 
For the 292 patients entered in the primary analysis (101 placebo, 97 pimobendan 2·5 mg/day and 94 
5 mg/day; table 3), the bars show by treatment group the mean changes in exercise time relative to 
baseline) after four, 12 and 24 weeks. The last available value was carried forward when data for 12 
or 24 weeks was missing. For the 101 patients on placebo in this analysis, the mean entry exercise 
time was 437 seconds and the mean changes were (standard errors between brackets): +25 (7) after 
four weeks, +32 (8) after 12 weeks and +30 (9) seconds after 24 weeks. In the pimobendan 2·5 
mg/day group the mean changes were +38 (7), +59 (8) and +59 (9), and in the 5 mg/day group +44 
(7), +49 (11) and +58 (10) seconds respectively (overall P = 0·06; 2·5 mg/day versus 5 mg/day P = 
0·9; 2·5 mg/day versus placebo P = 0·03, 5 mg/day versus placebo P = 0·05; all pimobendan versus 
placebo P = 0·02). 
 
 
Figure 2 shows the cumulative distributions of changes in exercise time at 24 
weeks for the 108 patients assigned to placebo and the 209 patients assigned to pi-
mobendan (both dose groups combined), based on intention-to-treat and taking into 
account exercise tests which were not possible because of death or a contraindica-
tion. Of the 209 patients assigned to pimobendan, 63% were able to exercise at 24-
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weeks to at least the same level as at entry. Among the 108 patients assigned to pla-
cebo, this was the case in 59% (P = 0·5, non-parametric test). 
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Figure 2: Cumulative distributions of changes in exercise time at 24 weeks 
based on intention-to-treat for placebo (108 patients), and for both pimoben-
dan groups combined (209 patients) 
In ten cases in the placebo group (6 + 4, table 3) and 29 in the combined pimobendan groups (13 + 11 
+ 2 + 3; table 3, P = 0·2), the 24-week exercise test was missing because of death or a cardiovascular 
contra-indication for exercise testing. Hence, for placebo the curve starts at the 10·2th (11/108) and 
for pimobendan at the 14·4th (30/209) percentile. Whenever the 24-week test was missing for other 
reasons (4 placebo, 5 + 1 pimobendan; table 3), the last available value was carried forward. The 
medians do not differ significantly (difference between medians = 18 seconds, P = 0·5) but in this 
trial more patients assigned to pimobendan showed improvement in exercise time than patients as-
signed to placebo, despite their higher incidence of death or contra-indications for exercise testing. 
 
 
 
In the subgroup of 35 patients allocated to placebo who had gas exchange meas-
urements the mean peak oxygen consumption was 13·1 ml/min.kg at entry; and 
13·7, 13·3 and 13·9 ml/min.kg after four, 12 and 24 weeks respectively. At these 
time points, the mean effects of pimobendan 2·5 mg/day (relative to placebo, per-
protocol analysis) on this variable were 0·2, 0·8 and 0·4 (P = 0·4) and of pimoben-
dan 5 mg/day 0·6, 0·8 and 0·3 ml/min.kg respectively (P = 0·4). 
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New York Heart Association class and quality of life 
Of those assigned to placebo, 4% (4/108) were in a better New York Heart Associa-
tion class at least once during follow up than at entry and never worsened or died 
before the 24 week visit. The corresponding figure for those assigned to pimoben-
dan was 10% (20/209; P = 0·06). 
For the 103 patients on placebo analysed for Minnesota Living with Heart 
Failure questionnaire scores, the mean total score at entry was 27·7 units; and 25·0, 
25·6 and 26·1 units after four, 12 and 24 weeks respectively. At these time points, 
the mean effects of pimobendan 2·5 mg/day (relative to placebo, per-protocol 
analysis) were –0·4, –1·6 and –1·2 (P = 0·5) units and of pimobendan 5 mg/day –
0·0, +0·7 and –1·0 units respectively (P = 0·9). 
 
Clinical outcome 
During the efficacy phase proarrhythmia based on 24-hour electrocardiography 
was observed in 20 patients assigned to placebo, 15 to pimobendan 2·5 mg/day and 
14 to pimobendan 5 mg/day. When sudden cardiac death was considered as proar-
rhythmia also, these numbers became 24, 22 and 19 respectively (P = 0·5). 
Data on the clinical outcome at the end of the efficacy phase (i.e. at 24 weeks) 
is given in table 4. Double blind medication was stopped or reduced significantly 
more often in patients allocated to pimobendan than to placebo (11 + 8 = 19 pla-
cebo, 21 + 13 = 34 pimobendan 2·5 mg/day, 16 + 13 = 29 pimobendan 5 mg/day; P 
= 0·04). 
Data on mortality and hospitalisation for cardiovascular reasons during the en-
tire trial (that is, efficacy and extended follow up phase combined) based on inten-
tion-to-treat is given in table 5. The mean follow up was 11 months and 44% of 
patients were followed for at least one year. In total, 47 patients died. While taking 
double blind medication, eight died on placebo, 14 on pimobendan 2.5 mg/day and 
11 on pimobendan 5 mg/day. The causes of death are also given in table 5. More 
than half of all deaths were classified as sudden. Cardiovascular deaths caused by 
myocardial infarction (one in each treatment group), worsening heart failure (one 
placebo, two pimobendan 2·5 mg/day and five pimobendan 5 mg/day), multiple 
organ failure (one placebo), cerebrovascular accident (one pimobendan 2·5 
mg/day) and peripheral vascular disease (one pimobendan 2·5 mg/day). The two 
non-cardiac deaths were caused by bladder cancer (placebo) and pneumonia (pi-
mobendan 5 mg/day). 
Although there was a trend towards a higher mortality hazard among patients 
allocated to pimobendan, neither comparison with placebo was statistically signifi-
cant at the 5% level (each confidence interval includes one, table 5). In both pimo-
bendan groups combined, the mortality was 1·8 times higher (0·9 to 3·5) than in the 
placebo group. Similarly, there was a non-significant trend towards higher hazards 
of the combined event death or first hospitalisation for cardiovascular reasons. 
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Table 4: Clinical events (excluding extended follow up) 
 Number of patients with event* Ranked clinical outcome at 24 weeks† 
 
Event: 
 
Placebo 
(N = 108) 
Pimobendan
2·5 mg/day 
(N = 106) 
Pimobendan 
5 mg/day 
(N = 103) 
 
Placebo 
(N = 108) 
Pimobendan
2·5 mg/day 
(N = 106) 
Pimobendan
5 mg/day 
(N = 103) 
Death (all causes) 6 13 11 6 13 11 
Acute myocardial infarction 2 1 1 1 0 1 
Hospitalisation for worsening 
heart failure‡ 0 1 4 0 1 2 
Hospitalisation for arrhythmia§ 4 3 5 3 1 5 
Hospitalisation for other cardio-
vascular reasons 14 17 16 8 10 5 
Medication for heart failure 
added or increased  29 25 22 17 12 10 
Anti-arrhythmic agents added 6 7 6 1 3 0 
Other cardiac medication added 
or increased¶ 3 5 0 1 0 0 
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Double blind medication 
stopped by physician 11 21 16 5 5 2 
Double blind medication re-
duced by physician 8 13 13 4 5 7 
Hospitalisation for non-
cardiovascular reasons** 12 13 18 3 1 4 
None of the above – – – 59 55 56 
* Each patient with at least one of the events listed counted. 
† Each patient counted once and assigned to the uppermost applicable 
event listed. 
‡ In-hospital addition of intravenous inotropics (including digitalis). 
§ In-hospital addition of an anti-arrhythmic agent (including digitalis). 
Diuretics, ACE-inhibitors, intravenous inotropics, digitalis, nitrates or 
molsidomine added or increased at any time. 
¶ Calcium-antagonists, beta-blockers or other vasodilators added or 
increased at any time. 
** Except hospitalisation for procedures already planned before entry 
 
 
  
C
hapter 2 
16 
 
 
Table 5: Mortality and mortality or first hospitalisation for cardiovascular reasons (intention-to-treat; including extended 
follow up) 
 
 
Placebo 
(N = 108) 
Pimobendan 
2·5 mg/day 
(N = 106) 
 
HR 2·5/pl* 
(95% CI) 
Pimobendan 
5 mg/day 
(N = 103) 
 
HR 5/pl* 
(95% CI) 
Deaths (all causes) 11 20  16  
 Sudden cardiac death† 7 15  7  
 Other cardiovascular death† 3 5  6  
 Non-cardiovascular death† 1 -  1  
 Unknown cause - -  2  
Hazard‡ (per 100 person-years) 10·8 21·3 2·0 (0·9 - 4·1) 17·4 
1·6 
(0·7 - 3·4) 
No. of deaths or 1st hospitalisation 27 40  33  
Hazard‡ (per 100 person-years) 29·5 48·5 1·6 (1·0 - 2·7) 41·2 
1·4 
(0·8 - 2·3) 
* Hazard ratios (HR) comparing patients assigned to pimobendan 2·5 
mg/day and to pimobendan 5 mg/day respectively with patients as-
signed to placebo; with 95% confidence intervals (CI). 
† As assessed by the Critical Events Committee 
‡ Number of events divided by person-time of follow up until event or 
until end of extended follow up 
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The adjusted estimates from the Cox regression model of the hazard ratios for 
death or hospitalisation for cardiovascular reasons were 1·5 comparing pimobendan 
2·5 mg/day with placebo (95% confidence interval 0·9 to 2·5), and 1·2 (0·7 to 2·1) 
comparing pimobendan 5 mg/day with placebo. Conditionally independent and 
significant (P < 0·05) covariates associated with a reduced risk in the Cox model 
were (hazard ratios between brackets): change of systolic blood pressure during 
exercise (0·983/mm Hg rise), resting systolic blood pressure (0·980/mm Hg), exer-
cise time (0·998/second), and previous coronary bypass grafting (0·5). Covariates 
associated with an increased risk were previous hospitalisation for heart failure 
(2·6), history of symptomatic arrhythmia (1·6) and history of high blood pressure 
treated with drugs (1·7). The adjusted estimates are similar to those given in table 
5. Conditional on the covariates mentioned, age, sex, NYHA class, ejection fraction 
and use of digitalis were not associated with the risk. 
DISCUSSION 
The main finding of this trial confirms earlier findings that pimobendan improves 
exercise capacity.10-12 Relative to placebo, the magnitude of this effect seemed to 
increase until 12 weeks of treatment and then to persist at the same level at 24 
weeks (figure 1). This is not only the largest placebo-controlled trial to date but 
also the first one with a treatment period of this duration. This sustained effect has 
therefore not been reported before. 
The largest earlier placebo-controlled trial studied 198 patients in NYHA class 
III who were treated for 12 weeks with either placebo, or 2·5, or 5, or 10 mg/day of 
pimobendan.11 Mean exercise duration increases (rounded to whole seconds) of 30, 
68, 122 and 81 respectively were observed. Adding these mean increases to the 
mean entry exercise time in the placebo group (536 seconds) yields mean follow up 
exercise durations of 566, 604, 658, and 617 seconds respectively for placebo or 
2·5, or 5 or 10 mg/day of pimobendan. Hence, in that trial the effect of treatment 
expressed as the percentage difference compared placebo was [(604 - 566) 
x100]/566 or 7% for treatment with 2·5 mg/day of pimobendan. Calculated in the 
same way, the treatment effects for 5 and for 10 mg/day of pimobendan were 16% 
and 9% respectively. In another smaller earlier trial, 10 treatment effects calculated 
in similar manner of 16% and 13% for 5 and 10 mg/day of pimobendan respec-
tively were observed. 
Based on the data given in table 2 and figure 1 and by the same method of cal-
culation, treatment effects at 24 weeks in this trial were 6% for 2·5 and also 6% for 
5 mg/day of pimobendan. Thus the magnitude of effect of 2·5 mg/day of pimoben-
dan in this trial was similar to that in the largest earlier trial11 but the effect of 5 
mg/day was considerably less than observed before.10,11 Based on the dose-
response relations observed in these earlier trials, the 10 mg/day dose was not stud-
ied in this trial. Contrary to the largest earlier trial,11 no difference was observed 
between the 2·5 and 5 mg/day dosages with respect to their effect on exercise dura-
tion. One can only speculate why the effect on exercise duration of the 5 mg/day 
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dose in this trial was less marked than observed earlier. In the largest earlier trial,11 
all patients were in NYHA class III. In this trial that was the case in 48% (table 2). 
We found no relation between the effect of pimobendan and NYHA class at entry. 
Hence, it seems unlikely that this can explain the difference between this and the 
earlier result. Similarly, it is unlikely that the difference in angiotensin converting 
enzyme inhibitor use (80% in the largest earlier trial, all patients in the present one) 
or digitalis use (88% in the largest earlier trial, 59% in the present one) can explain 
the difference. Whether there is a relationship between the use of angiotensin con-
verting enzyme inhibitors and the effect of pimobendan is not known and in our 
data there was no relation between the effect of pimobendan and use of digitalis. A 
factor may have been that patients in this trial were older than in the earlier trial 
(65·5 mean age in this one, 61 in the largest earlier trial) and that ischaemic heart 
disease was a more frequent aetiology (69% in this trial and 44% in the largest ear-
lier trial). This, and the different exercise methodology used,25 may have influenced 
the results. Alternatively, the larger efficacy of pimobendan 5 mg/day relative to 
2·5 and 10 mg/day in the largest earlier trial11 may to a certain extent have been a 
chance finding. An argument in favour of this that the 10 mg dose has produced the 
largest haemodynamic improvement.10 In any case, this trial together with earlier 
trials10,11 suggest that the therapeutic range of pimobendan is 2·5 to 5 mg/day. 
This trial did not reproduce the statistically significant effects of pimobendan 
peak oxygen consumption10,11 and on Minnesota Living with Heart Failure ques-
tionnaire11 scores seen in earlier trials. Again, one can only speculate about the rea-
sons. Peak oxygen consumption was measured only in a sub-group of patients and 
the power may have been insufficient. The Minnesota Living with Heart Failure 
questionnaire may be less sensitive to changes in patient well being and/or less re-
producible when this instrument is used in different cultural settings than the one 
for which it was originally developed and validated. 
This trial followed a classical pattern for exercise capacity trials in heart fail-
ure. Several additional design features, however, allowed us to clarify further the 
efficacy and safety of adding pimobendan to the prevailing basic heart failure 
regimen. As in the largest earlier trial,11 we randomised only those patients who 
tolerated a test dose of pimobendan. No patient was excluded because of acute in-
tolerance. In fact, the present data show that pimobendan in the dosages studied is 
well tolerated. The number of patients in whom treatment had to be discontinued 
was small (table 4). No clinically relevant signs of proarrhythmia were observed. 
The number of patients in whom proarrhythmia was observed by 24-hour electro-
cardiography based on accepted criteria17 was highest in the placebo group even 
when sudden cardiac death in the absence of proarrhythmia based on 24-hour elec-
trocardiography was also regarded as proarrhythmia. 
When the clinical situation permitted, follow up exercise testing was per-
formed in patients in whom pimobendan had been discontinued. This allowed for 
the ranking of patients based on exercise capacity at 24 weeks and on intervening 
clinical events as shown in figure 2. We believe this to be an important additional 
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evaluation of the efficacy of chronic heart failure treatment. Effects on clinical out-
come may either dilute or enhance effects on exercise capacity.26 In the present 
case, the trend towards a higher mortality in patients started on pimobendan raises 
the question whether the benefit related to the positive effect of pimobendan on 
exercise capacity in the survivors is negated by the higher mortality risk associated 
with this treatment. The ranking in figure 2 shows that patients started on pimo-
bendan have a higher chance of surviving 24 weeks and improving their exercise 
capacity than patients started on placebo. The difference was, however, not statisti-
cally significant. The major limitation of this trial is therefore that it does not allow 
a definitive conclusion about the benefit/risk ratio of treatment with pimobendan 
and it is this benefit/risk ratio which would merit further study in a larger trial. 
To collect further data on the safety of pimobendan, all patients were followed 
until a common stopping date after they completed the 24-week efficacy phase, and 
those who consented were kept on medication. This design feature optimises the 
number of patient-years of follow up which can be accumulated within a given 
time. Hence it was possible to evaluate mortality and the combined rate of death or 
first hospitalisation for cardiovascular reasons over a mean follow up of 11 months 
based on intention-to-treat. Even though the differences were not significant, the 
hazards of both events were higher in the pimobendan than in the placebo groups 
(table 5). This was largely due to an increased incidence of sudden cardiac death, in 
particular in the pimobendan 2·5 mg/day group. The results of Cox multivariate 
proportional hazard analysis showed that these differences are unlikely to be re-
lated to imbalance between treatment groups for important predictors of clinical 
outcome.  
Because of its different mechanism of action,9 the trend towards a higher mor-
tality in patients treated with pimobendan in this trial is unexpected despite earlier 
findings with predominantly cyclic adenosine monophosphate dependent phos-
phodiesterase inhibitors such as milrinone and enoximone.6,7 Our findings may be 
attributable to chance because the trend observed was not statistically significant. 
Another potential explanation is a hitherto unknown interaction between digitalis 
and a positive inotropic compound such as pimobendan. The excess mortality in 
the pimobendan groups in this trial occurred predominantly in patients who were 
also on digitalis at entry. Thirty five of the 47 deaths observed (table 5) occurred in 
patients on digitalis at entry, divided as follows over the treatment groups: eight 
placebo, 15 pimobendan 2·5 mg/day and 12 pimobendan 5 mg/day. The corre-
sponding numbers of deaths among patients not on digitalis at entry were three, 
five and four respectively. The number of events in each subgroup was small, this 
sub-group analysis had not been specified in advance and the apparent interaction 
between the effect of pimobendan on mortality and the use of digitalis at entry was 
not statistically significant. Nevertheless, our data raise the question whether the 
benefit/risk ratio of treating heart failure patients with positive inotropic agents de-
pends on co-treatment with digitalis. Theoretically, calcium sensitisation enhances 
the effects of digitalis, which acts by increasing the ionised calcium concentration 
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within the myocardial cell.27 Possibly, this leads to overstimulation. Rather than 
being dependent on co-treatment with digitalis, the benefit/risk ratio may also de-
pend on the prognosis in general. In this trial, patients on digitalis were sicker (as 
evidenced by lower ejection fractions) and had a worse prognosis than patients not 
on digitalis. In any case, these potential sources of effect modification of pimoben-
dan, and possibly of other positive inotropic agents, warrant further investigation. 
The extent to which such questions can be answered in placebo controlled trials 
will depend to a large extent on the outcome of the currently ongoing large-scale 
digitalis trial. 
In conclusion, as regards exercise capacity this trial confirmed the efficacy of 
the addition of pimobendan to the basic regimen of patients with chronic heart fail-
ure. The effect of pimobendan as monotherapy has not been studied in controlled 
trials thus far. Pimobendan was well-tolerated and clinically relevant proarrhythmia 
was not observed. There was a trend towards improved clinical condition in pa-
tients treated with pimobendan, but also towards a higher mortality. Hence, the bal-
ance between benefit and risk, which may depend also on concomitant use of digi-
talis, remains to be established. 
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Chapter 3 
Combined Endpoints: Can we use them? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
Analysing specific non-fatal events in isolation may lead to spurious conclusions 
about efficacy unless the events considered are combined with all-cause mortality. 
The use of combined endpoints has therefore become widespread, at least in car-
diovascular disease trials. Combining all-cause mortality with selected non-fatal 
events is useful because event-free survival, an important criterion in therapy 
evaluation, is addressed in this manner. In many clinical trials symptoms, signs or 
paraclinical measures (e.g., blood pressure, exercise duration, quality of life scores) 
are used as endpoints. If the patient died before the endpoint was measured, or it 
was otherwise not possible to perform follow up assessments as planned, the effect 
of treatment on these endpoints may be distorted if the patients concerned are ig-
nored in the analysis. Examples are given of how distortion can be avoided by in-
cluding all patients randomised in an analysis that uses a ranked combined end-
point based both on clinical events and on paraclinical measures. A distinction is 
made between a pseudo intention-to-treat analysis that disregards study medication 
status at the time of endpoint assessment, but is confined to patients with data; and 
a true intention-to-treat analysis that takes into account all patients randomised 
based on a ranked combined endpoint. 
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In clinical trials there are usually multiple outcomes that can be observed during 
follow up. To avoid multiplicity it is customary to focus on one specific outcome 
and to design the trial so that an efficacy question with respect to one pre-specified 
primary endpoint can be answered. 
Focusing on one particular outcome has several limitations. A disease such as 
atherosclerosis may result in different disease manifestations that all have the same 
underlying cause. A treatment that affects atherosclerosis can therefore affect sev-
eral different disease manifestations at the same time even when only patients pre-
senting with one type of atherosclerotic disease are considered. Recently cardio-
vascular disease trials have combined several different causally related clinical 
events into one combined primary endpoint. Multiplicity is avoided in this manner. 
The power of the trial to detect a treatment effect may be enhanced and the overall 
clinical effect of certain treatments may be better understood when the total burden 
of a disease is evaluated by a combined endpoint. 
Another limitation of focusing on one particular outcome occurs when the trial 
has an endpoint that pre-supposes that follow up assessments are complete after 
study medication has been taken for the specified period of time. Blood pressure in 
patients with hypertension, or exercise duration in patients with heart failure, are 
relevant examples. In trials focusing on such endpoints it is unavoidable that some 
planned follow up assessments will not be performed for reasons that relate to the 
clinical course of the patient following start of study medication. Confining the 
analysis to patients for whom follow up assessments were performed ignores the 
clinical outcome in those patients who were started on study medication but for 
whom follow up assessments were incomplete. It is not always appreciated that this 
may distort the comparison for the endpoint considered. Similarly, it is not always 
appreciated that distortion may occur when a specific clinical event, such as hospi-
talisation, is analysed while ignoring circumstances (such as death) that preclude 
the occurrence of the event considered. 
Outcome information used as endpoints in clinical trials may be ranked hierar-
chically (Figure 1).1 Distortion can occur when the analysis for an endpoint other 
than all-cause mortality (level 1 in Figure 1) ignores information from higher lev-
els. Whether such distortion has occurred can be assessed by using endpoints that 
combine information from several levels, as will be shown in the examples that 
follow. Their purpose is also to show that combined endpoints often allow for a 
better understanding of treatment effects. 
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Figure 1: Hierarchical levels of outcome information to be considered in the 
analysis of clinical trial data 
Level 4 information (e.g. blood pressure, symptoms) can only be obtained in patients who are still 
alive and must be considered in the context of non-fatal clinical events that may have affected the 
information. Non-fatal clinical events can only occur in patients who have survived up to the time of 
the event. Specific causes of death can only occur in patients who didn’t die from another cause. 
 
COMBINING MULTIPLE CLINICAL EVENTS 
We first consider how combining clinical events from levels 1 – 3 (Figure 1) can 
help to understand what is achieved clinically by a certain treatment. Suppose that 
hospitalisation is the event of interest. Hospitalisation is a clinical event that be-
longs to level 3. Death – level 1 – reduces the risk of subsequent hospitalisation to 
zero. Hence, death and hospitalisation cannot be considered as independent enti-
ties. It would therefore be appropriate to report trial data on death and hospitalisa-
tion as shown in Table 1. Note that in this table all possible outcomes are consid-
ered and that they are displayed in mutually exclusive categories. It would be ap-
propriate to consider only hospitalisation for certain reasons, such as aggravation 
of a specific underlying condition common to all patients at the time of randomisa-
tion. All-cause mortality, however, must be included to ensure that all patients en-
All-cause mortality 
Cause-specific mortality 
Non-fatal clinical events 
Symptoms, signs and paraclinical 
measures 
Level 1 
Level 3 
Level 2 
Level 4 
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tered in the trial can be assigned to one of the four outcome categories considered 
in Table 1. 
 
Table 1: Structure of data on death and hospitalisation (hypothetical data) 
 Treatment 
 Active Control 
Died but never hospitalised during follow up (%) 15 5 
Hospitalised and died during follow up (%) 5 15 
Hospitalised, alive at the end of follow up (%) 20 20 
None of the above (%) 60 60 
 
Suppose that the percentages in Table 1 represent the results of a trial compar-
ing active treatment with control. Total mortality is the same for both groups: 20%. 
The percentage of patients without either of the two events considered – the out-
come category ‘none of the above’ in Table 1 – is also identical: 60%. The only 
effect of active treatment is a shift from hospitalisation and death (5% for active, 
15% for control) to death without hospitalisation (15% for active, 5% for control). 
Because of this, the number of patients that were hospitalised is affected too (25% 
for active, 35% for control).  
For the imaginary data in Table 1 it would be inappropriate to report only the 
total mortality and the number of patients that were hospitalised at any time. This 
would suggest that, without affecting mortality, active treatment reduced the risk of 
hospitalisation. The information that the percentage of patients without any of the 
two events considered was the same is suppressed. That this is not necessarily ap-
preciated in published reports is shown in the following example. 
 
Example 1: the dofetilide trial 
This trial compared dofetilide – a drug that stabilises heart rhythm – with placebo 
in patients with heart failure.2 In total, 762 patients were assigned to dofetilide and 
756 to placebo. The primary endpoint was death from any cause. Hospitalisation 
for worsening heart failure was one of several secondary endpoints. The report 
contains a figure (reproduced here as Figure 2) showing that the probability of sur-
vival over time is essentially the same for both treatment arms, but that the prob-
ability of freedom from hospitalisation for worsening heart failure is favourably 
affected by dofetilide. The survival curves address the first and second mutually 
exclusive outcomes listed in Table 1 combined (‘died but never hospitalised’, and 
‘died and hospitalised’). The freedom from hospitalisation curves on the other hand 
address the second and third mutually exclusive outcomes listed in Table 1 com-
bined (‘died and hospitalised’, and ‘hospitalised, alive at the end of follow up’). 
Because of the resulting overlap, it is not possible to draw any conclusions based 
on the curves shown in Figure 2 about each of the four mutually exclusive out-
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comes. In the report no data are given on death without hospitalisation (the ‘died 
but never hospitalised’), or on survival without hospitalisation (the ‘none of the 
above’ outcome category).  
 
 
 
Figure 2: Kaplan-Meier estimates of the probability of survival and of freedom 
from hospitalisation for worsening congestive heart failure, according to the 
presence or absence of atrial fibrillation at base line 
(A) Probability of survival among patients with atrial fibrillation at baseline (hazard ratio for the 
dofetilide group, 1·01; 95 percent confidence interval, 0·75 to 1·36). (B) probability of survival 
among patients without atrial fibrillation at baseline (hazard ratio, 0·94; 95 percent confidence inter-
val, 0·78 to 1·13). (C) Probability of freedom from hospitalisation for worsening congestive heart 
failure among patients with atrial fibrillation at baseline (hazard ratio, 0·64; 95 percent confidence 
interval, 0·46 to 0·91). (D) Probability of freedom from hospitalisation for worsening congestive heart 
failure among patients without atrial fibrillation at baseline (hazard ratio, 0·80; 95 percent confidence 
interval, 0·65 to 0·98). Reproduced by permission of Massachusetts Medical Society from reference 
[2]. 
 
The abstract states that dofetilide was effective in reducing the risk of hospitalisa-
tion for worsening heart failure, but had no effect on mortality.2 That there was no 
effect on mortality, and that there were fewer patients in the dofetilide than in the 
placebo arm who were hospitalised for worsening heart failure, is clear from Figure 
2. Whether this is relevant is another matter. Many patients and doctors would con-
sider it clinically useful to prescribe a drug that, while not prolonging life per se, 
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keeps the patient out of hospital; a drug in other words that prolongs hospitalisa-
tion-free survival. Few would however take a drug if its only effect were to be that 
death occurs outside hospital rather than after admission. The dofetilide report2 
does not address hospitalisation-free survival. Hence, the clinical relevance of the 
conclusion in the abstract is unclear.  
Similarly, it makes no sense to consider only cause-specific mortality. A pa-
tient who died from a cause other than the one considered and who was not hospi-
talised would not be counted. As is shown in the next example, this causes prob-
lems of interpretation that affect many trial reports when several different clinical 
events are combined into one primary endpoint. 
 
Example 2: the HOPE trial 
In the HOPE trial, 4645 patients with risk factors for coronary disease were ran-
domised to the ACE-inhibitor ramipril and 4652 to placebo.3 The mean follow up 
was five years and the combined primary endpoint was cardiovascular death, or 
myocardial infarction (MI), or stroke. The numbers of patients with events are 
given in Table 2 in the same manner as listed in Table 3 in the original report3.  
 
Table 2: Incidence of the primary outcome and of deaths from any cause in 
the HOPE trial 
 Assigned treatment 
 Ramipril N = 4645 
Placebo 
N = 4652 
MI, stroke or CV death (primary endpoint) 651 826 
Cardiovascular (CV) death 282 377 
Myocardial Infarction (MI) 459 570 
Stroke 156 226 
Non-CV death 200 192 
All deaths 482 569 
Reproduced by permission of Massachusetts Medical Society from Table 3 in the original report.3 
 
There were 651 and 826 patients in the ramipril and placebo arms respectively who 
either died from a cardiovascular cause, or had MI, or stroke. The number of pa-
tients who died from a cardiovascular cause, had MI or stroke are also given in the 
report and in Table 2. To fully understand the manner in which the results are pre-
sented, it is useful to add up the number of patients listed as cardiovascular death, 
MI and stroke respectively. For the ramipril group this yields 282 + 459 + 156 = 
897. The reason that this exceeds the 651 patients who reached the combined pri-
mary endpoint in this arm is that a patient who had an MI, then a stroke and then 
died from a cardiovascular cause is counted only once among the 651 patients who 
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reached the combined primary endpoint. The same patient is also counted once in 
each of the component outcome categories of the primary endpoint. The same pa-
tient is counted three times, however, when the counts of outcome events are 
summed. 
Just as the freedom from hospitalisation curves in Figure 2 do not represent 
hospitalisation-free survival, the Kaplan-Meier curves for the primary endpoint 
given in the HOPE report do not represent MI- and stroke-free survival. In the re-
port and in Table 2, the numbers of non-cardiovascular deaths are also given. 
Nonetheless, it is not possible to derive the outcome category ‘none of the above’ 
from the data given. Adding the 200 non-cardiovascular deaths to the 651 primary 
endpoints in the ramipril group does not yield the number of patients with any of 
the events considered because a patient who had an MI followed by non-
cardiovascular death is counted twice in the total of 200 + 651 = 851 events. Thus, 
it is not possible to determine from the HOPE report how many patients were alive 
at the end of follow up and also free of MI and stroke.  
COMBINING A CONTINUOUS OUTCOME WITH CLINICAL EVENTS 
In many trials an endpoint belonging to level 4 (Figure 1) is used as criterion for 
efficacy. Clinical events belonging to levels 1 – 3 will by nature interfere with the 
assessment of an endpoint belonging to level 4. In analysing the results for such an 
endpoint this is often ignored. Important information may be suppressed in this 
manner, as is shown in the following example. 
 
Example 3: The PICO trial 
In the PICO trial, pimobendan (a drug that improves the heart’s pump function) 
was compared with placebo in patients with heart failure.4 Change from baseline in 
exercise duration was the primary criterion for efficacy. This is an endpoint that 
belongs to level 4. As regards its design, PICO is a standard ‘surrogate endpoint’ 
trial for the indication concerned. During a stabilisation phase, patients were se-
lected based on repeated exercise tests to assess baseline exercise duration and 
clinical stability. Eligible patients were randomised to one of two different dosages 
of pimobendan, or placebo. Follow up exercise tests were done after 4, 12 and 24 
weeks of treatment. Unless there was a clinical contraindication for exercise test-
ing, follow up tests were also performed in patients for whom study medication had 
been stopped before the end of the trial, a design improvement that is not necessar-
ily standard practice in this type of study. All patients were followed for clinical 
events until the planned end of the trial. Hence, data were also available on the rea-
sons why follow up exercise tests were not performed. 
The routine analysis of exercise capacity data for a trial such as PICO is lim-
ited to patients who had exercise testing during follow up. One so-called ‘per pro-
tocol’ approach is to consider only patients who completed at least one follow up 
exercise test on study medication. Another is to consider all patients who per-
formed at least one follow up exercise test but to disregard whether the patient was 
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still taking study medication at the time of the test. This second approach is often 
described as ‘intention-to-treat’. 
The routine analyses of the PICO trial have been published.4 As expected 
based on previous similar trials, there was a statistically significant positive effect 
on exercise capacity. Relative to placebo, there was also a trend towards an in-
creased mortality in patients assigned to pimobendan. This raises the question to 
what extent the positive effect on exercise capacity is negated by the negative ef-
fect on mortality. In the publication, this question is addressed by an analysis that 
combines information on exercise duration for patients who underwent the 24-
week exercise test (level 4) with information on clinical outcome (levels 1 – 3). 
The results are summarised in Table 3. 
 
Table 3: PICO trial: ranked clinical outcome at 24 weeks 
 Assigned treatment 
 Pimobendan N = 209 (100%) 
Placebo 
N = 108 (100%) 
Exercise test performed: same or higher 
exercise duration than at baseline 132 (63%) 64 (59%) 
Exercise test performed: lower exercise 
duration than at baseline 48 (23%) 34 (31%) 
Too sick to undergo exercise testing 5 (2%) 4 (4%) 
Died before 24 weeks 24 (12%) 6 (6%) 
Adapted from The Pimobendan in Congestive Heart Failure (PICO) Investigators.4 
 
In this table all patients randomised (209 for both pimobendan dose groups com-
bined, 108 for placebo) are represented based on a ranking of clinical outcome at 
the planned end of the trial into four mutually exclusive and exhaustive categories. 
The ranking has an unarguable order and starts with the best possible outcome: pa-
tients who were physically able to undergo the 24-week exercise test and who per-
formed at least as well at this test as at baseline. The worst ranked outcome consid-
ered in Table 3 is death. Two intermediary outcomes are shown also. Note that the 
analysis in Table 3 is truly ‘intention-to-treat’ in the sense that all patients random-
ised are counted. Note also that because of this the percentages in the table can now 
directly be extrapolated to clinically meaningful probabilities. Patients who start 
taking pimobendan have a better chance to be alive after 24 weeks and to be able to 
exercise at least as well as at baseline as patients on placebo do (63% versus 59%). 
This is so despite the fact that patients who start taking pimobendan have twice the 
chance of dying within 24 weeks as patients on placebo (12% versus 6%). When 
only patients with exercise testing data at 24 weeks are considered, the chances of 
at least maintaining exercise capacity are 132/(132 + 48) = 132/180 = 73% for pi-
mobendan and 64/(64 + 34) = 64/98 = 67% for placebo. However, while the effect 
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of pimobendan appears superior, the comparison of 73% versus 67% is not clini-
cally meaningful because it ignores that more patients assigned to pimobendan than 
to placebo (29 versus 10 respectively) were unable to exercise at 24 weeks either 
because they were bed-ridden, or because of death. These patients should be taken 
into account when assessing the effect of a drug on a surrogate endpoint such as 
exercise duration. The example shows how this can be done based on a ranking that 
takes both the continuous outcome and clinical events into account. 
In the example based on the PICO trial, ranking at one specific point in time 
after a relatively short duration of follow up was considered. The same principle 
can be applied to the analysis and presentation of results from trials with long-term 
follow up when the data allow ranking of the clinical condition at several time 
points during follow up. 
 
Example 4: the Stockholm metoprolol trial 
In the Stockholm metoprolol trial, metoprolol (a beta-blocker) was compared to 
placebo in patients who had MI.5 All patients (154 metoprolol, 147 placebo) were 
followed for three years by regular out-patient clinic visits. At each visit the clinical 
status of those still alive was ranked on a five-point scale6 as shown in Table 4 
based on information belonging to levels 3 and 4. 
 
Table 4: Stockholm metoprolol trial: total mean survival and mean number of 
days spent in different categories of clinical status 
 Assigned treatment 
 Metoprolol N = 154 
Placebo 
N = 147 
Total mean survival (days) 992 964 
1. After atherosclerotic complication 95 151 
2. In NYHA class III/IV 78 91 
3. In NYHA class II 541 546 
4. In NYHA class I with side effects of treat-
ment 57 20 
5. In NYHA class I without side effects of treat-
ment 221 156 
NYHA, New York Heart Association. Adapted from Olsson et al.6 
 
Category 1 – ‘atherosclerotic complication’ – was assigned to patients who were 
alive but who had sustained a reinfarction or a stroke, or who had undergone coro-
nary bypass surgery, or a leg amputation for peripheral vascular disease (level 3). 
When a patient was assigned to this category at any one follow up visit, he/she was 
assigned to the same category at all subsequent follow up visits as long as he/she 
was alive. Categories 2 – 5 on the five-point scale describe the patient’s sympto-
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matic status as based on the New York Heart Association functional class and on 
the presence of suspected side effects of treatment (level 4). As long as the patient 
did not belong to category 1 at the time of a follow up visit, he/she could be in any 
of the categories 2 – 5. For each patient, the survival time in the study was taken as 
the time that had elapsed from randomisation to either death or end of follow up. 
This time was then subdivided for the time spent in each of the 5 categories. If the 
patient was in a different symptomatic status category at a given follow up visit 
than at the previous one, the assumption was made that the transition had occurred 
half-way between the two visits. Individual survival times and their subdivisions 
were then averaged for all patients in each of the two treatment arms (Table 4). The 
analysis shows that patients assigned to metoprolol on the average live longer (992 
days compared to 964 days for placebo), and are also on the average free of cardiac 
symptoms or side effects for a longer period of time, 221 days compared to 156 
days for placebo (Table 4). An analysis of this type combines information from all 
levels and the presentation of the results is better for patients who are being in-
formed about what can be expected from the long-term use of treatment. 
DISCUSSION 
Claims based on trials published in major journals affect how drugs are marketed 
and how patients are treated. The example taken from the dofetilide trial raises 
questions about the basis for the claim made in the report that the treatment con-
cerned reduced the risk of hospitalisation for worsening heart failure.2 This particu-
lar claim is clinically relevant only if dofetilide increased hospitalisation-free sur-
vival. In this regard, no data was given in the report however. When asked in writ-
ing, the first author of the dofetilide trial report2 was unable to provide the relevant 
data, citing that the project team had been dissolved.  
The conclusions from the HOPE study were: “Ramipril significantly reduces 
the rates of death, MI, and stroke in a broad range of high-risk patients who are 
known to have a low ejection fraction or heart failure”.3 This wording suggests that 
ramipril improves MI and stroke-free survival. While this conclusion is undoubt-
edly correct, the extent to which this is so cannot be assessed from the data pub-
lished. It would have been helpful if the relevant table in the report had contained a 
line ‘none of the above’. The effect of ramipril on MI and stroke-free survival 
could then have been calculated directly from the data given.  
Apart from the number of patients who reached the combined primary end-
point, the HOPE investigators also reported the number of patients who died from a 
cardiovascular cause, had MI or had a stroke at any time. That this was done was 
made clear by a footnote to the relevant table in the HOPE report.3 Not all trials 
that rely on a combined primary endpoint report component endpoints in the same 
manner. In the NORDIL study7 – which compared two different regimens for treat-
ing hypertension – the number of patients who reached each component endpoint 
was reported in the same manner as for HOPE. NORDIL was published back-to-
back with a similar study called INSIGHT.8 For the latter study, only the numbers 
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of patients who reached each component endpoint as the first manifestation of the 
primary endpoint were reported. The reader of the NORDIL report can find how 
many patients had a stroke. For INSIGHT on the other hand one can only find how 
many patients reached the primary endpoint because of a stroke. The total number 
of patients with a stroke is not given because a patient who had an MI followed by 
stroke and who is alive at the end of the study is counted in INSIGHT as MI only. 
It is possible to report clinical events in a manner that also allows the reader to 
define combined endpoints. An example of how to do this can be found in the 
PICO report.4 The principle is to define a priori a rank order from ‘worst’ to ‘best’ 
for the clinical events to be considered. For HOPE3 this rank order could have 
been: ‘death’ – ‘stroke’ – ‘MI’. That stroke precedes MI is based on a (perhaps de-
batable) judgement that morbidity from stroke is usually more serious than from 
MI. For two treatments the relevant results table must have four columns. In the 
first two, the total number of events is given by treatment arm. In the second two, 
the final outcome of each patient is counted once by treatment arm based on the 
worst event that occurred. For instance, a patient who sustains two MIs followed 
by a stroke but who is alive at the end of the study, contributes two MIs and one 
stroke to the event columns. The same patient is counted only once as a stroke in 
the outcome columns as this is the worst event that occurred. Reporting clinical 
events in this manner allows the reader to create directly from the table the com-
bined event categories ‘death or stroke’, and ‘death or stroke or MI’. Those inter-
ested in cost effectiveness are better served also by this presentation of events as 
the costs of care are determined to a large extent by the number and kind of morbid 
events that occur.  
As explained earlier, MI and stroke-free survival is not addressed in the HOPE 
report.3 This leaves relevant clinical questions concerning what can be achieved by 
treatment with ramipril unanswered. Because of the lower cardiovascular mortality 
in the ramipril arm, the number of patient-years of follow up in the ramipril arm 
must exceed that in the placebo arm. Even if ramipril, relative to placebo, does not 
increase the rate of non-cardiovascular death per unit time of patient follow up, this 
will result in a higher absolute number of non-cardiovascular deaths in the ramipril 
than in the placebo arm. In the case of HOPE, the difference is small – only 8 more 
cases of non-cardiovascular death in the ramipril arm (Table 2) – but goes in the 
expected direction. Obviously, this must be taken into account when assessing the 
impact of ramipril on mortality and morbidity. Incorporating all-cause mortality in 
a combined endpoint such as that used in HOPE has the additional advantage of 
removing bias that may have affected the classification of the cause of death. Bias 
in cause of death classification can occur even in double blind trials.9,10 
The examples from the PICO4 and the Stockholm metoprolol5,6 trials expand 
on the relevance of event-free survival in therapy evaluation. Some treatments are 
associated with a risk of death that must be accepted in order to achieve sympto-
matic improvement, or avoid morbidity. Hip replacement is an obvious example. 
Were one to compare hip replacement with medical management in a large random-
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ised trial, there is no doubt that the hip replacement arm would show a higher mor-
tality than the medical management arm because of the risk of surgery. Mortality is 
not necessarily an appropriate surrogate for overall clinical benefit, and nobody 
seems to bother much about the surgical risk of hip replacement. The symptomatic 
improvement in survivors of surgery is apparently so important that the risk is con-
sidered worth taking. 
A similar situation exists with respect to drugs in the same class as pimoben-
dan. These drugs improve exercise capacity in patients with heart failure, but also 
increase mortality. The conventional presentation of the results of a trial such as 
PICO is a per-protocol analysis for the continuous outcome of interest. While in-
formation on clinical outcome is usually given also, it is generally not possible to 
summarise from published results the data in the same manner as in Table 3. Be-
cause of this it is impossible to judge whether the higher mortality risk negates 
symptomatic improvement. Therapy selection requires a value judgement. Those 
who are severely disabled by reduced exercise capacity may want to take the drug 
to increase the chance of enjoying symptomatic improvement. Those who are more 
concerned about dying will avoid the drug. It should be emphasised that only a 
presentation of the data as in Table 3 can show whether there is room for personal 
preference in treatment selection. Had the mortality in the pimobendan group been 
even higher, it is conceivable that the difference between the groups concerning the 
chances of being alive after 24 weeks and being able to exercise at least as well as 
at baseline would have disappeared completely. This could occur even if an analy-
sis confined to patients who were able to undergo exercise testing at 24 weeks 
showed a positive effect.  
We consider it inappropriate to use the term ‘intention-to-treat’ when analysis 
is confined to patients who were able to undergo exercise testing at 24 weeks. Such 
an analysis should perhaps be called ‘pseudo intention-to-treat’ to distinguish it 
from a real intention-to-treat that incorporates all patients randomised, as is the 
case in a mortality trial. Carrying forward the last available exercise duration value 
obtained for patients who died or who were unable to exercise does not solve the 
problem of ‘pseudo-intention-to-treat’. All patients randomised may be included in 
the analysis, but the reasons that follow up assessments were missed are ignored. In 
the PICO trial, the positive effect on exercise capacity was partly negated by the 
trend towards a higher mortality in patients treated with pimobendan. Had this 
trend been in the other direction, incorporation of mortality in the analysis for ex-
ercise capacity would have enhanced the apparent treatment effect. It is generally 
accepted that drugs from the same class as ramipril reduce morbidity and mortality 
in patients with heart failure, but do not have a major effect on exercise capacity. A 
reanalysis of data from exercise capacity trials with ramipril in heart failure has 
shown that the latter conclusion may have been the result of failing to take morbid-
ity and mortality into account when analysing the effect of these drugs on exercise 
capacity.11 
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The example taken from the Stockholm metoprolol trial6 shows how an analy-
sis that combines several different types of follow up information available at one 
time point (as for the PICO trial4) can be extended to several time points. This 
method is particularly suited to describe effects on morbidity and mortality ob-
served in trials with a long duration of follow up. In the Stockholm metoprolol 
trial, the treatment both prolonged mean survival and mean survival without symp-
toms.6 In the case a certain treatment reduced mean survival because of an in-
creased mortality risk, but prolonged mean survival without symptoms because of a 
positive effect on symptoms, an analysis of this nature would show this. Hence, 
such methods should be particularly appropriate to assess therapies that combine a 
positive effect on symptomatic status with no or an adverse effect on mortality. The 
Stockholm metoprolol trial had a fixed planned follow up of three years. This is not 
required for this analysis method; individual survival times and their subdivisions 
can readily be calculated also for trials with a variable duration of follow up. 
An essential feature of Kaplan-Meier curves showing the probability of free-
dom from hospitalisation for worsening heart failure as in Figure 1 is that death 
preceding hospitalisation is considered as censoring. Kaplan-Meier analysis is 
based on the assumption that “there is no information in the times of censored ob-
servation”.12 In our view censoring for death is a violation of this principle. The 
same objection can be made to the Kaplan-Meier curves showing the probability of 
the primary endpoint over time that may be found in the reports on the HOPE3 and 
other trials.7,8 Censoring because of non-cardiovascular death cannot be considered 
as non-informative. 
Although exceptions can be quoted both from past13 and from ongoing trials,14 
ignoring non-cardiovascular death from a cardiovascular combined primary end-
point has become widespread at least in cardiovascular disease trials. One reason 
for this may relate to the temptation of choosing the primary endpoint such that one 
can expect the p-value to be as low as possible. Including non-cardiovascular 
deaths in a cardiovascular combined primary endpoint will generally lead to higher 
p-values unless the treatment reduces non-cardiovascular death also. This effect on 
the p-values-to-be is entirely predictable and the statement that ‘it was pre-
specified to consider only cardiovascular death in the primary analysis’ is neither 
reassuring nor relevant. 
We have dealt neither with the question how to assess the overall statistical 
significance of differences between groups for any of the analyses discussed, nor 
how to assess the statistical significance of the individual components of a com-
bined endpoint. The analysis for the PICO trial4 summarised in Table 3 is an exam-
ple of a worst-rank score analysis with informatively missing observations as dis-
cussed recently by Lachin.15 Power calculation methods for composite ranking of 
survival and non-fatal outcome have been published by McMahon et al.16 These 
authors deal with the power of a rank test, assuming that the treatment has a bene-
ficial effect on the non-fatal outcome but no effect on mortality. This assumption 
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may not always be tenable and further theoretical development in this area would 
be valuable.  
The examples given focused on single trials. The same methods could be used 
in meta-analyses. For instance, one could estimate survival curves based on several 
large mortality trials. From other studies one could obtain estimates of ranked 
symptomatic status for survivors at various time points. Results could then be 
combined into sets of curves showing survival in each category of symptomatic 
status considered and could then be presented in the same form as in Table 4 based 
on a surface area calculations. 
Finally, it must be noted that the use of a combined endpoint should be con-
sidered in the design stage of a trial. As an example, consider again an exercise ca-
pacity trial in patients with heart failure such as PICO. In the latter, follow up exer-
cise tests were also performed in patients who had been withdrawn from study 
medication.4 It is customary to define both the primary endpoint and the primary 
analysis for the endpoint chosen before the trial starts. If the primary analysis 
specified is a per-protocol analysis confined to patients who had their follow up 
assessments of the chosen endpoint while still on study medication, it is tempting 
to omit the assessments that remain after premature withdrawal of study medication 
because these will not be used in the primary analysis. The protocol of the PICO 
trial specified that exercise tests had to be performed as planned also in patients 
who were withdrawn from study medication before the end of the study. Had this 
not been done, the ranked analysis at the end of follow up presented earlier would 
not have been possible. It should be standard practice always to perform all as-
sessments as planned also for patients who are withdrawn from study medication 
ahead of schedule. 
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ABSTRACT 
Aims: To present the design of ACTION (A Coronary disease Trial Investigating 
Outcome with Nifedipine GITS), an ongoing multi-centre clinical outcome trial 
with nifedipine GITS (Gastro-Intestinal Therapeutic System) in patients with stable 
angina pectoris. 
Methods: At least 6,000 patients with optimally treated stable angina without de-
pressed left ventricular function are randomised in equal proportions to either 
nifedipine GITS or matching placebo (starting dose 30 mg, maintenance dose 60 
mg once daily). Patients are followed for at least four years. The primary endpoint, 
to be analysed by assigned treatment, includes all-cause mortality, acute myocar-
dial infarction, emergency coronary angiography for refractory angina, overt heart 
failure, debilitating stroke and peripheral revascularisation. For this endpoint, the 
trial has a power of 95% to detect a relative risk reduction of 18% at the 5% level 
of significance, and is large enough to exclude an excess mortality caused by 
nifedipine GITS of 3·1 deaths per 1,000 years of treatment or greater. The pre-
specified early termination rule is more conservative in the case of a beneficial ef-
fect than in the case of an adverse effect of nifedipine GITS. The first patient was 
randomised on November 29, 1996. By the end of April 1998, about 5,200 patients 
had been started on study medication. 
Conclusions: Results will be available in the autumn of 2003. 
Chapter 4 
40 
The most common symptoms in patients with stable atherosclerotic coronary artery 
disease are regular attacks of anginal chest discomfort due to transient myocardial 
ischaemia.1 The clinical management of this ‘stable angina’ syndrome has two ob-
jectives: to prevent or alleviate anginal attacks, and to prevent complications of the 
disease (such as sudden cardiac death, myocardial infarction and overt heart fail-
ure). Despite important recent advances (coronary revascularisation, lipid lower-
ing), current treatment provides no cure and many patients remain symptomatic. 
Hence, maintenance treatment with anti-anginal drugs is often needed. 
For many years, nitrates, beta-blockers and calcium channel antagonists 
(CCAs) have been the cornerstones of treatment for angina.2,3 Nifedipine is the 
most widely used CCA for this indication. Historically, anti-anginal drugs have 
been introduced based primarily on proof of efficacy in reducing the symptoms. 
Their long-term safety has been of less concern although the safety of some anti-
anginal drugs (notably the beta-blockers) is supported by the positive results of 
trials in patients with a history of acute myocardial infarction.4 All this has changed 
due to the recent debate on the safety of CCAs, which resulted from a meta-
analysis of trials in coronary disease5,6 and observational data in hypertension.7 The 
single most important conclusion on which all sides in this debate agreed is that 
there is a lack of data from well-designed long term trials.8-16 
ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine 
GITS) is a multi-centre, randomised, double blind, placebo controlled trial that has 
started recruitment on November 29, 1996. Its primary objective is to assess, rela-
tive to placebo, the effect of nifedipine on the cardiovascular event-free survival of 
ambulatory patients who otherwise receive optimal treatment for stable angina and 
who do not have severely depressed left-ventricular function. The planned sample 
size is at least 6,000 patients with mean treatment duration of five years. 
ACTION is the first large-scale trial with an anti-anginal drug in patients with 
stable angina that focuses on the long-term clinical outcome rather than on the an-
ginal symptoms. The GITS (Gastro-Intestinal Therapeutic System) extended-
release formulation of nifedipine is used. During its passage through the intestine, 
the GITS tablet releases active substance at a constant rate. Chronic once daily ad-
ministration results in an even plasma level above the therapeutic minimum con-
centration for 24 hours.17 The debate on the safety of nifedipine was based on data 
from studies using the original capsule formulation of this compound, which causes 
large plasma variations.18 It is therefore opportune that the ACTION trial is under-
taken, not only because of the general concern about the safety of CCAs, but also 
because a GITS formulation of nifedipine has become available that avoids large 
plasma concentration variations. This potentially more optimal formulation17,19,20 
has thus far not been tested in large scale long term trials in patients with stable 
angina. Below, we describe the main design features of this ongoing trial. 
ACTION is not the only trial that will provide data on the long term safety of 
nifedipine GITS. To assess the efficacy and safety in hypertension of the same 
CCA, the INSIGHT (International Nifedipine GITS Study – Intervention as a Goal 
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in Hypertension Treatment) trial was mounted.21 Recruitment of INSIGHT was 
completed in 1995 and 6,570 patients have been randomised. Results are expected 
in 1999. 
TRIAL ORGANISATION 
ACTION has been designed and is carried out by an independent research group. 
The role of the sponsor (Bayer) is limited to drug supply and on-site monitoring. 
The sponsor is not involved in data base management and has no direct access to 
the study medication code (see also below). A brief overview of the organisational 
structure of ACTION is as follows (a list of participants is given in Appendix I): 
 
Coordination 
The trial is coordinated by an independent research institute, which is responsible 
for overall trial management, data base management, quality assurance and report-
ing. These tasks are handled from two regional coordinating centres: one for Can-
ada and one for the rest of the world. The same research institute is also responsible 
for the scientific programme of all trial related meetings. 
 
Investigators 
More than 300 investigators in 19 countries in Europe, Canada, Israel, Australia 
and New Zealand are participating. Most of these are hospital-based cardiologists. 
A complete list of participating centres can be obtained upon request. Investigators 
are required to inform the Steering Committee about participation in other studies 
that compete for the same type of patient. 
 
Steering Committee 
This committee approved the final version of the protocol and maintains scientific 
integrity while the trial is ongoing up to reporting of the main results. It has no ac-
cess to the study medication code and has an independent chairman. The protocol 
specifies that members, who also represent the various participating countries, must 
discuss potential conflicts of interest with the chairman. Meetings are usually at-
tended by designated non-voting representatives of the other parties involved but 
the committee meets also in the absence of these. 
 
Executive Committee 
This committee consists of the chairman, the three co-chairmen of the Steering 
Committee and designated representatives of the other parties involved. It is re-
sponsible for day-to-day management of the trial. 
 
Data Monitoring and Ethical Review Committee 
This committee consists of four clinical scientists with a statistician-chairman who 
are otherwise not involved in any way with the trial or its sponsor. Its main task is 
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to perform the pre-specified interim analyses. The random treatment allocation plan 
for the trial was generated by the chairman and access to the study medication code 
is controlled by him. 
 
Critical Events Committee 
This committee, which consists of six investigators and an external neurologist, 
decides on the final diagnostic classification of critical clinical events. 
 
Core laboratories for echocardiography 
Locally recorded echocardiograms are analysed centrally by a standardised com-
puter-assisted method at the core laboratories of the regional coordinating centres. 
Investigators cannot participate in the study before the core laboratory has ap-
proved a test recording. 
 
Study medication supply 
Study medication for clinics in Canada and Israel is packed and supplied by the 
pharmacy of Bayer Inc, Etobicoke, Ontario, Canada. Medication for the rest of the 
world originates from the pharmacy of Bayer AG, Leverkusen, Germany. 
 
On-site monitoring 
During recruitment each centre is monitored on site according to good clinical 
practice (GCP) every six to eight weeks. After recruitment has been completed, the 
frequency will be reduced to every three months. Local Bayer subsidiaries are re-
sponsible for on-site monitoring. In some countries, sub-contractors have been en-
gaged by the sponsor. 
 
Endpoint verification 
For all serious adverse events, the documentation and relevant patient data are veri-
fied on-site by coordinating centre personnel before the data are submitted to the 
Critical Events Committee for diagnostic classification. 
 
Auditing 
The trial will be audited by the Clinical Quality Assurance department of the spon-
sor. In addition, independent audits may be performed upon instruction from the 
Steering Committee. 
ETHICS 
ACTION is carried out in accordance with the provisions of the Declaration of 
Helsinki (last revised version, 1987) and ICH guidelines for good clinical practice 
(GCP). 22 Local ethics committees approved the protocol and the informed consent 
procedure for each centre. The trial is monitored on-site according to GCP. 
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To protect patient safety while the trial is in progress, an independent monitor-
ing committee (see trial organisation) will perform pre-specified interim analyses. 
PATIENT SELECTION 
ACTION focuses on the following three subgroups of patients with angina pecto-
ris: 
1. those with a history of acute myocardial infarction who have had angina ever 
since, or have developed angina again after an angina-free period; 
2. those who had a coronary revascularisation procedure but continued to have 
angina, or developed recurrent angina; 
3. those who have angina presumably caused by coronary artery disease, but have 
no history of infarction or revascularisation. 
The specific inclusion and exclusion criteria are listed in Table 1. 
 
Table 1: Selection criteria 
Inclusion criteria 
1. Age 35 years or older. 
2. In a stable clinical condition for at least one month while requiring oral and/or 
transdermal treatment for symptomatic angina either to prevent, or to treat, 
anginal attacks. 
3. On unchanged oral treatment for symptomatic angina without a calcium chan-
nel blocker during the last two weeks. 
4. Presence of at least one of the following criteria for coronary artery disease: 
4.1 Unequivocal myocardial infarction (presence of two of the following three: 
typical chest pain lasting at least 30 minutes, cardiac enzymes at least 
twice the upper limit of normal, ECG changes typical for acute myocardial 
infarction) at least three months prior to start of study medication. 
4.2 PTCA or CABG at least three months prior to start of study medication. 
4.3 Coronary artery disease documented by angiography. 
4.4 If coronary angiography has never been performed: a positive exercise 
test ( 1 mm ST-depression at maximal exercise), or a perfusion defect 
(thallium scan). 
5. Screening left-ventricular ejection fraction at least 40%. 
6. On lipid-lowering treatment, if such treatment is indicated based on current 
internationally accepted guidelines. 
7. Ambulatory, able to come to the out-patient clinic on his/her own and willing to 
participate based on a signed Declaration of Consent in accordance with na-
tional laws and regulations. 
Exclusions related to medical history 
1. Coronary or peripheral revascularisation; acute myocardial infarction, unstable 
angina, syncope, stroke or major surgery within three months before start of 
study medication. 
2. Planned coronary angiography or revascularisation (PTCA or CABG). 
3. Known intolerance to dihydropyridine calcium channel blockers. 
4. Clinically significant valvular disease. 
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5. Severe obstructive airway disease. 
6. Unstable insulin-dependent diabetes mellitus requiring frequent changes in 
insulin dosing. 
7. Chronic or intermittent diarrhoea, ulcerative colitis, regional enteritis or any 
other gastro-intestinal condition that could result in incomplete absorption of 
nifedipine GITS. 
8. Severe gastro-intestinal stenosis which could hinder the passage of GITS tab-
lets. 
9. Presence of any condition other than coronary artery disease which limits life 
expectancy. 
Exclusions related to current symptoms or findings 
10. Clinically significant heart failure, based on the presence of at least two of the 
following: in NYHA class II or higher, peripheral oedema, presence of rales 
over two-thirds of the chest, pulmonary congestion on a chest X-ray, cardio-
thoracic ratio greater than 0·5. 
11. Symptoms of orthostatic hypotension or supine systolic blood pressure 90 mm 
Hg or lower. 
12. Systolic blood pressure 200 mm Hg or higher and/or diastolic blood pressure 
105 mm Hg or higher despite blood-pressure lowering treatment. 
13. Plasma or serum creatinine above twice the local upper limit of normal. 
14. Alanine aminotransferase (ALAT; old name GPT = glutamic-pyruvic transami-
nase) or aspartate aminotransferase (ASAT; old name GOT = glutamic-
oxaloacetic transaminase) above three times the local upper limit of normal. 
Exclusions related to current treatment 
15. On a daily dose of diuretics exceeding 20 mg furosemide, 5 mg bendroflume-
thiazide or equivalent. 
16. On combination therapy with an ACE-inhibitor and a diuretic for heart failure. 
17. Treated with any of the following which could not be stopped: calcium channel 
blockers, cardiac glycosides (unless given for supra-ventricular arrhythmias), 
other positive inotropic agents, class I or III anti-arrhythmics other than amio-
darone or sotalol, cimetidine, anti-psychotic and anti-epileptic drugs, rifampicin 
or rifampine. 
Miscellaneous exclusions 
18. Problems with compliance or follow up anticipated. 
19. Pregnancy, breast feeding or risk of pregnancy (fertile women using an ac-
ceptable method of contraception according to local regulations can partici-
pate). 
20. Participation in another trial or study. 
 
Only patients in stable clinical condition who require oral and/or transdermal 
treatment either to prevent, or to treat, anginal attacks are eligible. It is not required 
that patients are actually symptomatic at the moment study medication is started; it 
suffices that in the past anti-anginal treatment was started specifically to treat angi-
nal attacks. 
As nifedipine is contra-indicated in patients with depressed left ventricular 
function, inclusion criterion 5 (Table 1) specifies that the left-ventricular ejection 
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fraction must be at least 40%. To establish that this is the case, a two-dimensional 
echocardiogram must be made during screening. This is recorded on videotape and 
re-analysed centrally. Investigators are not required to postpone start of study 
medication until the Core Laboratory has also assessed the ejection fraction. If an 
echocardiogram could not be obtained (some patients have an unsuitable anatomy 
for this purpose), participation based on an ejection fraction value measured by 
another method is allowed. Other criteria are used to exclude patients who may 
develop heart failure because of another cardiac condition (exclusion criterion 4, 
Table 1), or already have clinical heart failure (exclusion criterion 10 and 15-17). 
The remaining exclusion criteria in Table 1 either refer to incompatible medication 
which cannot be stopped, or to co-morbidity that could interfere with the assess-
ment of the effect on nifedipine GITS on cardiovascular event-free survival. 
ENDPOINTS 
The primary endpoint is the combined rate of death from any cause, unequivocal 
acute myocardial infarction, emergency coronary angiography for refractory an-
gina, hospitalisation for overt heart failure, debilitating stroke, and peripheral re-
vascularisation. This endpoint can also be viewed as ‘cardiovascular event-free 
survival’, i.e. survival free of the events mentioned. 
All patients will be followed for all events that may occur until death or until 
the planned end of the trial. Hence, event rates will also be reported separately for 
each specific event incorporated in the primary endpoint. Unless done on an emer-
gency basis, coronary angiography and coronary revascularisation procedures 
without complications are not included in the primary endpoint. 
The occurrence of the events incorporated in the primary endpoint is moni-
tored by standard reporting procedures for serious adverse events. As soon as a se-
rious adverse event has been reported, investigators are required to supply addi-
tional pre-specified clinical information to allow for diagnostic classification by the 
Critical Events Committee according to pre-set criteria. This committee has no ac-
cess to the study medication code, even if the treating physician has broken the 
code to decide on further treatment in an emergency. 
STUDY MEDICATION DOSE, SUPPLY AND BLINDING 
The study medication (which is added to treatments already in use, see below) con-
sists of either nifedipine GITS or matching placebo. The starting dose is 30 mg 
once daily. If this is well tolerated, the dose must be increased to 60 mg once daily 
within six weeks. Study medication is then continued at this dose until the planned 
end of the trial (i.e. at least four years for the last patient started on study medica-
tion). If signs of intolerance to the treatment regimen occur, investigators are en-
couraged to first attempt resolving the problem by adjusting the concomitant medi-
cation regimen. If this is not successful, the dose of study medication may be re-
duced again to 30 mg; or study medication may be interrupted. Clinical situation 
permitting, investigators are always allowed to either restart study medication; or 
Chapter 4 
46 
increase the dose to 60 mg. The aim is to keep patients on study medication as 
much as possible. The only restriction is that ejection fraction must be reassessed 
by echocardiography, and must be above 40%, before study medication can be re-
started after a clinical event that could have reduced ventricular function (such as 
acute myocardial infarction, bypass surgery). 
In the case study medication had been started in violation of the selection cri-
teria, investigators are instructed by the coordinating centre to stop study medica-
tion. 
Initially study medication was allocated centrally by telephone every time the 
patient visited the clinic. Because of logistic problems, this system was stopped in 
March 1997 and replaced by a conventional system of drug supply and preserva-
tion of blinding. This included the generation of a new random treatment allocation 
plan, stratified by centre. Centres are now supplied directly by the pharmacies of 
the sponsor with numbered study medication packs that contain both the 30 and 60 
mg dose for at least six months of treatment. No telephone call is required to iden-
tify the study medication to be handed out. 
Blinding is maintained throughout in several ways. The chairman of the Data 
Monitoring and Ethical Review Committee generated the currently used random 
treatment allocation plan and sent one copy to each of the two pharmacists respon-
sible for packing purposes only. Coding envelopes for emergency unblinding by an 
investigator were also prepared. The on-site monitors check that these normally 
remain unopened. Unblinding for the purpose of reporting to regulatory authorities 
can only be obtained on a case by case basis through protected access to a tele-
phone system operated by the chairman of the monitoring committee. A treating 
physician other than the investigator who has no access to the coding envelope can 
also use this system in a medical emergency. All instances of code breaking are 
reported to the coordinating centre (without mentioning the actual code to maintain 
blinding). The coordinating centres have no access to the study medication code 
until the end of the trial. For the purpose of confidential interim analyses, the 
chairman of the monitoring committee will combine the code with data supplied by 
the coordinating centres. 
CONCOMITANT TREATMENT 
After start of study medication, all patients continue to receive the concomitant 
treatment regimen on which they have been stabilised before. Drugs that cannot be 
combined with study medication are specified in the selection criteria (see Table 1). 
During screening, any patient not already on lipid lowering treatment must be 
evaluated for this treatment based on at least a screening assessment of total choles-
terol. Investigators are free how to assess and treat elevated lipids, but must comply 
with current nationally accepted guidelines for lipid lowering.23 In patients who 
appear to require lipid lowering during screening, treatment must be started at least 
one week before start of study medication. 
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Participation in ACTION does not restrict access to other generally accepted 
anti-anginal treatments other than CCAs. There are no restrictions as regards 
changes in concomitant treatment after start of study medication provided that the 
adjustments made are compatible with the use of nifedipine. Coronary revasculari-
sation may be performed to treat angina that cannot be managed satisfactorily by 
adjusting the concomitant treatment regimen. Whether study medication is contin-
ued or interrupted during such a procedure, or during any other clinical event, is 
left to the discretion of the investigator. Study medication must be interrupted how-
ever when an indication arises for compounds mentioned in exclusion criterion 17 
(Table 1). 
FOLLOW UP 
Two and six weeks after start of study medication, patients are seen at the out-
patient clinic to assess whether the dose of study medication can be increased to 60 
mg once daily. From then onwards the patient must be seen at the outpatient clinic 
at least every six months, and must be contacted in-between by telephone. 
During outpatient clinic visits, the evolution of symptoms and signs, vital 
signs, changes in concomitant treatment and compliance with study medication 
must be documented. Also, a standard 12-lead electrocardiogram must be made. 
Routine laboratory tests are required 6 months after start of study medication; and 
after 2, 4, and 6 years. Telephone contacts require only that the patient is ques-
tioned about the evolution of symptoms and treatment compliance. 
Unscheduled clinic visits for moderate or severe adverse events must be 
documented in similar manner as planned visits. Laboratory tests, electrocardiogra-
phy and echocardiography (for assessment of ejection fraction when a decision 
must be taken about restarting previously interrupted study medication) done on 
clinical indication must be documented also. Otherwise, all clinical events and 
those diagnostic procedures which either carry a risk to the patient (such as an-
giography), or may affect treatment (such as exercise testing), must be documented 
as adverse events in a manner which is standard for phase III clinical trials. Serious 
adverse events must be reported to the coordinating centre within 24 hours of the 
investigator’s awareness. 
All patients who have taken at least one tablet of study medication (and are 
therefore considered as randomised) will be followed in this manner until a ‘com-
mon stopping date’ is announced to investigators. At present, this common stop-
ping date is planned for four years after the last patient has been randomised. 
Planned visits and contacts take place irrespective of withdrawal of study medica-
tion ahead of schedule as long as the patient is willing and able to co-operate. 
While participating in ACTION, patients are not allowed to participate in any 
other trial, ancillary or side-arm study unless this other trial or study has been ap-
proved by the Steering Committee. 
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DATA MANAGEMENT AND QUALITY ASSURANCE 
Investigators enter data directly on conventional Case Report Forms printed on 
triplicate NCR paper. These are arranged visit by visit and contain extensive in-
structions and relevant definitions. All treatments are recorded in treatment logs. 
Standard adverse event forms are used to document adverse events and relevant 
clinical procedures that have been carried out. After verification of the data entered 
according to GCP, one copy of each completed Case Report Form page is removed 
by the on-site monitor and sent immediately by mail to the coordinating centre. 
There, a concurrent database is maintained. All incoming forms, original standard 
12-lead electrocardiograms and copies of laboratory reports are scanned for elec-
tronic storage. After scanning, documents are archived. Data is entered in a spe-
cially developed relational data base management system. Data entry screens show 
the scanned document on the left half of the screen and the data entry fields on the 
right half. Scanned documents remain accessible on-line after data entry. The data 
entry module contains on-line range and logical checks. For data that are found 
missing, illegible or inconsistent, data clarification forms are generated which are 
sent to the on-site monitor for resolution. 
Certain events must be reported immediately by the investigator by telefax on 
pre-printed forms directly to the coordinating centre. Examples are: informed con-
sent and start of screening, start of study medication, serious adverse events and 
premature withdrawal of study medication. The reporting of serious adverse events 
complies with national regulatory requirements. 
STATISTICAL CONSIDERATIONS 
Sample size and power 
Of all trials reported before ACTION began, the Scandinavian Simvastatin Sur-
vival Study24 (4S) is closest as regards patient selection, size and duration of follow 
up. In the simvastatin arm of 4S, the combined hazard of death, acute myocardial 
infarction, emergency coronary angiography for refractory angina, overt heart fail-
ure, debilitating stroke and peripheral revascularisation (the primary endpoint of 
ACTION) was about 5·6 events per 100 patient-years (see Appendix II). This haz-
ard was used as a basis for sample size calculations. 
The planned size is 6,000 patients divided equally between nifedipine GITS 
and placebo who are followed for a minimum of four, and a mean of five years. For 
this size and mean follow up, the magnitude of the effect of nifedipine relative to 
placebo (expressed as a hazard ratio) that can be detected with a given power was 
calculated for varying assumptions about the hazard of the primary endpoint in the 
placebo arm (see Appendix II). Results are shown in Figure 1 (next page). 
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Figure 1: The hazard ratios that can be detected with a given power for a 
given hazard in the placebo arm 
Assuming N = 3,000/arm, mean observation time = 5 years and two-sided  = 0·05, the hazard ratio 
(vertical axis to the left) which can be detected with a given probability (power) is plotted for the 
power choices shown (uninterrupted curves) against the hazard in the placebo arm, expressed as 
number of events per 100 patient-years (horizontal axis). The figure also shows (+++ curve) the ex-
pected number of events in the placebo arm (vertical axis to the right) and a 50% power curve for 
detecting an adverse effect of nifedipine GITS. 
 
When the hazard of the primary endpoint in the placebo group is assumed to be 5·6 
(as in the simvastatin arm of 4S, see above), Figure 1 shows that ACTION has 95% 
power to detect a hazard ratio of 0·82 (i.e. an 18% reduction of the primary end-
point by nifedipine, relative to placebo) with a 5% two-sided level of significance. 
The power to detect hazard ratios of 0·86 (14% reduction) and 0·90 (10% reduc-
tion) is 80% and 50% respectively (Figure 1). These hazard ratios represent rela-
tively modest effects of nifedipine on the primary endpoint. 
ACTION is also undertaken to confirm that nifedipine GITS is safe for 
chronic clinical use. To assess the excess event rate attributable to nifedipine GITS 
that can be excluded when the event rates are equal in both treatment arms, two-
sided confidence intervals around a hazard ratio of one were calculated for varying 
assumptions about the hazard in the placebo group (see Appendix II). Results are 
shown in Figure 2 (next page). 
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Figure 2: Two-sided 90% and 95% confidence intervals around a hazard ratio 
of one for a given hazard in the placebo arm 
Assuming N = 3,000/arm, mean observation time = 5 years and two-sided  = 0·05, two-sided 90% 
(inner curves) and 95% (outer curves) confidence intervals (CIs) around a hazard ratio of one (verti-
cal axis to the left) are plotted for a given hazard in the placebo arm, expressed as number of events 
per 100 patient-years (horizontal axis). The figure also shows (+++ curve) the expected number of 
events in the placebo arm (vertical axis to the right). 
 
 
When the hazard of the combined endpoint monitored for safety (all-cause death, 
myocardial infarction and stroke) in both ACTION treatment arms is assumed to be 
3·2 per 100 patient-years (as observed in the simvastatin arm of the 4S study, see 
Appendix II), the 95% confidence interval ranges from 0·88 to 1·14 (around a haz-
ard ratio of one). The 90% confidence interval is shown also in Figure 2. Hence, 
when the combined rates of death, non-fatal acute myocardial infarction and stroke 
are as assumed, an increase in the rate of these events caused by nifedipine GITS in 
excess of 14% can be excluded with confidence. Assuming a mortality of 1·5 per 
100 patient-years (as in the simvastatin arm of 4S) in both treatment arms, the cor-
responding upper limit of the 95% confidence interval is 1·21. In absolute terms 
this represents the exclusion of an excess mortality of 3·1 deaths per 1,000 years of 
treatment or greater. 
For the hazards mentioned above, the hazard ratio’s which can be detected for 
a given power and the number of events to be expected (calculated with the formu-
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lae given in Appendix II, assuming n = 3,000 and t = 5 years) are tabulated in Table 
2. 
 
Table 2: Relative and absolute reductions which can be detected with a given 
power 
Hazard placebo arm 
(events/100 patient-
years) 
Hazard ratio 
Relative 
reduction 
(%) 
Expected 
number of 
events pla-
cebo 
Expected 
number of 
events 
nifedipine 
Absolute 
reduction 
5·58 (primary criterion 
for efficacy):      
95% power 0·82 18 731 614 117 
80% power 0·86 14 731 639 92 
50% power 0·90 10 731 667 64 
3·23 (primary criterion 
for safety):      
95% power 0·77 23 447 353 94 
80% power 0·82 18 447 373 74 
50% power 0·87 13 447 395 52 
1·45 (mortality):      
95% power 0·68 32 210 144 66 
80% power 0·74 26 210 158 52 
50% power 0·82 18 210 173 37 
N = 3,000/arm. Mean observation time = 5 years. Two-sided  = 0·05 
 
Guideline for early termination 
The guideline for early termination as defined in the protocol is reproduced in Ap-
pendix III. The guideline is based on 30,000 planned patient-years of follow up 
(6,000 patients with a mean follow up of 5 years) and distinguishes between a pre-
ventive and an adverse effect of nifedipine observed at a pre-specified interim 
analysis. For a preventive effect (efficacy), the criterion for early termination is the 
primary endpoint of the study evaluated after 10,000 and after 20,000 patient-years 
of follow up. For an adverse effect (safety), the criterion monitored is the combined 
rate of death of any cause, acute myocardial infarction and stroke. This criterion is 
evaluated after every 5,000 patient-years of follow up. Although the guidelines for 
efficacy and for safety are both based on a two-sided p-value of 0·05, the boundary 
shape is different. As a consequence, the boundary for efficacy is initially more 
conservative than for safety. 
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Statistical analysis 
The essential features of the planned statistical analysis are as follows. Two analy-
sis populations are distinguished: all-randomised and valid-for-efficacy. The former 
consists of all patients who have taken at least one tablet of study medication and 
the latter of the subset of patients who are documented to comply with the selection 
criteria. Using Kaplan-Meier plots and log-rank tests for comparing censored time-
to-event data, the primary endpoint will be analysed by assigned study medication. 
Effects of nifedipine GITS relative to placebo will be expressed as hazard ratios 
with 95% confidence intervals. Analyses will be presented both for the all-
randomised and for the valid-for-efficacy population but analyses for the all-
randomised population will be considered as ‘primary’. It is expected that the two 
analyses will give essentially the same results. 
To assess the relationship between patient characteristics at entry and event 
hazards, multivariate proportional hazard regression analysis according to Cox25 
will be used; with age, sex, NYHA class, ejection fraction, history of myocardial 
infarction, use of a beta-blocker at entry, use of lipid-lowering therapy at entry and 
use of a CCA before entry as pre-specified co-variates. Modification of the effect 
of nifedipine GITS by these patient characteristics (subgroup analysis) will be as-
sessed using interaction tests. 
In the protocol several secondary analyses are specified, some of which ad-
dress pharmaco-economic issues, generalisability to specific patient sub-groups 
based on a multivariate risk score and effect of nifedipine GITS on NYHA class 
over time.26 
CURRENT STATUS AND PLANNING 
The first patient was recruited on November 29, 1996. After 205 patients had been 
started on study medication, recruitment was interrupted on March 16, 1997 due to 
the problems encountered with central telephone allocation of study medication. 
After the drug supply system had been redesigned, recruitment was resumed on 
April 22, 1997. By the end of April 1998; about 5,200 patients had been random-
ised and recruitment was ahead of schedule. 
Recruitment is planned to be completed in July 1999 at the latest. To make up 
for patients who are entered in violation of selection criteria, it is expected that 
about 7,000 patients must be started on study medication. The last patient started 
will have a minimum of four years of follow up. Hence, the main results of 
ACTION are expected to be available in the autumn of 2003. 
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DISCUSSION 
ACTION is designed to resolve whether nifedipine GITS favourably affects the 
long-term clinical outcome of patients with stable angina (secondary prevention). 
Nifedipine GITS is registered in many countries for the treatment of anginal symp-
toms, but nowhere for secondary prevention. In the case the results of ACTION 
show that nifedipine GITS indeed has a secondary preventive effect, an expansion 
of its registered indications may be sought. For this reason, ACTION has not been 
designed as a phase IV trial of an already marketed drug, but as a phase III trial 
intended as a basis for registration. Its design follows the current standard pattern 
for phase III trials, including detailed case documentation, immediate reporting of 
serious adverse events and on-site monitoring according to GCP. 
Several design features of ACTION were a matter of debate before the trial 
was started. The selection criteria in earlier versions of the protocol required the 
presence of coronary artery disease but did not require that the patient be treated 
for anginal symptoms. In the light of the recent debate on the safety of nifedipine, 
it was considered inappropriate to treat asymptomatic patients with this compound 
even in the context of a clinical trial. Hence, inclusion was restricted to patients 
who are on anti-anginal treatment started to treat anginal symptoms (rather than for 
another indication, such as secondary prevention as in the case of a beta-blocker). 
Anginal symptoms must have occurred after the last infarct or revascularisation 
procedure. Hence, anti-anginal treatment other than a CCA (i.e. predominantly ni-
trates and/or beta-blockers) is part of the concomitant treatment regimen of all pa-
tients. It is therefore a limitation of ACTION that the study will not address the role 
of nifedipine GITS monotherapy in stable angina. 
As eventual conclusions based on trial results are customarily driven by p-
values, it is desirable to pre-specify one primary endpoint. All-cause mortality as a 
primary criterion was rejected for a variety of reasons. Death is not the only out-
come that matters in symptomatic patients. Also, there were doubts that mortality 
could significantly be reduced even further in a patient group with already a low 
mortality due to recent advances in treatment. This being so, a composite endpoint 
which takes into account several aspects of the effect of a treatment is the best al-
ternative. For ACTION, major cardiovascular event-free survival was adopted as 
the primary endpoint. All-cause mortality is by definition included in this endpoint. 
Non-fatal acute myocardial infarction, emergency coronary angiography for refrac-
tory angina, hospitalisation for overt heart failure, debilitating stroke and peripheral 
revascularisation were included as all of these represent cardiovascular morbidity 
which physicians aim to prevent when treating patients with stable angina. An ad-
ditional argument to include stroke and peripheral revascularisation was that these 
two might possibly also be prevented by nifedipine due to its blood pressure lower-
ing27,28 and anti-atherosclerotic effects.29,30 On the other hand, coronary revasculari-
sation procedures as such were not included as these nowadays are so frequent that 
they can hardly be considered as morbidity to be avoided unless peri-procedural 
complications such as infarction or stroke occur. The primary endpoint chosen cov-
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ers an important aspect of clinical safety since it includes death from non-
cardiovascular causes. It is conceivable that a drug induces an excess mortality but 
at the same time increases morbidity-free survival (as is the case for many common 
surgical procedures). If this is the case for nifedipine GITS, ACTION will show 
this. 
As regards the study medication, the option was considered to use 30 mg 
GITS tablets throughout and allow the investigator freedom to adjust the dose indi-
vidually while maintaining the blinding. This option was rejected because 60 mg 
nifedipine GITS once daily is the standard recommended dose. Also considered 
was the option to precede start of double blind study medication by an open-label 
run-in phase on nifedipine GITS to assess tolerance and initial effects of the drug 
on symptoms and vital signs. While this may provide relevant additional informa-
tion and allows exclusion of patients who do not tolerate the drug, this option was 
rejected because of the added complexity and because nifedipine GITS in the start-
ing dose of 30 mg once daily is generally well tolerated. 
The concomitant treatments that are allowed follow directly from the objec-
tives of ACTION and the type of patient involved. Patients with symptomatic an-
gina cannot be left untreated. Hence, all anti-anginal drugs and all other medication 
that can be combined with nifedipine are allowed as concomitant treatment. On the 
usual indications, a coronary revascularisation procedure may be performed at any 
time after start of study medication. The only restrictions are drugs that may inter-
act with nifedipine, or are used for a cardiac or another condition that renders the 
patient unsuitable for the trial. 
Lipid lowering as a component of the concomitant treatment regimen is of 
special interest as lipid lowering has been shown to have important secondary pre-
ventive effects in patients with coronary artery disease.24 If investigators were left 
completely free in prescribing lipid lowering, and if the occurrence of symptomatic 
angina induces clinicians to assess lipids and start lipid lowering treatment, the 
fraction of patients using this treatment at the end of the trial in the placebo arm 
would be higher than in the nifedipine arm despite randomisation and double blind-
ing. When this occurs, nifedipine would not have a fair chance to show a secondary 
preventive effect. To prevent unbalance as regards lipid lowering as much as possi-
ble, investigators are required to evaluate all patients for this type of treatment dur-
ing screening, and start treatment before start of study medication if indicated. 
After an initial estimate, detailed sample size calculations were performed to 
assess the power of the trial for the sample size and duration of follow up chosen. 
The guideline for early termination after an interim analysis was constructed in 
such a way that the overall significance level assumed in the power calculations is 
maintained. The methods used are standard and computationally simple (see Ap-
pendix II) but the presentation of the results in Figure 1 is perhaps unusual. The 
figure shows that the hazard ratio that can be detected with a given power depends 
strongly on the event hazard in the placebo arm for low event rates. For higher 
event rates, the relationship is less steep. The hazard of the primary endpoint in the 
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placebo arm of ACTION is likely to be higher than the hazard of the same endpoint 
in the simvastatin arm of the 4S study24 on which sample size calculations were 
based (see Appendix II) as all patients in this arm of 4S were treated with a potent 
lipid lowering agent. In ACTION this is unlikely to be the case. 
The power calculations showed that ACTION has ample statistical power to 
detect relatively small effects on cardiovascular event-free survival. The trial is on 
the other hand likely to be criticised by some as having insufficient power for mor-
tality only. This potential criticism has been specifically considered by a panel of 
international experts which was consulted while the design was finalised. Based on 
the calculations performed to assess the excess mortality which can be excluded 
with confidence in the case the mortality turns out to be the same in both treatment 
arms (see also Figure 2 and Appendix II), there was unanimous agreement that the 
chosen sample size of ACTION is sufficient to assess the clinical safety of a drug 
of which the efficacy in treating anginal symptoms is not in dispute. 
The guideline for early termination (see Appendix III) is initially more con-
servative in the case of a beneficial than in the case of an adverse effect of nifedip-
ine GITS. Various arguments can be made that a guideline for early termination 
should be asymmetrical. The reason in this case was that nifedipine GITS has no 
future when interim data show an adverse effect on the endpoints monitored for 
safety (death, myocardial infarction and stroke) as alternative anti-anginal agents 
are available. On the other hand, when no safety problem in this sense is observed 
‘ad interim’ there is interest to complete the trial as planned in order to estimate the 
magnitude of any positive effects precisely. The guideline is constructed in such a 
way that there is probability of 0·025 that nifedipine GITS is declared unsafe while 
in fact no adverse effect on the endpoints monitored for safety exists. 
An important question that must be considered already in the design phase of 
a trial is how to handle patients who are started on study medication in violation of 
the selection criteria. Under pressure to recruit, investigators tend to develop their 
own opinions on the interpretation and/or the clinical relevance of certain selection 
criteria. Hence, the inclusion of patients who are in fact not eligible is unavoidable 
unless the data are verified for each individual patient still in screening before in-
vestigators are allowed to start study medication. This is difficult to arrange in a 
large multi-centre trial and causes an additional burden to patients who must wait, 
or even come back another time, to hear whether clearance has been obtained to 
start study medication. 
To avoid ambiguity when the results are presented, the protocol requires that 
investigators must follow ineligible patients started on study medication until the 
planned end of the trial. Such patients are considered as belonging to the all-
randomised population in the analysis plan, which will be analysed based on the 
conventional concept of ‘intention-to-treat’ analysis. The protocol also specifies an 
analysis by treatment assignment that is confined to eligible patients only (the 
valid-for-efficacy population). This analysis will show whether the primary analy-
sis is unduly distorted by the presence of ineligible patients. 
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The strategy for the handling of ineligible patients has unwanted consequences 
for trial management. Investigators who are required to follow ineligible patients as 
planned require to be supported for this. This is in fact an extra incentive for inves-
tigators to start study medication in ineligible patients. By diligent monitoring and 
exclusion of investigators who repeatedly start study medication in ineligible pa-
tients an effort is made to limit the number of ineligible patients entered into 
ACTION. At the same time a scientific discussion on how to handle ineligible pa-
tients entered in clinical trials is overdue. 
The protocol prohibits that patients participate also in another trial or study 
unless approved by the Steering Committee. This was inserted to discourage inves-
tigators to arrange ancillary studies of their own that may interfere with the objec-
tives of ACTION. While the trial was designed, it was proposed to assess both 
clinical and coronary angiographic outcomes in one large trial by also performing 
angiography during follow up in all patients. Complications that result from an-
giography for the purpose of a clinical study must be counted as clinical events but 
are unlikely to be affected by treatment. This would tend to dilute the effect of 
treatment on clinical outcome. For ethical reasons, angiograms for purpose of a 
clinical study cannot be left unanalysed until the study is completed. Hence, the 
management of patients in a trial with angiographic outcomes will not be represen-
tative for ‘usual medical care’, with angiography done only on indication. Based on 
these considerations, the study procedures of ACTION were limited to what is 
‘usual medical care’ for patients with stable angina. Several ancillary studies in 
ACTION patients that do not require procedures that influence patient manage-
ment, or carry a risk, have been approved by the Steering Committee. Ancillary 
studies focusing on quality of life, coronary calcification assessed by fast computer 
tomography and non-invasive assessment of carotid intima-media thickness are 
underway in subsets of patients. The prognostic value of QT-dispersion is also as-
sessed in a subset, as is the evolution of left-ventricular mass by an additional 
echocardiogram at the end of the trial. In order to stay as close as possible to the 
intended nature of the trial, patients may participate only in one ancillary study that 
requires repeated additional procedures during follow up. 
Large randomised trials have been criticised because the results are difficult to 
generalise to individual patients seen in clinical practice. This may be so because 
the clinical entity entered in a trial is not well defined, the treatment studied is not 
what would normally be done in any case, and/or because the outcome assessed is 
not clinically relevant. In designing ACTION, an effort has been made to avoid all 
three. When the results become available in 2003, this study will redefine the use-
fulness of nifedipine GITS in patients with stable angina. 
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APPENDIX I 
ACTION participants are: 
 
PRINCIPAL INVESTIGATOR AND STUDY CHAIRMAN 
PA Poole-Wilson, Cardiac Medicine, National Heart & Lung Institute, Dove House Street, London 
SW3 6LY, UK, phone +44-171-351 81 79, fax +44-171-823 33 92. 
 
INVESTIGATORS 
313 centres in Australia (5), Austria (4), Belgium (6), Canada (49), Denmark (24), Finland (4), 
France(17), Germany(33), Greece(5), Israel(18), Italy(38), The Netherlands(28), New Zealand(3), 
Norway(18), Portugal(8), Spain(20), Sweden(17), Switzerland(3), UK(13). 
Regional Coordinating Centres: SOCAR Research SA, PO Box 2564, 1260 Nyon 2, Switzerland, 
phone, fax +41-22-994 43 09 (for Europe, Israel, Australia and New Zealand); SOCAR Cardiac 
Research Ltd., 4120 Yonge Street, Suite 306, North York, Ontario M4N 2G3 Canada, phone +1-416-
226 16 00, fax +1-416-226 44 40 (for Canada). 
 
SPONSOR 
Bayer AG, Leverkusen, Germany. 
 
STEERING COMMITTEE 
PA Poole-Wilson, London, UK (chairman); H Just, Freiburg, Germany (co-chairman); M. Motro, 
Tel-Hashomer, Israel (co-chairman); JD Parker, Toronto, Canada (co-chairman); MG Bourassa, 
Montreal, Canada; T Dart, Melbourne, Australia; J-M Detry, Brussels, Belgium; K Fox, Edinburgh, 
Scotland; P Hildebrandt, Frederiksberg, Denmark; A Hjalmarsson, Goteborg, Sweden; GP Molhoek, 
Enschede, the Netherlands, J-E Otterstad, Toensberg, Norway; P Rizzon, Bari, Italy; R Seabra-
Gomes, Carnaxide, Portugal; J Soler-Soler, Barcelona, Spain; S Weber, Paris, France. 
 
EXECUTIVE COMMITTEE 
PA Poole-Wilson (chairman); H Just, M Motro, JD Parker, BA Kirwan, J Lubsen, FJ van Dalen, AB 
Parker, M Llewellyn. 
 
DATA MONITORING AND ETHICAL REVIEW COMMITTEE 
SJ Pocock, London, UK (chairman); J-P Boissel, Lyon, France; WW Parmley, St-Francisco, USA; W 
Rutishauser, Geneva, Switzerland; L Wilhelmsen, Gothenburg, Sweden. 
 
CRITICAL EVENTS COMMITTEE 
N Danchin, Vandoeuvre-les-Nancy, France (chairman), A Battler, Beer Sheva, Israel; A Bayes de 
Luna, Barcelona, Spain; P Dunselman, Breda, The Netherlands; S Glasser, Tampa, USA; P 
Koudstaal, Rotterdam, the Netherlands; G Sutton, Uxbridge, UK. 
APPENDIX II 
Calculation of power and confidence intervals 
In the 2,221 patients allocated to simvastatin in the 4S study24 the following events 
were observed: 182 deaths, 164 definite non-fatal acute myocardial infarctions, 12 
intervention associated non-fatal acute myocardial infarctions and 47 non-fatal 
strokes. Overt heart failure requiring a change in heart failure treatment and refrac-
tory anginal chest pain were not specifically mentioned in the 4S report but are 
likely to have been incorporated in the 295 patients who had an ‘acute non-
myocardial infarction coronary heart disease’ event in the simvastatin arm. Taken 
Chapter 4 
58 
together this represents 700 events that are included in the primary endpoint of 
ACTION. 
The Kaplan-Meier estimate of the 5-year survival in the simvastatin arm was 
about 93% (cf. figure 1 of the original 4S report). Assuming that survival was ex-
ponential with a constant hazard (cf. equation 2 below), this corresponds with a 
hazard of death of -ln(0·93)/0·05 or 1·45 per 100 patient-years. Based on this 
data, the hazard of the primary endpoint to be expected in the placebo arm of this 
study is therefore of the order of 700 x 1·45/182 or 5·58 per 100 patient-years. 
Similarly, the expected hazard of the endpoints monitored for safety (based on 182 
deaths, 164 definite non-fatal acute myocardial infarctions, 12 intervention associ-
ated non-fatal acute myocardial infarctions and 47 non-fatal strokes or 405 events 
in 4S) is 405 x 145/182 or 3·23 per 100 patient-years. 
Power calculations were based on: 
1. the null-hypothesis (Ho) that there is no difference between allocation to 
nifedipine GITS and to placebo, 
2. a two-sided significance test for the rejection of Ho with a level  of 0·05, 
3. a planned sample size n of 3,000 per arm with a mean follow up by assigned 
treatment of five years. 
To assess the probability that Ho will be rejected (i.e. the power of this study) as a 
function of the risk reduction by nifedipine GITS and of the event hazard in the 
placebo arm, the following standard formula for the calculation of sample sizes 
when proportions in two equal groups are compared was used:31 
   
   n
p p p p
p p
f   

1 1 0 0
1 0
2
1 1. .
,    (1) 
In equation 1, p1 and p0 represent the event probabilities in the nifedipine GITS and 
placebo arms respectively. The power (1-) and the significance level  are set by 
the standard Normal distribution function f(,), which has values of 13·0, 7·9 and 
3·8 for a power of 95%, 80% and 50% respectively at a two-sided  of 0·05. 
Event probabilities were converted to hazards by exponential approximation, 
assuming a constant hazard:32 
p ei
h ti  1 .  for i = 1 and i = 0 (2) 
In this equation pi is as defined above and hi stands for the event hazard in a given 
treatment arm. As a mean observation time of 5 years is planned, t was set to 5 
years. 
For various choices of the event hazard ho in the placebo arm, po was calcu-
lated (by equation 2 with t = 5 years). Next, equation 1 was solved for p1 (with n = 
3,000) for each of the three values of f(,) given above. Using again equation 2, 
the p1 thus obtained was then converted to the corresponding hazard h1 in the 
nifedipine GITS arm. Finally, the hazard ratio was calculated as h1/h0. Results of 
these calculations are shown in Figure 1. 
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To calculate the expected lower and upper bounds of two-sided 90% and 95% 
confidence intervals around an observed hazard ratio (HR) equal to one, the follow-
ing formulas were used.33 The standard error of ln(HR) was taken as: 
  s e H R
e e
l n  1 1
1 0
 
where e1 and e0 stand for the number of events in the nifedipine GITS and placebo 
arms respectively. 
The lower and upper bounds LB and UB of a confidence interval (CI) of HR 
follow from: 
    HRsezHReUBLB lnln,   
For various choices of equal event hazards in the nifedipine GITS and placebo 
arms (h1 and ho), p1 and po were calculated (by equation (2) above, with t = 5 
years). From these, the expected numbers of events e1 and e0 were obtained, based 
on n = 3,000 per arm. Lower and upper confidence bounds around a hazard ratio of 
one were then obtained by the formula above by taking z = 1·645 for two-sided 
90% and z = 1·96 for 95% confidence intervals. Results of these calculations are 
shown in Figure 2. 
APPENDIX III 
Guideline for early termination 
The total number of patient-years of observation planned is 6,000 x 5 or 30,000 
patient-years. Interim analyses will be done each time an additional 5,000 patient-
years of observation has been collected (i.e. five interim and one final analysis). 
The first one will be performed shortly before the end of patient recruitment. 
The option to stop the trial because the combined hazard of death, acute myo-
cardial infarction and stroke appears to be increased by nifedipine GITS will be 
considered at each of these interim analyses and the trial will be stopped if the 
negative effect of nifedipine GITS (relative to placebo) on this combined rate is 
significant at the level of p = 0·01. This implies that there is a probability of 0·025 
(‘Pocock rule’34) that the trial will be stopped for an adverse effect on the endpoints 
monitored for safety while in fact no such effect exists. 
The option to stop the trial because the combined hazard of death, acute myo-
cardial infarction and stroke appears to be reduced by nifedipine GITS will be con-
sidered only at the 2nd and the 4th interim analysis mentioned above, i.e. only after 
10,000 and after 20,000 patient-years of observation have been collected. Based on 
a hazard in the placebo group of 3·23 per 100 patient-years, approximately 160 and 
320 cases of death, non-fatal acute myocardial infarction or stroke respectively are 
expected to have accrued at these time points in the placebo group. 
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The guideline for stopping is: 
first look: z > 3·47 (p < 0·0005), 
second look: z > 2·45 (p < 0·014). 
The calculation was performed with the EaStTM package35 to correct for ‘multiple 
looks’ in sample size calculation for survival data and was based on the following 
assumptions: 
1. two-sided  = 0·05 
2. a number of looks of three, 
3. boundary shape as described by O’Brien and Fleming.36 
It is noted that the z-values mentioned depend only on specific assumptions about 
, the number of looks and the type of boundary chosen. 
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Chapter 5 
Treatment of angina pectoris: associations with 
symptom severity 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
Objective: To evaluate whether the frequency of anginal attacks in medically 
treated patients with stable angina is related to the intensity of anti-anginal treat-
ment, the clinical history and coronary anatomy. 
Methods: Analysis of baseline data from the ACTION (A Coronary disease Trial 
Investigating Outcome with Nifedipine GITS) study, an ongoing placebo-
controlled trial in 7,669 patients with stable angina pectoris who require anti-
anginal treatment. 
Results: Prior to randomisation, 8% of 7,669 patients had no anginal attacks, 63% 
had occasional, 22% had regular, 4% had frequent and 3% had daily attacks. Men 
(79% of all patients) and patients with a history of MI (51%) had less frequent an-
ginal attacks (P<0·0001). The number of coronary angiograms ever performed 
(70% had at least one angiogram), the extent of angiographic coronary disease 
(32% of those who had angiography had more than two-vessel disease), a history 
of peripheral artery disease (12%), the number of anti-anginal drugs used (64% 
were prescribed two or more such medications) and a history of revascularisation 
(a history of coronary bypass surgery was present in 23% and of balloon dilatation 
in 26%) were each positively associated with anginal attack frequency. 
Conclusions: For the majority of patients with chronic stable angina not on a cal-
cium-antagonist, medical treatment with other anti-anginal drugs is sufficient to 
control symptoms and only a minority of patients are refractory to medical treat-
ment. Invasive treatments for chronic stable angina are only needed in a small pro-
portion where symptoms persist.  
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Stable angina pectoris caused by ischaemic heart disease (IHD) is an easily recog-
nised clinical entity. The frequency of anginal attacks is usually stabilised by the 
use of drugs tailored to the needs of the individual patient and the spectrum of 
treatment ranges from monotherapy to the use of multiple drugs and interventional 
procedures. Abnormalities found on coronary angiography vary greatly, even when 
only patients with typical angina pectoris without a history of myocardial infarction 
are considered.1 
The effect on symptoms of anti-anginal drugs used in clinical practice has 
been extensively assessed by placebo-controlled clinical trials but there is little 
evidence for a positive effect on mortality. The benefit from coronary artery bypass 
grafting (CABG) compared to medical treatment in selected patients with regard to 
symptoms and mortality is generally accepted.2 Percutaneous transluminal coro-
nary angioplasty (PTCA) has been shown to reduce angina but not mortality.3 Only 
limited information is available concerning to what extent treating physicians both 
attempt and succeed in reducing the frequency of anginal attacks, using therapies 
which have been proven in clinical trials. 
One way to address this question would be to perform an open randomised 
trial in patients who present with anginal symptoms, comparing a stepped protocol 
of medical and invasive treatment with no treatment at all. For ethical reasons such 
a trial will never be done. An alternative way of answering this question would be 
to determine whether there is a relationship between the frequency of anginal at-
tacks and the intensity of treatment in a cross-sectional study of patients with stable 
angina. If the degree of response to treatment varies between patients, one would 
expect such a study to show variability concerning the intensity of treatment 
amongst patients who report a similar frequency of anginal attacks. If some patients 
were more or less refractory to certain treatments, one would expect that patients 
who report frequent anginal attacks are treated more intensively than patients who 
have less frequent attacks. 
ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine 
GITS) is an on-going multicentre, prospective, randomised, double blind, placebo 
controlled trial. Its primary objective is to assess the effect of nifedipine on cardio-
vascular event-free survival of ambulatory patients who otherwise receive optimal 
treatment for stable angina. Its design and methods have been described else-
where.4 Prior to randomisation detailed data on the clinical history and current 
treatment were collected. These data allowed us to assess the associations between 
the frequency of anginal attacks and variables such as the intensity of medical 
treatment, the coronary anatomy and clinical characteristics. 
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METHODS 
Patients 
ACTION focuses on the following three subgroups of patients with angina pecto-
ris: 
1. Those with a history of acute myocardial infarction who subsequently had an-
gina or who developed angina after an angina-free period. 
2. Those with a history of coronary revascularisation who either continued to have 
angina or who developed angina after an angina-free period. 
3. Those with anginal complaints and a positive exercise test but without a history 
of myocardial infarction, coronary angiography or revascularisation. 
The ACTION inclusion and exclusion criteria have been described in detail else-
where.4 Angina pectoris was defined as typical chest discomfort localised in the 
central part of the chest with or without radiation and elicited by physical or psy-
chological stimuli. The symptoms were required to have been relieved gradually by 
rest or quickly by nitroglycerin. Included in the definition were breathlessness, fa-
tigue, or dyspnoea that behaved in a similar manner.5 Only patients in a stable 
clinical condition requiring oral and/or transdermal treatment either to treat, or to 
prevent, recurrent anginal attacks were eligible. It was not a requirement for pa-
tients to be symptomatic at the time of randomisation. It sufficed that anti-anginal 
treatment had been started in the past specifically to treat anginal attacks. Patients 
with clinical heart failure or an ejection fraction below 40% were excluded, as were 
patients with other important clinical conditions or contra-indications for nifedipine 
GITS. 
ACTION patients are followed up with 3-monthly contacts for a minimum of 
four years. The mean follow up will be five years and results are expected in 2004. 
 
Data collection 
The pre-randomisation data used in the present analysis was collected using a paper 
case report form (CRF). Using a pre-coded question, anginal attack frequency was 
documented as no attacks, occasional (less than one attack/week), regular (1 – 3 
attacks/week), frequent (4 – 6 attacks/week) or daily attacks. Functional class was 
rated using the New York Heart Association (NYHA) classification scale.6 The to-
tal number of coronary angiograms (CAGs), PTCAs and CABGs ever performed, 
the clinically significant lesions ever identified, and whether lesions were dilated or 
bypassed, were documented by items in the CRF as shown in Figure 1. Information 
concerning the history of myocardial infarction, claudication, transient ischaemic 
attacks and debilitating stroke was obtained by specific questions, as was informa-
tion concerning the presence of diabetes mellitus, smoking habits, hypertension and 
hyperlipidaemia treated with drugs. Details of treatments prescribed at the time of 
randomisation, body height and weight were also collected. Body mass index 
(BMI) was calculated according to the standard formula (weight in kg)/(height in 
m)2.  
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Figure 1: Items related to coronary angiography and to balloon dilatation 
(PTCA) as printed in the ACTION Case Report Form 
 
Statistical methods 
Proportions across frequency of anginal attack categories were compared by chi-
squared test for trend. Calculations were done using least-squares linear regression, 
which gives identical results.7 The dependent variable was always the frequency of 
anginal attacks, scored from 0 = none to 4 = daily. Dichotomous independent vari-
ables such as gender were scored as either 0 or 1. Least-squares linear regression 
analysis was also used to assess whether categorical variables were correlated with 
anginal attack frequency.  
Categorical variables were scored from zero to (N – 1), where N is the number 
categories considered. The following variables were considered in this manner: 
Number of coronary angiograms performed: 0 = none, 1 = one, 2 = more than one. 
Number of vessels with clinically significant lesions for all coronary angiograms 
performed: The number of specifically mentioned arteries as shown in Figure 1 
that were ticked by the investigator was counted. Left-main disease was considered 
as two-vessel disease.1 
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Table 1: Frequency of anginal attacks, NYHA class and history of cardiovascular disease 
  Frequency of anginal attacks*  
 Total None Occasional Regular Frequent Daily  
Total No. of patients 7,669 595 (8%) 4,869 
(63%) 
1,714 
(22%) 
290 (4%) 201 (3%) P-value# 
Age (years), median 
(range) 64 (35 – 89) 62 (35 – 88) 64 (35 – 88) 64 (35 – 89) 65 (36 – 85) 63 (39 – 89) 0·07 
Male gender 6,085 
(79%) 517 (87%) 
3,901 
(80%) 
1,304 
(76%) 219 (76%) 144 (72%) <0·0001 
In NYHA class I 4,137 
(54%) 521 (88%) 
2,825 
(58%) 654 (38%) 85 (29%) 52 (26%) <0·0001 
History of MI 3,890 
(51%) 307 (52%) 
2,557 
(53%) 802 (47%) 138 (48%) 86 (43%) <0·0001 
History of claudication 604 (8%) 41 (7%) 352 (7%) 158 (9%) 24 (8%) 29 (14%) 0·0001 
History of TIA 296 (4%) 20 (3%) 180 (4%) 68 (4%) 16 (6%) 12 (6%) 0·04 
History of debilitating 
stroke 132 (2%) 11 (2%) 81 (2%) 27 (2%) 10 (3%) 3 (1%) 0·5 
Any peripheral artery 
disease§ 938 (12%) 69 (12%) 559 (11%) 226 (13%) 41 (14%) 43 (21%) <0·0001 
Except for the top row, percentages are given for each category of attack 
frequency = 100%. NYHA, New York Heart Association; MI, myocardial 
infarction; TIA, transient ischaemic attack. 
* Occasional, less than one attack/week; regular, 1 – 3 attacks/week; fre-
quent, 4 – 6 attacks/week; daily, at least one attack every 24 hours. 
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# For test of trend across categories of attack frequency (c.f. statistical 
methods). 
§ Claudication and/or TIA and/or debilitating stroke. 
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Outcome of previous PTCA: Only specifically mentioned arteries as shown in Fig-
ure 1 were considered if ticked by the investigator. The result was scored as fol-
lows: 0 = complete failure (all dilatations unsuccessful); 1 = partial success (at least 
one but not all dilatations successful); 2 = complete success (all dilatations success-
ful). For both CAG and PTCA, significant lesions either seen or dilated that were 
documented in the section ‘other’ (c.f. figure 1) were ignored in this analysis. 
Number of anti-anginal medications used: 0 = none, 1 = one, 2 = more than one. 
Only drugs registered for symptomatic relief of angina were counted as anti-
anginal medication. 
Multiple linear regression analysis was used to assess which variables were 
conditionally independent correlates of anginal attack frequency. Separate back-
ward elimination procedures were used to determine which of the variables from 
Tables 1 – 4 respectively were statistically significant (P<0·05) conditionally inde-
pendent correlates. From Table 1, NYHA class was not considered. Indicator vari-
ables and the categorical variable number of coronary angiograms performed were 
entered in multivariate analyses coded as described earlier. To assess whether the 
number of lesions was an independent predictor, the categorical variable number of 
coronary angiograms performed was replaced by two indicator variables: one for 
history of angiography (coded as 0 = no, 1 = yes) and one for number of lesions 
(coded as 0 = no history of angiography, or no lesions, or one-vessel disease; 1 = 
left-main, two- or more than two-vessel disease). Similarly, history of PTCA and its 
result were represented by two indicator variables: one for history of PTCA (coded 
as 0 = no, 1 = yes) and one for result (coded as 0 = failure; 1 = partial or complete 
success as defined earlier). The variables thus identified from each table were then 
combined in one model. From this model, non-significant (P>0·05) variables were 
removed. Calculations were performed using SAS®. 
RESULTS 
Study population 
Between November 1996 and December 1998, 7,797 patients were randomised in 
298 centres from 19 countries (see Appendix). Because of irregularities observed 
during on-site audits, 5 centres were closed and all 128 patients randomised in the 
centres concerned were removed from the database. Hence, this analysis concerns 
7,669 patients who are currently participating in ACTION. 
 
Anginal attack frequency and clinical history 
Data concerning the frequency of anginal attacks in relation to clinical history at 
the time of randomisation are given in Table 1. Of 7,669 patients, 8% had no angi-
nal attacks while 63% had occasional, 22% had regular, 4% had frequent and 3% 
had daily attacks. The median age was 64 years (range 35 – 89), and was not re-
lated to the frequency of angina. 
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Table 2: Frequency of anginal attacks and coronary angiography 
  Frequency of anginal attacks*  
 Total None Occasional Regular Frequent Daily  
History of coronary angiography (number of angiograms performed): 
Total No. of patients 7,668§ 595 (8%) 4,869 
(63%) 
1,713 
(22%) 
290 (4%) 201 (3%) P-value# 
None 2,270 (30%) 219 (37%) 
1,431 
(29%) 481 (28%) 82 (28%) 57 (29%)  
One 3,229 (42%) 261 (44%) 
2,093 
(43%) 707 (41%) 105 (36%) 63 (31%) <0·0001 
> one 2,169 (28%) 115 (19%) 
1,345 
(28%) 525 (31%) 103 (36%) 81 (40%)  
Extent of coronary disease in patients with at least one coronary angiogram: 
Total No. of patients 5,398 376 (7%) 3,438 
(64%) 
1,232 
(23%) 
208 (4%) 144 (3%)  
No lesions  240 (4%) 19 (5%) 155 (5%) 50 (4%) 9 (4%) 7 (5%) 
1 VD  1,822 (34%) 145 (38%) 
1,174 
(34%) 400 (33%) 61 (29%) 42 (29%) 
2 VD or LM  1,632 (30%) 123 (33%) 
1,030 
(30%) 370 (30%) 61 (29%) 48 (33%) 
>2 VD  1,704 89 (24%) 1,079 412 (33%) 77 (38%) 47 (33%) 
0·001 
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(32%) (31%) 
Except for the top rows, percentages are given for each category of attack 
frequency = 100%. VD, vessel disease; left-main (LM) disease was con-
sidered as 2 VD, c.f. statistical methods. 
* Occasional, less than one attack/week; regular, 1 – 3 attacks/week; fre-
quent, 4 – 6 attacks/week; daily, at least one attack every 24 hours. 
# For test of trend across categories of attack frequency (c.f. statistical 
methods). 
§ History of coronary angiography unknown in one patient. 
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The percentage of males decreased across attack frequency categories from 87% 
for patients with no attacks to 72% for patients with daily attacks (P 0·0001). The 
percentage of patients in NYHA class I declined from 88% for patients with no an-
ginal attacks to 26% for patients with daily attacks (P<0·0001). The percentage of 
patients with a history of myocardial infarction changed from 52% for patients with 
no anginal attacks to 43% for patients with daily attacks (P<0·0001). The percent-
age of patients with a history of claudication, transient ischaemic attacks or debili-
tating stroke increased from 12% for patients with no anginal attacks to 21% for 
patients with daily attacks (P<0·0001). Data for a history of claudication, transient 
ischaemic attacks and debilitating stroke separately is given in Table 1 also. 
At least one coronary angiogram had been performed in 70% of all patients for 
whom this information was available (Table 2). The percentage of patients who in 
the past never had coronary angiography decreased with increasing attack fre-
quency from 37% for patients without anginal attacks to 29% of patients with daily 
attacks. Conversely, the percentage of patients who had more than one coronary 
angiogram increased from 19% for those without anginal attacks to 40% for those 
with daily attacks (P<0·0001). Patients with a higher anginal attack frequency had 
more severe angiographic coronary disease. The percentage of patients with no le-
sions or one-vessel disease decreased from 43% (19 + 145 of 376) for patients 
without anginal attacks to 34% (7 + 42 of 144) for patients with daily attacks. The 
percentage of patients with more than two-vessel disease increased from 24% for 
patients without anginal attacks to 38% for patients with frequent and to 33% for 
patients with daily attacks (P=0·001, Table 2). 
 
Anginal attack frequency and treatment 
Data on current medical and past invasive treatment are given in Table 3. The num-
ber of anti-anginal drugs prescribed increased with the frequency of anginal at-
tacks. Overall, one % of patients was not on any anti-anginal medication at the time 
of randomisation. The percentage of patients prescribed one anti-anginal drug or 
less decreased gradually from 48% (9 + 277 of 595) for patients without anginal 
attacks to 14% (5 + 23 of 201) for patients with daily attacks. Conversely, the per-
centage of patients prescribed two or more anti-anginal drugs increased from 52% 
for patients without anginal attacks to 86% for patients with daily attacks 
(P<0·0001, Table 3).  
Overall, 23% of patients had a history of CABG and 26% of PTCA (Table 3). 
Previous CABG was less frequent for patients without anginal attacks (15%) than 
for those with daily attacks (28%, p < 0·0001). The same applied to a history of 
PTCA (20% for patients without and 28% for patients with daily anginal attacks, p 
= 0·03). 
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Table 3: Frequency of anginal attacks and treatment 
  Frequency of anginal attacks*  
 Total None Occasional Regular Frequent Daily  
Total No. of patients 7,669 595 (8%) 4,869 
(63%) 
1,714 
(22%) 
290 (4%) 201 (3%) P-value# 
Anti-anginal medication: 
None  107 (1%) 9 (2%) 77 (2%) 16 (1%) - 5 (2%)  
On one anti-anginal Rx 2,659 (35%) 277 (46%) 
1,813 
(37%) 484 (28%) 62 (21%) 23 (12%) <0·0001 
On  2 anti-anginal Rx 4,903 (64%) 309 (52%) 
2,979 
(61%) 
1,214 
(71%) 228 (79%) 173 (86%)  
History of CABG 1,791 
(23%) 88 (15%) 
1,141 
(23%) 435 (25%) 70 (24%) 57 (28%) <0·0001 
History of PTCA 2,016 
(26%) 120 (20%) 
1,294 
(27%) 469 (27%) 77 (27%) 56 (28%) 0·03 
History CABG and 
PTCA 378 (5%) 13 (2%) 218 (4%) 112 (7%) 16 (6%) 19 (9%) <0·0001 
Result of PTCA in patients with a history of PTCA: 
Total No. of patients 1,996§ 116 (6%) 1,283 (64%) 466 (23%) 77 (4%) 54 (3%)  
Failure° 220 (11%) 10 (9%) 129 (10%) 64 (14%) 10 (13%) 7 (13%)  
Partial success° 67 (3%) 2 (2%) 46 (4%) 13 (3%) 1 (1%) 5 (9%) 0·02 
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Complete success° 1,709 (86%) 104 (89%) 
1,108 
(86%) 389 (83%) 66 (86%) 42 (78%)  
Except for the top rows, percentages are given for each category of attack 
frequency = 100%. CABG, coronary artery bypass grafting; PTCA, per-
cutaneous transluminal coronary angioplasty. 
* Occasional, less than one attack/week; regular, 1 – 3 attacks/week; fre-
quent, 4 – 6 attacks/week; daily, at least one attack every 24 hours. 
# For test of trend across categories of attack frequency (c.f. statistical 
methods). 
§ Result of PTCA unknown in 20 patients. 
° Failure, no successful dilatation(s); partial success, one or more, but not 
all dilatation(s) successful; complete success, all dilatation(s) success-
ful. 
 
 
Table 4: Frequency of anginal attacks and risk factors for cardiovascular disease 
  Frequency of anginal attacks*  
 Total None Occasional Regular Frequent Daily  
Total No. of patients 7,669 595 (8%) 4,869 
(63%) 
1,714 
(22%) 
290 (4%) 201 (3%) P-value# 
BMI (kg/m2), median 
(range) § 27 (15 – 69) 27 (19 – 40) 27 (15 – 69) 27 (16 – 57) 27 (17 – 38) 27 (19 – 39) 0·08 
Hyperlipidaemia° 5,336 (70%) 407 (68%) 
3,347 
(69%) 
1,241 
(72%) 202 (70%) 139 (69%) 0·09 
Hypertension° 3,025 (39%) 243 (41%) 
1,885 
(39%) 700 (41%) 118 (41%) 79 (39%) 0·5 
Current smoker 1,345 (18%) 97 (16%) 876 (18%) 283 (17%) 51 (18%) 38 (19%) 0·9 
Diabetes 1,094 77 (13%) 669 (14%) 257 (15%) 58 (20%) 33 (16%) 0·005 
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(14%) 
Diabetes treated with 
insulin 173 (2%) 8 (1%) 102 (2%) 49 (3%) 8 (3%) 6 (3%) 0·02 
Except for the top row, percentages are given for each category of attack 
frequency = 100%. BMI, body mass index. 
* Occasional, less than one attack/week; regular, 1 – 3 attacks/week; fre-
quent, 4 – 6 attacks/week; daily, at least one attack every 24 hours. 
# For test of trend across categories of attack frequency (c.f. statistical 
methods). 
§ Either body height or weight not recorded for 31 patients at baseline 
° Treated with drugs. 
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Only 5% of patients had a history of both CABG and PTCA. The percentage of 
patients with such a history increased gradually across attack frequency categories 
from 2% for patients without attacks to 9% for patients with daily attacks 
(P<0·0001). The success rates of PTCA were not related in a gradual manner to 
anginal attack frequency although the percentage of patients with complete success 
of PTCA was lowest (78%, Table 3) for patients with daily attacks. 
Data on standard risk factors for cardiovascular disease are given in Table 4. 
The only risk factor that showed a statistically significant trend towards a higher 
prevalence with increasing anginal attack frequency was diabetes. There were 13% 
diabetics amongst patients without anginal attacks while the corresponding per-
centages for patients with frequent and daily attacks were 20% and 16% respec-
tively (P=0·005). 
Multivariate analysis showed that the following variables were statistically 
significant (P<0·05) conditionally independent correlates of attack frequency: gen-
der, history of claudication, myocardial infarction and CABG; presence of diabetes, 
the number of anti-anginal drugs used and the number of coronary angiograms ever 
performed. As expected based on the results of univariate analyses, male gender 
and prior history of myocardial infarction were negatively associated with attack 
frequency also in multivariate analyses, while the other variables were positively 
associated. 
DISCUSSION 
The present report is based on pre-randomisation data from an ongoing trial in pa-
tients with stable angina pectoris (ACTION) who were treated with other anti-
anginal drugs than calcium-antagonists at the time of enrolment. Such data are 
cross-sectional in nature and reflect the spectrum of similar patients seen in clinical 
practice, rather than the natural history of disease. 
The main finding for the ACTION cohort is that anginal attacks at baseline 
were well controlled in the majority of patients. Eight % of patients were free of 
attacks and a further 63% reported less than one attack per week. Any CABG had 
been performed in 23% and any PTCA in 26% while 5% had a history of both pro-
cedures. Although the selection criteria of ACTION define a broad spectrum of 
patients with stable angina,4 our findings are limited to patients who are eligible for 
this study. Patients with clinical heart failure and patients who were prescribed cer-
tain drugs that could not be stopped for clinical reasons were excluded. These in-
cluded calcium-antagonists, anti-arrhythmic agents other than sotalol, and amio-
darone. The protocol required that calcium antagonists were stopped prior to ran-
domisation. This explains why overall 1% patients was not on any anti-anginal 
treatment at the moment of randomisation. Because of these and other restrictions 
that are inherent in selecting patients for participation in a clinical trial, the present 
analysis does not necessarily reflect the fraction of patients with a history of angina 
who in clinical practice remain symptomatic despite treatment. 
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All patients in this cohort had a medical history of exertional angina requiring 
treatment but it was not required that patients were symptomatic. Investigators, 
after interviewing the patient, scored the current anginal attack frequency using a 
pre-defined scale. Responses to the WHO Rose questionnaire8 completed by the 
patient are known to differ from what is stated in medical records.9 Absolute attack 
frequencies as observed in this study can therefore not be compared to results of 
studies using other methods for data collection. 
It is a limitation of cross-sectional data that both investigators and patients 
may be more likely to remember specific past events when the patient experiences 
daily, or almost daily, anginal attacks. For instance, a patient with daily anginal 
attacks may be more likely to remember that he/she had an MI in the past than a 
patient without attacks. Such a recollection bias would result in a higher frequency 
of a history of MI in patients with daily attacks than in patients without attacks. 
The opposite was observed.  
In the present analysis, the percentage of patients classified as NYHA class I 
decreased progressively across categories from 88% of patients without anginal 
attacks to 26% of patients with daily attacks (c.f. Table 1). The NYHA classifica-
tion is a four-point-scale for the assessment by the physician of a patient’s degree 
of disability due to cardiovascular disease. The scale ranges from class I = no limi-
tation of physical activity, to class IV = any physical activity causes discomfort.6 
That patients without anginal attacks are not always assessed as being in NYHA 
class I is not surprising as patients who must limit physical activity to avoid angina 
will be classified in NYHA class II or higher. That 27% of patients with daily angi-
nal attacks were nonetheless classified as in NYHA class I suggests that patients 
who report daily anginal attacks are not necessarily hindered by these attacks in 
their ordinary activities, at least not in the opinion of their treating physician. The 
differences in anginal attack frequency observed in this study may therefore in part 
be due to a more active lifestyle amongst patients with more frequent attacks. 
Twenty-nine percent of patients had at least one anginal attack per week (c.f. 
Table 1). This may suggest that in current clinical practice not all patients are 
treated to the extent that they become asymptomatic. Other than that none of the 
patients were using a calcium-antagonist, there may be several explanations for 
this. First, patients or even their doctors may not make an attempt to minimise 
symptoms as patients may chose to live within their symptoms. Second, the side 
effects of anti-anginal drugs may be so bothersome that a proportion of patients 
prefer not to be treated. Third, lack of compliance may be an issue, as some pa-
tients may not use their medication(s) as prescribed. Fourth, under dosing when 
multiple drugs are used may be a factor and, finally, in some patients the symptoms 
may be refractory to all currently available treatments.  
We believe that, in part, our data reflect the latter. As shown in Tables 3 and 4, 
patients with more frequent anginal attacks had coronary angiograms and revascu-
larisation procedures performed more often, had more extensive coronary artery 
disease and were prescribed more anti-anginal drugs. In our data there was no indi-
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cation that lower dosages of these were used when multiple anti-anginal drugs were 
prescribed, or when anginal attacks were more frequent. The number of coronary 
angiograms ever performed, a history of CABG and the number of anti-anginal 
drugs prescribed were independently associated with attack frequency in multivari-
ate analysis. These relationships indicate that the intensity of treatment (drugs 
and/or revascularisation) is at least in part symptom-driven and are compatible with 
the view that some patients are refractory to all currently available treatments.  
As the attack frequency increases, more anti-anginal drugs are prescribed. The 
same applies to revascularisation. Despite this, a fraction of patients remains symp-
tomatic. In the analysis only treatments with proven anti-anginal efficacy were 
considered. Thus, the association between the intensity of treatment and the fre-
quency of anginal attacks cannot be explained by the use of ineffective treatments. 
Rather, the conclusion must be that in clinical practice it is apparently sometimes 
difficult or even impossible to achieve complete control of anginal attacks with 
currently available treatments.  
The association between the number of drugs prescribed and the frequency of 
anginal attacks may in part be due to failure of revascularisation to achieve lasting 
symptomatic relief. This is supported by the strong association between the per-
centage of patients who had both CABG and PTCA and attack frequency, and by 
the lower partial or complete success rates reported for patients with more frequent 
anginal attacks who had PTCA (c.f. Table 3). At the same time, this observation 
reinforces the conclusion that currently available treatment has limitations.  
Our analysis of treatment does not include calcium-antagonists, a class of 
agents with proven anti-anginal efficacy. To comply with the ACTION selection 
criteria, a calcium-antagonist had been withdrawn in only 1% of patients before 
data on anginal attack frequency was collected. This percentage did not depend on 
the frequency of anginal attacks (c.f. Table 3). It is therefore unlikely that with-
drawal of a calcium-antagonist for the purpose of ACTION had an effect on the 
frequency of anginal symptoms. Nonetheless, the question whether a cross-
sectional survey that also covers patients on calcium-antagonists would have given 
different results cannot be answered. 
Data on age, gender and clinical history are given in Table 1 and on risk fac-
tors for cardiovascular disease in Table 4. The small p-values are both a reflection 
of the differences observed and the large number of patients in this analysis. We 
have no explanation why women experience more frequent attacks than men. 
Krogh et al.10 suggested that the threshold for perceiving or reporting angina is 
lower amongst women than amongst males. Non-anginal chest pain is more fre-
quent in women than in men. Whether this has contributed to the present result 
cannot be determined. It is unlikely that the relationship between anginal attack 
frequency and the number of anti-anginal medications and the number of coronary 
angiograms ever performed can be explained by the relationship with gender. All 
three were conditionally independent predictors of anginal attack frequency in mul-
tivariate analysis. Similarly, we have no explanation for the decreasing fraction of 
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patients with a history of myocardial infarction as the frequency of anginal attacks 
increases. One contributing factor may be that myocardial infarction increases the 
angina threshold, as there may be less residual ischaemia in post-MI patients. 
CONCLUSIONS 
In the majority of patients with chronic stable angina pectoris not on a calcium-
antagonist, who may have had a revascularisation procedure in the past, anginal 
attacks can be symptomatically controlled by currently available medical treatment 
with other anti-anginal drugs. Invasive treatments are only needed in a small pro-
portion where symptoms persist. A minority of patients remain symptomatic de-
spite multiple therapies. The findings support the view that a minority of patients 
with chronic stable angina are refractory to treatment. 
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Chapter 6 
SOCDAT®: a comprehensive clinical trial data and 
study management philosophy based on simultaneous 
display of scanned documents and corresponding 
database content 
 
 
 
 
 
ABSTRACT 
We describe a modular database and study management philosophy called 
SOCDAT® (Source Consultation Data Acquisition Tool) designed for clinical trials 
that use pre-printed case report forms (CRFs) for data capture. All CRFs and sup-
porting documents are registered in the database upon receipt, scanned and then 
archived. Further database management is entirely based on scanned images. 
Scanned images and corresponding database content are always simultaneously 
displayed on the user’s computer screen. The content of the database is therefore 
continuously validated each time the database is consulted. A standard relational 
database is used (ORACLE™). Tables contain links to the relevant document im-
ages, which are stored by page as separate files. Data such as names of investiga-
tors, local normal ranges, coding dictionaries, etc. are also stored within the same 
database. This allows applications to access both patient- and centre-specific data. 
The system allows for flexible implementation of applications for data checking 
and clarification, and for the generation of study management tools such as status 
reports, listings of outstanding documents, etc. Apart from continuous validation 
during database consultation, the system has several other advantages. Once 
scanned, original documents can be permanently archived. Scanning guarantees 
legibility of documents that fade over time, and images can be incorporated auto-
matically into reports. Double data entry and data checking can be done simultane-
ously at different locations. The scanned documents and the database can be stored 
together on removable mass storage media, which is an extra safeguard against 
loss. Database content and images can also be copied to a portable computer, which 
facilitates on-site monitoring and audits. The system runs on any platform sup-
ported by Oracle. 
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Over the past decade, the tools used to collect, manage and analyse data in clinical 
trials have gone through revolutionary changes. Although alternatives such as data 
fax with or without optical character recognition, remote data entry and internet-
based data management systems have become available, acceptance and implemen-
tation of such methods has been slow.1 Hence, many clinical trials today still rely 
on pre-printed paper Case Report Forms (CRFs) for data capture. 
Any large multi-centre trial needs to have a multi-functional and efficient data 
management system in place that meets international Good Clinical Practice (GCP) 
requirements2 and allows for customisation while the trial is ongoing. To meet 
these requirements for trials that rely either in part or completely on paper docu-
ments to capture patient data, we designed a ‘paperless’ concurrent data and docu-
ment management system called SOCDAT® (Source Consultation Data Acquisition 
Tool). The key features of this system are that all incoming completed CRFs and 
supporting documents, such as electrocardiograms, laboratory test print-outs, dis-
charge letters, etc. are registered in the database upon receipt, then scanned and 
archived. All subsequent data processing activities (data entry, data cleaning and 
review, processing of adverse events, coding of terms, etc.) are handled via com-
puter screens that simultaneously display the scanned image of patient data as 
completed by the investigator, and the corresponding content of the database. 
SOCDAT’s system architecture is based on a standard relational database. Other 
data relevant to the conduct of a specific study (investigator names and addresses, 
local laboratory normal ranges, dictionaries to code medical terms, etc.) can be in-
corporated into the same database. The system can thus support the varied logistic 
and study management functions required to execute clinical trials efficiently. Be-
low we describe the system’s architecture and functionality, using examples from 
the ongoing ACTION (A Coronary disease Trial Investigating Outcome with 
Nifedipine GITS) study, of which the design and methods have been described 
elsewhere.3 ACTION is a large randomised trial with fatal and non-fatal clinical 
endpoints in almost 8,000 patients from 299 centres in 19 countries. Patients were 
recruited between November 1996 and December 1998. The planned mean follow 
up is five years and main results are expected mid 2004. 
SYSTEM DESIGN AND IMPLEMENTATION 
The basic design considerations for the SOCDAT system were: 
1. Integration of concurrent database and document management based on scanned 
images of completed CRF pages and supporting documents simultaneously dis-
played with the corresponding database content. 
2. The use of only one standard software package that runs on a standard local 
area network (LAN) consisting of standard personal computers or workstations. 
3. User access to all functionalities required for the co-ordination and management 
of a study through one start-up screen. 
4. Possibility to port the system to other network and/or operating system envi-
ronments if necessary. 
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5. Modular architecture that allows for flexible addition of functions as the need 
arises. 
The core of SOCDAT is a standard relational database model based on tables con-
taining information which can be grouped together logically. Each record contains 
creator and time stamp identification, which is updated whenever the record is 
changed. Relations between tables specified during programming are maintained 
by the system. Names of investigators and co-workers, allocated patient identifica-
tion and medication numbers, local laboratory normal ranges, etc. are stored by 
centre within the same system. Hence, centre-specific data is directly accessible to 
all applications, and can be linked to patient data whenever required. 
The user interface consists of one start-up screen that allows access to all func-
tions available for any one study (c.f. Figure 1). 
 
 
Figure 1: Start-up screen for the ACTION study 
Each button allows access to a specific (set of) function(s) related to trial co-ordination and manage-
ment. Buttons with related functions are grouped together. 
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The system is developed and implemented using standard ORACLE™ software on 
a low-end local area network of standard personal computers, using Microsoft 
Windows NT™ as operating system, but will run without changes on any platform 
that is supported by Oracle (Linux, Sun Solaris, Novell, HP-UX, etc.). Because of 
Oracle’s client-server architecture, network traffic is kept to a minimum. So as a 
consequence, system response times both for forms and for scanned images are 
acceptable (less than 1 sec.) even on low-end standard 10 megabit/sec networks 
and with large numbers of images (>100 gigabytes). 
Documents are scanned using standard scanning equipment. We found that the 
best results are obtained using the compressed *.tif image file format. In this for-
mat, the image size ranges from 30 KB for CRF pages to 500 KB for standard 12-
lead electrocardiograms. Document images are stored by page as separate *.tif 
files. Data tables contain links to the document images that support the data in the 
table. The total disk space required to store the database for a trial as large as 
ACTION, including all scanned CRF pages and other documents, is 100 gigabytes. 
This is well within the current limits of PC technology. Because of the necessity to 
display image files, a 200 MHz Pentium™ PC or comparable MacIntosh™ is a 
minimum requirement for network client machines. Table 1 gives details on the 
projected magnitude of the database, including scanned documents, when the 
ACTION study is completed. 
 
Table 1: Projected size of the ACTION database at study completion 
Total number of patients ~8,000 
Number of tables containing patient data 72 
Mean number of variables per table, patient data 28 
Total number of records, patient data ~2,000,000 
Number of tables containing other data 76 
Mean number of variables per table, other data 12 
Total number of records, other data ~3,500,000 
Number of scanned pre-printed pages ~1,500,000 
Number of scanned supporting document pages ~500,000 
Total size of the database ~100 Gigabytes 
 
Initially, the system was implemented on one Local Area Network (LAN). 
More than 30 users within one building are connected simultaneously today. A sub-
sidiary location in another country has direct access to the main database through a 
256 Kbits/sec data line. To ensure an acceptable response time for images at the 
subsidiary location, scanned images are present at both locations, and are synchro-
nised between the two systems each night. 
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APPLICATION MODULES 
Below we summarise the various applications that can be distinguished within the 
SOCDAT system. 
 
Registering, scanning and tracking of documents 
Specially designed screens allow the user to register and track each data handling 
and processing step for patient-related documents. An example is shown in Figure 
2. 
Once registered by date of receipt and type of document, all patient-related 
documents are scanned. The start-up screen (c.f. Figure 1) contains buttons that 
allows user access to the scanning function for each type of document to be 
scanned. 
 
 
Figure 2: Typical tabular screen view used for tracking document processing 
Documents that are generated from the database, such as Data Clarification Forms (DCFs), are 
tracked from date created to date filed. Tabular screens are patient-specific. 
 
 
 
Chapter 6 
84 
Data entry 
The scanned image of the data to be entered appears on the left side of the screen, 
with a corresponding empty data entry window on the right. Data entry is per-
formed manually using the scanned images. A completed data entry screen is 
shown in Figure 3.  
 
 
Figure 3: Screen layout for data entry and data consultation 
 
For data entry, the scanned image of the CRF page to be entered appears on the left 
and a corresponding empty data entry template on the right. Repeated pressing of 
the Page Down key gives access to other scanned documents that support the data-
base content shown on the right (such as a completed DCF, a laboratory report, an 
electrocardiogram, etc.), which are shown in sequence on the left side of the screen. 
Note that the second part of item 8.3 on the CRF page shown in the figure was not 
answered by the investigator. In addition, there is a discrepancy between image and 
database content for item 9.1. The Page Down key and the DCF button allow the 
user to consult the audit trail that explains such discrepancies (c.f. Figure 4 next 
page). Data entry of free text is facilitated by a dictionary of pre-defined terms, 
which is accessible via a specific button attached to the appropriate field. The latter 
prevents typing errors and ensures consistent data entry of similar terms. The user 
can however enter any text string. 
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Figure 4: Data clarification system as implemented for ACTION 
The same database content page as illustrated in Figure 3 is shown. After pressing Page Down, the 
DCF completed by the investigator appears on the left side and explains the discrepancy for item 8.3 
(c.f. Figure 3). The DCF sub-screen shown in the figure is accessed via the DCF button. The first 
block shows the query text for item 8.3. The second block justifies the discrepancy for item 9.1. The 
DCF sub-screen can be opened at any time during data entry or consultation, and the user can enter 
data clarification queries as required. When the cursor is put in any field in the database content page, 
the field name appears to the left in the sub-screen when the DCF button is clicked. The DCF button 
remains red until all outstanding DCFs for a given page have been processed. 
 
Data checking and quality control 
SOCDAT allows for the implementation of any combination of data checking and 
quality control procedures that are compliant with GCP requirements.2 Pre-defined 
checks to detect inappropriate character formats are automatically performed on 
initial data entry. Access to scanned images allows double data entry to be done 
concurrently on different workstations. Data checking programs created in Stan-
dard Query Language (SQL) are run regularly to check for completeness and plau-
sibility. Based on the SQL output, the scanned images are used to make the appro-
priate changes in the database. Specific screens continuously track the checking of 
each data module. Standard locking procedures for checked data are implemented. 
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Data clarification 
To query missing, incorrect or non-plausible data, Data Clarification Forms (DCFs) 
are generated from the database and sent to investigators for completion. Data 
clarification queries are field-specific and directly linked to the item that needs to 
be clarified. Figure 4 shows a screen view of the DCF system in SOCDAT. One 
DCF is generated for each data item to be clarified. The data clarification query can 
be inserted automatically by a data-checking program, or typed in manually. A dic-
tionary of pre-defined queries for the data field concerned can be made available 
but the user can enter any text string. DCFs are tracked from date of creation to 
date filed, and are printed using a merge-file that is imported into standard word-
processing software. When the DCF is printed, patient and investigator identifica-
tion is added automatically (c.f. Figure 4). 
The DCF system is also used to attach to any field a comment that explains a 
difference between scanned image and corresponding database content in the ab-
sence of a DCF that was completed by the investigator. 
 
Coding of medical terms and drug names 
The dictionaries used to standardise medical terms and drug names are stored as 
separate tables in the database. The initial code for any given term is selected 
manually from the coding dictionary. Once coded, if the same term is repeated in 
the database, the code is then automatically assigned. Each time a term is changed 
in the database, the code that was assigned is removed automatically. In order to 
ensure accurate and consistent coding, distinct coded terms are validated by an in-
dependent coder using a screen specifically designed for this purpose. 
 
Data consultation 
Within SOCDAT, different ways of consulting database content have been imple-
mented. Page views as shown in Figure 3 allow the user to consult document im-
ages and corresponding database content – including codes that were assigned to 
medical terms – for any specific patient by page. Tabular views as shown in Figure 
2 allow the user to consult pre-selected data in horizontal rows. More complex 
views are also possible (c.f. Figure 4).  
Apart from using standard queries and views that are already available within 
the system, users can also consult the database on a read-only basis by user-defined 
SQL queries. 
 
Document generation 
Because both patient- and study-specific data are stored in the same database, 
documents can be generated for a variety of purposes. Two classes of documents 
can be distinguished: single documents and data listings. 
Single documents (such as DCFs, c.f. Figure 4) relate to a specific patient. Se-
lected data can be automatically combined with relevant scanned images. Single 
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documents can either be printed directly at the time of generation, or in bulk at 
regular intervals. The date of generation is inserted into the database automatically. 
Listings generated by SQL show the output of data checking programmes, or 
selected data fields for patients that fulfil certain conditions. Listings are used to 
optimise tracking of patient data, and data checking. Examples of listings that can 
be generated from the database are study status reports, listings of documents that 
are still outstanding, visits that need to be done during a certain time interval, etc. 
 
Management of study medication supplies 
SOCDAT contains applications to manage study medication supplies. The medica-
tion numbers allocated to each participating centre are tracked, and a unique link 
between medication number and patient is established. Other functions, such as 
ordering study medication supplies, can be added if necessary. Because these are an 
integral part of the database management system, medication orders are automati-
cally ceased for patients who die or who stop study medication prematurely. For 
long-term studies such as ACTION, the system can track medication expiry dates 
to prevent patients using study medication that has expired.  
 
Study management tools 
The system allows for the flexible addition of study management tools to support 
efficient trial execution as the need arises. Examples are the tracking of Investiga-
tor, CRA and Committee meetings and tracking of on-site monitoring visits. 
 
Provisions for data analysis 
The system is not primarily designed as a data analysis tool. Because the architec-
ture is based on a standard relational database development environment, any sta-
tistical package that support ODBC (Open Data Base Connectivity) can be used to 
retrieve and analyse data directly from the system.  
SYSTEM VALIDATION 
A flexible system that evolves continually because of the addition of new applica-
tions needs continuous validation. Because of the modular structure, this can be 
done per module. 
Before a study is started, the document logging, scanning and the data entry 
application modules are validated by processing a number of completed CRFs that 
contain dummy data. The data are then read and verified directly from the database. 
We rely in addition on continuous validation by always showing the user scanned 
images together with corresponding database content (c.f. Figure 3).  
For the validation of other applications we rely on three methods. The first 
method is the introduction of data satisfying pre-defined conditions to ensure that 
the desired result is produced by the system. A second method is independent pro-
gramming of the same application by different programmers. Thirdly, independ-
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ently written SQL queries are used to verify that the output produced by a routine 
or application is correct. 
DISCUSSION 
In designing SOCDAT, our main goal was to bring together within one system all 
applications that are necessary for efficient concurrent document, database and 
study management for clinical trials. Our purpose was also to design a system that 
is both flexible and can easily be adapted to the requirements of any trial. Nonethe-
less, SOCDAT has two features that we consider essential components: (1) simul-
taneous display of scanned documents and corresponding database content, and (2) 
both study-specific and patient-specific data are stored within the same relational 
database architecture. We believe the first component to be unique to SOCDAT. 
Commercial systems that manage document scanning and archiving are widely 
available but we are not aware of a system that displays database content simulta-
neously with corresponding scanned documents. We consider this a major advan-
tage over other systems. Brandt el al.4 have commented that “while one can pro-
gram all kinds of checks without limit, even the most over-engineered system can-
not protect against wilful entry of incorrect data that still passes all the checks.” 
Because of the simultaneous display of scanned images and corresponding data-
base content, continuous data validation is an integral part of the system. Although 
difficult to quantify, we believe that errors that “still passes all the checks” are 
greatly reduced by this approach. 
Storage of document images directly linked to the corresponding database 
content within the same system has a number of other advantages. We have found 
the possibility to incorporate scanned images into reports generated from the data-
base particularly important. For the purpose of diagnostic adjudication by a special 
committee, a patient-specific report is automatically generated for selected Serious 
Adverse Events (SAEs) in the ACTION study. This report combines data on the 
patient’s history with scanned images of relevant discharge letters, electrocardio-
grams and laboratory reports. The possibility of using scanned images for this pur-
pose removes the need for photocopying of relevant documents, which saves time. 
Also, the resulting documents can be printed as many times as necessary, are al-
ways of the same quality, and can be stored on a CD. There are many other advan-
tages of scanning. The need for physical handling of documents is reduced to a 
minimum. All data processing can be done concurrently, which again saves time. 
Legibility is preserved for documents that fade over time. The complete database 
including all scanned documents can be stored on removable mass storage media. 
This is an extra safeguard against loss, and makes it possible to consult the com-
plete documentation and database content from a portable computer without the 
need for Internet access. This should make both on-site monitoring, and auditing of 
study sites by company auditing departments or regulatory authorities a great deal 
more efficient.  
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Simultaneous display as shown in Figure 3 for the purpose of consultation is 
useful only when the user can determine the explanation for any discrepancy be-
tween the left and the right side of the screen. This also determined our approach to 
data clarification as the Page Down key and the DCF button give the user access to 
the full audit trail that explains discrepancies noted on the screen while consulting 
data (c.f. Figure 4). 
SOCDAT allows for the flexible implementation of any function that relates to 
standard quality control and assurance procedures for clinical trials. Identification 
of areas where customisation is of benefit is a continual and incremental process as 
the system evolves to meet the needs of diverse functions and users over time. Be-
cause incoming and outgoing documents are registered, listings can be provided of 
outstanding documents. Laboratory data can be compared to local normal ranges, 
as the latter are also stored in the system. The same applies to signatures of local 
study personnel authorised to sign study forms. Listings can be produced of out-
standing documents, which can be used by Clinical Research Associates (CRAs) as 
a monitoring tool. Hence, SOCDAT is not just a data management system for use at 
the coordinating centre, but is also a management tool for improving quality stan-
dards of study execution in general.  
While designing the basic system architecture certain deliberate choices were 
made. We chose to use a classical relational database design, with each variable 
represented by a column in a multi-column table. Within the same programming 
environment it would also have been possible to use an Entry-Attribute-Value 
(EAV) design, with all data stored in one table as described by Brandt et al.4 While 
an EAV design would have greater flexibility, it would also have been slow on the 
low-end PC-based platform that we use for large databases. 
Another choice was not to implement skip logic and automatic code, range, 
logical or completeness checks during data entry. While automatic checks during 
data entry may reduce errors, it may also reduce the productivity of data entry per-
sonnel, and lead to entering “data” that passes the checks rather than reflects what 
was entered by the investigator on the document concerned. We prefer therefore to 
only prevent the entry of character strings in the wrong format. Reliability of data 
entry is assured by double data entry. Thereafter, data quality is assured by fre-
quently run batch data checks. 
In a concurrent data processing environment, records that are already present 
in a database may need to be updated at any time. We chose not to store the previ-
ous version of an existing record at each update, although this would be possible 
within the same programming environment – albeit at the cost of a larger database 
and a slower response time. We believe that storing previous record versions is not 
necessary with the continuous visual data verification that is inherent to simultane-
ous display of scanned image and database content. Because each record contains a 
time stamp and all returned DCFs are logged upon receipt, it is possible to query 
the database for records that should have been updated. 
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The approach used in designing SOCDAT may also be used to design a system 
for a trial that uses a means of local data capture other than pre-printed CRFs. 
Amongst the options that may be considered in this regard are transmittal of com-
pleted pre-printed forms by telefax to the coordinating centre combined with opti-
cal character recognition, direct data entry on local workstations, etc. We do not 
use optical character recognition for two reasons: (1) the inherent constraints that 
apply to form design, and (2) relative to manual data entry, little efficiency is 
gained as character recognition must be verified by an operator. Local direct data 
entry poses problems of source data verification, data authentication and system 
security for which generally accepted tried-and-tested solutions are only partly 
available at present. Nonetheless, SOCDAT can be adapted for a hybrid data cap-
ture system that relies partly on transfer by telefax or internet of locally entered 
data, and partly on scanning of paper documents. 
Since only one standard development environment is used, system implemen-
tation and maintenance does not require large amounts of specialised programming. 
On a Microsoft Windows NT™ platform the system is stable and system crashes 
do not occur. Although the current implementations of SOCDAT run on low-end 
PCs even for studies as large as ACTION, it is noted that actual patient data takes 
less than half of the total amount of data fields (c.f. Table 1). Apparently, it takes 
more data to manage data than the actual data itself. In the past this would have 
been a major disadvantage. Today, storing large amounts of data within complex 
relational databases structures is no longer a problem. Hence, the implementation 
of applications related to data checking and management is limited only by the 
availability of programming capacity. 
CONCLUSIONS 
Linking and storing scanned documents and data within the same database as is the 
case in SOCDAT has five major advantages: 
1. Automatic display of scanned images in conjunction with corresponding data-
base content ensures integrated continuous validation of data. 
2. Scanned images can be incorporated automatically in reports generated by the 
system 
3. After scanning, documents can be permanently archived. Scanning guarantees 
legibility of documents that fade over time. 
4. Data entry and data checking can be done concurrently and at different loca-
tions. 
5. Scanned documents and database can be stored together on removable mass 
storage media as an extra safeguard against loss, and to facilitate on-site moni-
toring or study audits. 
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1 INTRODUCTION 
This document describes the Statistical Analysis Plan (SAP) for the ACTION 
study. ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine 
GITS) is a multinational, multicentre, randomised, double blind, placebo con-
trolled, clinical trial designed to evaluate the effect of (long-acting) nifedipine 
GITS on major cardiovascular event-free survival in patients with chronic symp-
tomatic coronary artery disease (angina pectoris) who are otherwise optimally 
treated. In total 7,669 patients were randomised to either nifedipine GITS or pla-
cebo between November 1996 and December 1998. Patients still under observation 
had a final end-of-study visit during March – September 2003. 
The design and methods of the main ACTION study are described in detail in 
the main ACTION study protocol version 6.03, dated August 27, 1996 as revised in 
amendment no. 1 dated June 13, 1997 (the ‘protocol’). This SAP has been finalised 
following the close of patient follow up but before the database was locked and the 
study medication code was added. The criteria for evaluation of study results and 
the analysis populations are defined in section 10 of the protocol and an outline of 
the statistical analysis plan may be found in section 11.2 of the same document. 
The purpose of this document is to describe the analyses that will be performed in 
accordance with the protocol in more detail. In addition, this document outlines 
changes and/or additions made by the Steering Committee to the analyses specified 
in the protocol. 
 
Changes and/or additions to the analyses specified in the protocol are boxed in this 
document. 
 
1.1 Study objectives 
As stated in section 2 of the protocol, the primary objective for efficacy of 
ACTION is to assess, relative to placebo, the effect of nifedipine GITS on the 
combined rate of death from any cause, acute myocardial infarction, emergency 
coronary angiography for refractory angina, overt heart failure, debilitating stroke 
and peripheral revascularisation in ambulatory patients with chronic symptomatic 
coronary artery disease (angina pectoris) but without severely depressed left-
ventricular function, who otherwise receive optimal treatment. 
The primary criterion for safety is the combined rate of death from any cause, 
acute myocardial infarction and debilitating stroke. 
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1.2 Study endpoints 
1.2.1 Primary endpoint for efficacy 
As stated in section 10.1 of the protocol, the primary criterion for efficacy is major 
cardiovascular event-free survival; defined as the time that each patient is under 
observation and free of all following events: 
1. Death from any cause. 
2. Unequivocal acute myocardial infarction. 
3. Emergency coronary angiography for refractory angina. 
4. Overt heart failure requiring hospitalisation and a change in heart failure treat-
ment. 
5. Debilitating stroke. 
6. Peripheral revascularisation. 
The primary criterion for efficacy will be based on the diagnoses made by the 
Critical Events Committee (CEC, c.f. 1.2.4). As regards the second event men-
tioned above, it is noted that the CEC distinguishes between Acute Myocardial In-
farction (AMI) and Procedural or accompanying Myocardial Infarction (PMI). 
Overt heart failure that occurred during hospitalisation is considered equivalent to 
the fourth event mentioned above. 
 
1.2.2 Primary endpoint for safety 
As stated in section 10.2 of the protocol, the primary criterion for safety is the 
combined rate of death from any cause, non-fatal acute myocardial infarction and 
debilitating stroke. This criterion will also be based on the diagnoses made by the 
Critical Events Committee (CEC, c.f. 1.2.4). 
 
1.2.3 Secondary endpoints 
The following secondary endpoints for efficacy are mentioned in section 10.1 the 
protocol: 
- The occurrence of any of the following cardiovascular events as diagnosed by 
the CEC: cardiac death, acute myocardial infarction, emergency coronary an-
giography for refractory angina, overt heart failure, debilitating stroke or pe-
ripheral revascularisation. 
- The percentage observation time that patients are using additional cardiac 
medications for symptomatic relief of angina and of heart failure. These per-
centages will be estimated from data about start and stop dates of concomitant 
medications collected at each assessment. Patients who undergo CABG or 
PTCA will be considered to be using additional cardiac medication from the 
date of the procedure onwards. 
Contrary to what is stated in the protocol (c.f. above paragraph), the analysis for 
percentage observation time that patients are using additional cardiac medication 
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will be limited to medications registered for symptomatic relief of angina while 
CABG and PTCA will be ignored (c.f. 2.3.10). 
- The percentage of major cardiovascular event-free survival time that patients 
were in NYHA class I, II, III and IV respectively. As described elsewhere (Ols-
son et al., Br Med J 1986;292:1491-93) these percentages will be estimated 
from data about NYHA class collected by assuming that transitions from one 
class to another occur, on the average, half-way between assessments. 
- The need for coronary angiography and revascularisation procedures as as-
sessed by coronary angiography, revascularisation and major cardiovascular 
event-free survival. 
In event counts, PTCA and coronary angiography performed on the same date will 
be counted as PTCA only (c.f. 4.3.2). 
The following secondary endpoints for safety are mentioned in section 10.2 of the 
protocol: 
- ECG findings. 
- Laboratory test results. 
- Vital signs. 
- Non-fatal adverse events not included in the primary criteria for efficacy and 
safety. 
Total mortality is an additional secondary safety criterion 
 
1.2.4 Centralised assessment of endpoints 
The clinical histories of patients who have potentially sustained any of the events 1 
– 6 mentioned in section 1.2.1 of this document have been assessed by the Critical 
Events Committee (CEC) based on the diagnostic criteria given in the ACTION 
study document Diagnostic Classification of Cardiovascular Events and Cause of 
Death: Criteria and Critical Event Committee Procedures (version 3.0, dated 8 
May 2002). The CEC distinguishes the following diagnostic categories: 
1. Cause of death (cardiovascular / non-cardiovascular / unknown). 
2.1 Acute myocardial infarction (AMI). 
2.2 Procedural or accompanying myocardial infarction (PMI). 
3. Refractory angina requiring emergency coronary angiography without pro-
gression to myocardial infarction. 
4. Overt heart failure requiring hospitalisation (or occurred during hospitalisa-
tion) which led to start of, or change in, heart failure treatment. 
5. Debilitating stroke. 
6. Peripheral revascularisation. 
All analyses will be based on the diagnosis made by the CEC. It is noted that the 
CEC has assessed all clinical events for potential endpoints – not just the first one 
that occurred – and was required also to determine the date of each event. In the 
Chapter 7 
100 
case two or more events occurred on the same date (e.g. emergency coronary an-
giography for refractory angina and heart failure) the CEC also determined the 
order of occurrence. 
 
 
1.3 Definition of analysis populations 
In accordance with section 10.3 of the protocol, two analysis populations will be 
distinguished. All tabulations and analyses described in this document will be pro-
duced for both populations. 
 
1.3.1 All-randomised population 
Membership of the all-randomised population is defined by a valid start date of 
study medication in the field RANDOM.STARTDT in the ORACLE® database. 
Hence, this population consists of those patients who are known to have taken at 
least one tablet of study medication. Compliance with study medication and proto-
col violations are otherwise irrelevant. 
 
1.3.2 Valid-for-efficacy population 
This population consists of the subset of the all-randomised population of patients 
who comply with certain criteria relating to eligibility and availability of informa-
tion. The field RANDOM.ELIG_CHK in the ORACLE® database defines member-
ship of the valid-for-efficacy population. If this field contains “OK”, no protocol 
violation was detected and the patient is a member of the valid-for-efficacy popula-
tion. If this field contains “PV”, one or more protocol violations were detected and 
the patient is a member of the all-randomised, but not of the valid-for-efficacy 
population. 
The criteria for membership of the valid-for-efficacy population mentioned in sec-
tion 10.3 of the protocol were relaxed by the Steering Committee (see minutes of 
meeting dated 21 August 1998). 
All patients were checked for screening protocol violations based on the following 
criteria (as relaxed by the Steering Committee): 
 
Eligibility criterion: In case of violation, criterion violated (item in the CRF): 
Age 35 years or older 12.2, #1 
In a stable clinical condition for at least 10 days prior to randomisation 12.2, #2 
Presence of qualifying angina 12.2, #3 
On anti-anginal medication 12.2, #3 
Not on a calcium-antagonist during the last 10 days, or any change 
made to anti-anginal medication  12.2, #3 
Presence of at least one criterion for coronary artery disease as men-
tioned in item 12.2, #4 of the CRF 12.2, #4 
Local EF measured and at least 40%, core lab ejection fraction (if 
present) at least 35% 12.2, #5 
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Eligibility criterion: In case of violation, criterion violated (item in the CRF): 
Ambulatory 12.2, #7 
Signed Declaration of Consent 12.2, #7 
Major CV event or surgery within two months 12.3, #1 
PTCA or CABG planned 12.3, #2 
Known intolerance to dihydropyridines 12.3, #3 
Clinically significant valvular disease 12.3, #4 
Severe obstructive airway disease 12.3, #5 
Unstable insulin-dependent diabetes 12.3, #6 
Gastro-intestinal condition limiting absorption or passage 12.3, #7 or #8 
Non-CAD condition limiting life expectancy 12.3, #9 
Clinically significant heart failure 12.3, #10 
Orthostatic hypotension or supine SBP lower than or equal to 90 mm 
Hg, or SBP unknown 12.3, #11 
SBP greater than or equal to 200 mm Hg and/or DBP greater than or 
equal to 105 mm Hg despite treatment, or BP unknown  12.3, #12 
Creatinine above 2 x upper limit of normal, or creatinine unknown 12.3, #13 
ALAT or ASAT above 3 x upper limit of normal, or ALAT or ASAT 
unknown 12.3, #14 
Dose of diuretics above limit 12.3, #15 
On ACE-inhibitor plus diuretic for heart failure 12.3, #16 
On other incompatible medication 12.3, #17 
Anticipated problems with compliance or follow up  12.3, #18 
Pregnancy, breast feeding or risk of pregnancy (females only) 12.3, #19 
Participation in another trial or study 12.3, #20 
Time window violations:  
EF assessed more than 6 weeks (echo), or more than one year (other 
methods) before start of study Rx  
Lab tests assessed more than 6 weeks before start of study Rx  
12-lead ECG recorded more than 10 days before start of study Rx  
Screening medical history assessed more than 10 days before start 
of study Rx  
Vital signs/baseline physical assessed more than 10 days before start 
of study Rx  
Final check inclusion / exclusion criteria more than 10 days before 
start of study Rx  
 
1.4 Standard descriptive statistics 
1.4.1 Continuous variables 
Unless specified otherwise, the following standard descriptive statistics will always 
be obtained for continuous variables: number of available values (% of planned 
values, defined as the number of values that would have been available had there 
been no loss to follow up – not counting death – and no missing information), 
mean and standard deviation, median and 95% range, lowest and highest value. 
The standard table layout for tabulating descriptive statistics for continuous vari-
ables appears as Table 1 in Appendix I – table and figure layouts. 
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1.4.2 Categorical variables 
For categorical values, the number of values in each category and the correspond-
ing percentage of the total number of values available will be calculated. In addi-
tion the number of values that are missing will be given, defined as the number of 
values that would have been available in addition, had there been no loss to follow 
up (not counting death) and no missing information. The standard table layout for 
tabulating descriptive statistics for categorical variables appears as Table 1 in Ap-
pendix I – table and figure layouts. 
 
1.5 Statistical inference 
In accordance with section 11.2 of the protocol, the intention-to-treat analyses for 
the all-randomised population will be considered as primary. P-value based claims 
about efficacy and safety will be based on p-values without correction for interim 
analysis and without adjustment for covariates for the following analyses by as-
signed treatment (i.e. ‘intention-to-treat’) for the all-randomised population: 
1. Primary analysis for efficacy (c.f. 4.1). 
2. Primary analysis for safety (c.f. 4.2). 
3. Analysis for all-cause mortality (c.f. 4.3.1). 
Data from centres that have been discontinued by the Steering Committee will not 
be considered in any analysis but a listing of adverse events that were reported up 
to the date of discontinuation will be provided by treatment group for the centres 
concerned in the integrated clinical trial report. In the main results paper, the num-
ber of centres excluded and the number of patients concerned will be mentioned 
without giving further details (c.f. Figure 1, Appendix I – table and figure layouts). 
Although region-treatment and centre-treatment interaction will be considered 
(c.f. 4.4.2), no region or centre will be excluded from the primary analysis and 
claims about efficacy or safety will not be made for specific regions only. 
It is the intention to report 95% confidence intervals for all analyses unless 
this is inappropriate or technically not possible; and to report p-values only for the 
primary analyses mentioned earlier, and for interaction tests. 
 
1.6 Handling of missing information 
1.6.1 Incomplete calendar dates 
Data Clarification Forms (DCFs) have been sent for calendar dates that were in-
complete on the CRF as appropriate. Whether, for example, an exercise test re-
ported on the baseline CRF (i.e. visit 0) for which the date is (partly) missing was 
indeed performed before start of study medication was confirmed by a DCF. None-
theless, the day, the month or the year may still be missing. When the day has been 
entered, the month and the year must be present also. When the day is missing, the 
month and the year must both be present unless the month is also missing. Incom-
plete dates where only the year was known were entered as xx/xx (day/month). 
Completely missing dates were entered in the data base as -99. 
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For the purpose of statistical analysis, the following rules apply for imputing 
missing values in calendar dates: 
1. When the day is missing but the month and the year are present, the day is taken 
as 15. 
2. When the day and the month are missing but the year is present, the day is taken 
as 15 and the month as 06 (i.e. June). 
3. When the year is also missing, the date is considered as unknown. 
The following rules apply for using incomplete calendar dates in date difference 
calculations: 
1. When one or both calendar days are missing and the month and the year are the 
same, the difference will be considered as unknown. 
2. When one or both calendar months are missing and the year is the same, the 
difference will be considered as unknown. 
3. When one or both calendar days are missing and the months are different, the 
fifteenth will be imputed for the missing day(s). 
4. When one or both calendar months are missing and the years are different, 06 
will be imputed for the missing month(s). 
Other rules may need to be defined as analysis programming progresses. 
 
1.6.2 Missing data 
In general only data documented by investigators will be tabulated and analysed. 
However, certain analyses may require that absent data are imputed for the analysis 
to be meaningful. The exact rules for imputations to be made and their number will 
be documented with each analysis that requires imputation. If absent values need to 
be imputed, for instance for performing an overall test of significance of blood 
pressure differences, the last-observation-carried-forward (LOCF) method will be 
used for patients who were known to be alive or were lost to follow up. Subsequent 
to death, either zero will be imputed or the LOCF method will be used as appropri-
ate. 
2 DESCRIPTION OF STUDY POPULATION 
2.1 Analysis populations 
The number of selection criteria violations that occurred in the all-randomised 
population will be tabulated as shown in Appendix I – table and figure layouts, Ta-
ble 2. The valid-for-efficacy population is defined as the subset of patients for 
whom no selection criteria violation was noted (c.f. 1.3.2). 
 
2.2 Patient disposition 
The contribution of each centre to each of the two treatment arms for both the all-
randomised and the valid-for-efficacy population will be tabulated. The tabulation 
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will be sorted by country and then by centre as shown in Appendix I – table and 
figure layouts, Table 3. 
 
 
2.3 Baseline characteristics 
The general format for tabulating patient characteristics at the time of randomisa-
tion is shown in Appendix I – table and figure layouts, Table 1. Variables to tabu-
late are (by treatment group to be shown in table captions): 
 
2.3.1 Demographics 
 
CRF 
Variable label: 
Page Item 
Comment / category labels: 
Age 15 17.5 Take as (start date of study medication – date of birth ex-
pressed in days)/365.25. Tabulate as continuous variable 
(c.f. Table 1). 
Gender 15 17.6 Tabulate N (% of total in analysis population) male. 
Race 1 1.5 Tabulate N (% of total in analysis population) white / black / 
Asian / other. List free-text entries with Pat ID No. 
 
2.3.2 Ejection fraction 
 
CRF 
Variable label: 
Page Item 
Comment / category labels: 
Method used 1 2.1 Tabulate N (% of total in analysis population) 2D-echo / 
radionuclide / contrast / not done. When the date of 
measurement (item 2.2 CRF) is after start date of study 
medication (as entered on CRF page 15, item 17.8), con-
sider as ‘not done’ irrespective of what was ticked for this 
item. 
EF core laboratory N/A N/A Tabulate No. (% of total in analysis population) of patients 
with a valid core laboratory EF value (N1). Valid core labo-
ratory values are those with a recording date in the core 
laboratory database (NOT item 2.2 CRF) before or on the 
start date of study medication. Tabulate summary statis-
tics as described in section 1.4.1. 
Date of measurement 
(relative to start date of 
study medication) 
  Take as (start date of study medication – valid recording 
date in the core laboratory database) in days. Tabulate 
median and range. Tabulate N (% of N1) for 0 – 14 days / 
15 – 42 days / 43 – 182 days / 183 – 365 days / more 
than 365 days ago / unknown (c.f. Table 1 for layout). 
Investigator value only: 
2D-echo 
  N (% of total in analysis population) = N2 = number of 
patients with a valid investigator 2D-echo value only (see 
below). 
Investigator value only: 
radionuclide 
  N (% of total in analysis population) = N3 = number of 
patients with a valid investigator radionuclide value only 
(see below). 
Investigator value only: 
contrast 
  N (% of total in analysis population) = N4 = number of 
patients with a valid investigator contrast value only (see 
below). 
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CRF 
Variable label: 
Page Item 
Comment / category labels: 
Total number of values 
in tabulation (do not 
tabulate) 
  N1 + N2 + N3 + N4 must be equal to number of patients in 
tabulation for the valid-for-efficacy population. 
Investigator value only 
(all methods combined) 
1 2.3 Use value only when there is no core laboratory value 
with a recording date before or on the start date of study 
medication and the date of measurement (CRF page 1 
item 2.2) is before or on the start date of study medica-
tion. Tabulate No. (% of total in analysis population) of 
available values (must be equal to N2 + N3 + N4) and 
summary statistics (c.f. Table 1 for layout). 
Date of measurement 
(relative to start date of 
study medication) 
  Take as (start date of study medication – valid date of 
measurement in item 2.2, page 1 CRF) in days. Tabulate 
median and range. Tabulate N (% of N2 + N3 + N4) for 0 – 
14 days / 15 – 42 days / 43 – 182 days / 183 – 365 days / 
more than 365 days ago / unknown (c.f. Table 1 for lay-
out). 
Core lab echocardiography data are stored in the table ACTION_ECHO_2D_ALL 
in the ORACLE® database. Note that this table may contain more than one value 
for any given patient. The core lab baseline ejection fraction value must be taken 
from the record that has the last core lab date (field CLDT) before or on the start 
date of study medication (RANDOM.STARTDT_ CRF). 
Whenever possible, the core lab made three assessments of ejection fraction 
for each analysable echocardiogram (EF1, EF2 and EF3). When all three are avail-
able, the ejection fraction value to be used in the analysis is the median. When only 
two values are available, the value to be used in the analysis is the arithmetic mean. 
When one value is available, the value present will be used. 
 
2.3.3 Standard laboratory tests 
Baseline blood chemistry tests will be considered as having been performed if the 
date of sampling (item 3.1, CRF page 2) is valid and on or before the start date of 
study medication. The same applies to haematology. Laboratory tests with incom-
plete sampling dates will also be considered as having been performed (tests done 
before randomisation has been confirmed by a DCF). 
The time elapsed between date of sampling and start date of study medication 
will be taken as (start date of study medication – date of sampling) in days. For 
chemistry and haematology separately, the median and range will be tabulated, as 
well as N (% of total in analysis population) for 0 – 14 days / 15 – 42 days / 43 – 
182 days / 183 – 365 days / more than 365 days ago / unknown (c.f. Appendix I – 
table and figure layouts, Table 1 for layout). 
Except for total cholesterol, haematocrit and haemoglobin, available baseline 
laboratory test data will be tabulated by treatment group as follows: 
- Standard descriptive statistics for continuous variables (c.f. 1.4.1). 
- N (% of No. of available values) above global upper limit of normal. 
- N (% of No. of available values) below global upper limit of normal. 
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As the normal range for these assays depends on gender, haematocrit and haemo-
globin will be tabulated separately for men and women. 
For total cholesterol, the following will be tabulated: 
- Standard descriptive statistics for continuous variables. 
- N (% of No. of available values) below 5·0 mmol/l / 5·0 - 6·5 mmol/l / above 
6·5 mmol/l. 
Standard units and global limits of normal are given in Appendix II – Standard 
laboratory test units (not incorporated in this thesis). 
 
2.3.4 Standard 12-lead ECG 
The baseline ECG will be considered as having been recorded if the date of the 
ECG (item 5.1, CRF page 3) is valid and on or before the start date of study medi-
cation. Baseline ECGs with an incomplete date will also be considered as having 
been recorded (ECG made before randomisation has been confirmed by a DCF). 
The time elapsed between date of recording and start date of study medication 
will be taken as (start date of study medication – date of recording) in days. The 
median and range will be tabulated, as well as N (% of total in analysis population) 
for 0 – 14 days / 15 – 42 days / 43 – 182 days / 183 – 365 days / more than 365 
days ago / unknown (c.f. Appendix I – table and figure layouts, Table 1 for layout). 
For ventricular rate (item 5.3, CRF page 3), PR or PQ interval (item 5.4, CRF 
page 3), QRS interval and QT interval (item 5.4, CRF page 3), standard descriptive 
statistics for continuous variables (c.f. 1.4.1) will be tabulated (ventricular rate in 
beats/min; cardiac cycle measurements in milliseconds, i.e. the value entered in 
item 5.4, CRF page 3 multiplied by 103). 
In addition, the following will be tabulated for item 5.5, CRF page 3: 
- N (% of No. of available values) within normal limits / abnormal, not clinically 
significant / abnormal, clinically significant / ECG recorded but item not com-
pleted. 
- N (% of No. of available values) atrial fibrillation/flutter (item 5.6, CRF page 3, 
rhythm-conduction finding #105 or #106 ticked). 
- N (% of No. of available values) pacemaker (item 5.6, CRF page 3, rhythm-
conduction finding #111 ticked). 
 
2.3.5 Cardiovascular medical history 
 
CRF 
Variable label: 
Page Item 
Comment / category labels: 
(N = number of patients) 
History assessed 4 6.1 N (% of total in analysis population) for which date in 
item 6.1 is on or before start date of study medication. 
History of qualifying 
angina 
4 6.2 Tabulate N (% of total with history assessed) = yes. 
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CRF 
Variable label: 
Page Item 
Comment / category labels: 
(N = number of patients) 
Duration of qualifying 
angina (days) 
12 16 Take as (start date of study medication – onset date) in 
days. Tabulate median and range. Tabulate N (% of total 
with history assessed and item 6.2 = yes) for 0 – 14 
days / 15 – 42 days / 43 – 182 days / 183 – 365 days / 
more than 365 days ago / unknown (c.f. Table 1 for lay-
out). 
Attack frequency 12 16 Tabulate as categorical variable (c.f. 1.4.2). 
NYHA class 4 6.3 Tabulate as categorical variable (c.f. 1.4.2). 
History of documented 
AMI 
4 6.4 Tabulate N (% of total with history assessed) = yes AND 
date most recent MI is complete and on or before start 
date of study medication (no date check is required for 
incomplete date of most recent MI). 
Number of MIs 4 6.4 Tabulate N (% with history of MI) for one / multiple / 
number unknown. 
Time since most recent 
MI (days) 
4 6.4 Take as (start date of study medication – date most 
recent MI) in days. Tabulate median and range. Tabu-
late N (% of total with history of MI) for 0 – 14 days / 15 
– 42 days / 43 – 182 days / 183 – 365 days / more than 
365 days ago / unknown (c.f. Table 1 for layout). 
History of claudication 4 6.5 Tabulate N (% of total with history assessed) = yes. 
History of TIA 4 6.6 Tabulate N (% of total with history assessed) = yes. 
History of any stroke 12 16 Tabulate N (% of total with history assessed) for stroke 
mentioned on CRF page 12 (ICD 9 code = 430, 431, 
432, 434.91 or 436). 
History of debilitating 
stroke 
4 6.7 Tabulate N (% of total with history assessed) = yes. 
History of claudication, 
TIA or stroke 
  Tabulate N (% of total with history assessed) = any 6.5 – 
6.7 = yes or stroke mentioned on CRF page 12. 
Exercise test performed 5 6.9 Tabulate N (% of total with history assessed) = yes AND 
date most recent test is complete and on or before start 
date of study medication OR date most recent test is 
incomplete (i.e. test done before randomisation has 
been confirmed by a DCF). 
Time since last test 
(days) 
5 6.9 Take as (start date of study medication – date last test) 
in days. Tabulate median and range. Tabulate N (% of 
total with valid test) for 0 – 14 days / 15 – 42 days / 43 – 
182 days / 183 – 365 days / more than 365 days ago / 
unknown (c.f. Table 1 for layout). 
Result 5 6.9 Tabulate N (% of total with valid test) positive for CAD / 
negative for CAD / unknown. 
Perfusion scintigraphy 
performed 
5 6.10 Tabulate N (% of total with history assessed) = yes AND 
date most recent test is complete and on or before start 
date of study medication OR date most recent test is 
incomplete (i.e. test done before randomisation has 
been confirmed by a DCF). 
Time since last test 
(days) 
5 6.9 Take as (start date of study medication – date last test) 
in days. Tabulate median and range. Tabulate N (% of 
total with valid test) for 0 – 14 days / 15 – 42 days / 43 – 
182 days / 183 – 365 days / more than 365 days ago / 
unknown (c.f. Table 1 for layout). 
Result 5 6.10 Tabulate N (% of total with valid test) positive for CAD / 
negative for CAD / unknown. 
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CRF 
Variable label: 
Page Item 
Comment / category labels: 
(N = number of patients) 
Coronary angiography 
(CAG) performed 
5 6.11 Tabulate N (% of total with history assessed) = yes AND 
date most recent angiogram is complete and on or be-
fore start date of study medication OR date most recent 
angiogram is incomplete (i.e. angiogram done before 
randomisation has been confirmed by a DCF). 
Number of CAGs 5 6.11 Tabulate N (% of total with valid CAG) one / two / three 
or more / unknown how many. 
Time since last CAG 
(days) 
5 6.9 Take as (start date of study medication – date most 
recent CAG) in days. Tabulate median and range. Tabu-
late N (% of total with valid CAG) for 0 – 14 days / 15 – 
42 days / 43 – 182 days / 183 – 365 days / more than 
365 days ago / unknown (c.f. Table 1 for layout). 
Result unknown 5 6.11 Tabulate N (% of total with valid CAG) for whom none of 
the items 1 – 6 in the box concerned was ticked. 
No significant lesions 5 6.11 Tabulate N (% of total with valid CAG) ‘no significant 
lesions’ ticked AND no other lesion 2 – 6 ticked in the 
box concerned. 
Left main (LM) 5 6.11 Tabulate N (% of total with valid CAG) ticked. 
Left anterior descending 
(LAD) 
5 6.11 Tabulate N (% of total with valid CAG) ticked. 
Right coronary (RC) 5 6.11 Tabulate N (% of total with valid CAG) ticked. 
Circumflex (CX) 5 6.11 Tabulate N (% of total with valid CAG) ticked. 
Other 5 6.11 Tabulate N (% of total with valid CAG) ticked. 
No. of lesions:    
Other only 5 6.11 N (% of total with valid CAG) other ticked; none of LM, 
LAD, RC, CX ticked. 
One vessel (other than 
LM) 
5 6.11 N (% of total with valid CAG) LM not ticked plus one of 
LAD, RC, CX ticked. 
Two vessels (LM 
counted as two) 
5 6.11 N (% of total with valid CAG) LM but not LAD, RC, CX 
ticked; or LM not ticked and two of LAD, RCA, CX 
ticked. 
Three vessels (LM 
counted as two) 
5 6.11 N (% of total with valid CAG) LM ticked plus one of LAD, 
RCA, CX ticked; or LM not ticked and all three LAD, 
RCA, CX ticked. 
Four vessels (LM 
counted as two) 
5 6.11 N (% of total with valid CAG) LM ticked plus two of LAD, 
RCA, CX ticked. 
Five vessels (LM 
counted as two) 
5 6.11 N (% of total with valid CAG) LM ticked plus LAD, RCA, 
CX all ticked. 
PTCA performed 5 6.12 Tabulate N (% of total with history assessed) = yes AND 
date most recent PTCA is complete and on or before 
start date of study medication OR date most recent 
PTCA is incomplete (i.e. PTCA done before randomisa-
tion has been confirmed by a DCF). 
Number of PTCAs 5 6.12 Tabulate N (% of total with valid PTCA) one / two / three 
or more / unknown how many. 
Number of PTCAs with 
stenting 
12 – 
14 
 Tabulate N (% of total with valid PTCA) with stenting 
mentioned on CRF page 12 – 14. 
Time since last PTCA 
(days) 
5 6.9 Take as (start date of study medication – date most 
recent PTCA) in days. Tabulate median and range. 
Tabulate N (% of total with valid PTCA) for 0 – 14 days / 
15 – 42 days / 43 – 182 days / 183 – 365 days / more 
than 365 days ago / unknown (c.f. Table 1 for layout). 
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CRF 
Variable label: 
Page Item 
Comment / category labels: 
(N = number of patients) 
Total No. of vessels 
dilated 
5 6.12 Tabulate N (% of total with valid PTCA) one / two / three 
or more / unknown how many. 
Total No. of vessels 
successfully dilated 
5 6.12 Tabulate N (% of total with valid PTCA) one / two / three 
or more successes ticked / unknown how many suc-
cesses. 
Left anterior descending 
(LAD) dilated 
5 6.12 Tabulate total N (% of total with valid PTCA) LAD di-
lated. 
Result for LAD 5 6.12 Tabulate total N (% of total with valid PTCA and LAD 
dilated) that were ticked as successful = no / successful 
= yes / unknown 
Right coronary (RC) 
dilated 
5 6.12 Tabulate total N (% of total with valid PTCA) RC dilated. 
Result for RC 5 6.12 Tabulate total N (% of total with valid PTCA and RC 
dilated) that were ticked as successful = no / successful 
= yes / unknown. 
Circumflex (CX) dilated 5 6.12 Tabulate total N (% of total with valid PTCA) CX dilated. 
Result for CX 5 6.12 Tabulate total N (% of total with valid PTCA and CX 
dilated) that were ticked as successful = no / successful 
= yes / unknown. 
Other dilated 5 6.12 Tabulate total N (% of total with valid PTCA) other di-
lated. 
Result for other 5 6.12 Tabulate total N (% of total with valid PTCA and other 
dilated) that were ticked as successful = no / successful 
= yes / unknown. 
CABG performed 6 6.13 Tabulate N (% of total with history assessed) = yes AND 
date most recent CABG is complete and on or before 
start date of study medication OR date most recent 
CABG is incomplete (i.e. CABG done before randomisa-
tion has been confirmed by a DCF). 
Number of CABGs 6 6.13 Tabulate N (% of total with valid CABG) one / two / three 
or more / unknown how many. 
Time since last CABG 
(days) 
5 6.9 Take as (start date of study medication – date most 
recent CABG) in days. Tabulate median and range. 
Tabulate N (% of total with valid CABG) for 0 – 14 days / 
15 – 42 days / 43 – 182 days / 183 – 365 days / more 
than 365 days ago / unknown. 
Total No. of vessels 
bypassed 
6 6.13 Tabulate N (% of total with valid CABG) one / two / three 
or more / unknown how many. 
Left main (LM) by-
passed 
6 6.13 Tabulate total N (% of total with valid CABG) LM by-
passed. 
Left anterior descending 
(LAD) bypassed 
6 6.13 Tabulate total N (% of total with valid CABG) LAD by-
passed. 
Right coronary (RC) 
bypassed 
6 6.13 Tabulate total N (% of total with valid CABG) RC by-
passed 
Circumflex (CX) by-
passed 
6 6.13 Tabulate total N (% of total with valid CABG) CX by-
passed. 
Other bypassed 6 6.13 Tabulate total N (% of total with valid CABG) other by-
passed. 
Risk factors:    
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CRF 
Variable label: 
Page Item 
Comment / category labels: 
(N = number of patients) 
History of hypertension 
treated with drugs at the 
time of randomisation 
6 6.14.1 Tabulate N (% of total with history assessed) where 
hypertension is mentioned on CRF page 12 (ICD 9 code 
= 401.9 has been assigned during data entry), any drug 
registered for lowering blood pressure is documented on 
CRF pages 125-129, date first used of drug(s) con-
cerned is before or on date of first study medication 
intake (or ticked as prescribed at moment of randomisa-
tion in the case date first used is incomplete) and route 
of administration is ticked as PO/O. 
History of hyperlipidae-
mia treated with drugs 
at the time of randomi-
sation 
6 6.14.2 Tabulate N (% of total with history assessed) = yes. 
Diabetes 6 6.14.3
6.14.4 
Tabulate N (% of total with history assessed) 6.14.3 = 
yes OR 16.4.4 = yes. 
Treated with insulin 6 6.14.3 Tabulate N (% of total with history assessed) and 6.14.3 
= yes. 
Smoking 6 6.14.5 Tabulate N (% of total with history assessed) never 
smoked / ex-smoker / current smoker / unknown. 
Ex-smokers stopped   Tabulate N (% of total with history assessed and ex-
smoker) within last year / 1 – 5 years ago / more than 5 
years ago / unknown. 
Pack-years smoked   Tabulate as continuous variable (c.f. 1.4.1). 
 
2.3.6 Other cardiovascular medical history 
 
CRF 
Variable label: 
Page Item 
Comment / category labels: 
(N = number of patients) 
History assessed 4 6.1 N (% of total in analysis population) for which date in item 
6.1 is on or before start date of study medication. 
History other CV condi-
tion 
  Tabulate N (% of total with history assessed) with any 
other CV condition listed on CRF page 12 – 14. 
 12 – 
14 
 List/count cardiovascular conditions mentioned by treat-
ment group, sorted by total number of patients con-
cerned. 
 
2.3.7 Non-cardiovascular medical history 
 
CRF 
Variable label: 
Page Item 
Comment / category labels: 
(N = number of patients) 
History assessed 4 6.1 N (% of total in analysis population) for which date in item 
6.1 is on or before start date of study medication. 
History non-CV condi-
tion 
  Tabulate N (% of total with history assessed) with any 
non- CV condition listed on CRF page 12 – 14. 
 12 – 
14 
 List/count non-cardiovascular conditions mentioned by 
treatment group sorted by total number of patients con-
cerned. 
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2.3.8 Height, weight and vital signs 
Height, weight and vital signs measurements will be considered as having been 
performed if the date of assessment (item 8.1, CRF page 7) is valid and on or be-
fore the start date of study medication. Baseline vital signs with an incomplete date 
will also be considered as having been recorded (assessments done before randomi-
sation confirmed by a DCF). 
The time elapsed between date of assessment and start date of study medica-
tion will be taken as (start date of study medication – date of assessment) in days. 
The median and range will be tabulated, as well as N (% of total in analysis popu-
lation) for 0 – 14 days / 15 – 42 days / 43 – 182 days / 183 – 365 days / more than 
365 days ago / unknown (c.f. Appendix I – table and figure layouts, Table 1 for 
layout). Standard descriptive statistics for continuous variables (c.f. 1.4.1) for body 
weight, seated pulse rate and body height respectively will be tabulated by treat-
ment group (c.f. Appendix I – table and figure layouts, Table 1 for layout). For item 
8.3 (pulse rate) N (% of No. of available values) regular / irregular / unknown will 
be given also. 
Body mass index (BMI): 
BMI will be taken as weight in kilograms divided by the squared height in metres 
and will be tabulated as follows: 
- Standard descriptive statistics for a continuous variable (c.f. 1.4.1). 
- N (% of No. of available values) below 25 kg/m2 / 25·00 – 29·99 kg/m2 / 30·00 
– 39·99 kg/m2 / 40·00 kg/m2 or above. 
Systolic blood pressure (SBP): 
In addition to standard descriptive statistics for a continuous variable (c.f. 1.4.1), 
N(% of No. of available values) below 100 mm Hg / 100 - 119 mm Hg / 120 - 139 
mm Hg / 140 - 159 mm Hg / 160 - 179 mm Hg / 180 mm Hg or above will be tabu-
lated (c.f. Appendix I – table and figure layouts, Table 1 for layout). 
Diastolic blood pressure (DBP): 
In addition to standard descriptive statistics for a continuous variable (c.f. 1.4.1), 
N(% of No. of available values) below 70 mm Hg / 70 - 79 mm Hg / 80 - 89 mm 
Hg / 90 - 99 mm Hg / 100 - 109 mm Hg / 110 mm Hg or above (c.f. Appendix I – 
table and figure layouts, Table 1 for layout). 
Blood pressure classification (1999 WHO/ISH classification): 
Tabulate as categorical variables (c.f. Appendix I – table and figure layouts, Table 1 
for layout): 
- N (% of No. of available values) optimal (SBP < 120 and DBP < 80) / normal 
(SBP 120 – 129, DBP 80 – 84) / high normal (SBP 130 – 139, DBP 85 – 89) / 
Grade 1 hypertension (SBP 140 – 159, DBP 90 – 99) / Grade 2 hypertension 
(SBP 160 – 179 or DBP 100 – 109) / Grade 3 hypertension (SBP > 179 or DBP 
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> 109). When a patient’s systolic and diastolic blood pressures fall into different 
categories, the more severe category will apply. 
- N (% of No. of available values) isolated systolic hypertension (SBP > 139 and 
DBP < 90). 
 
 
 
2.3.9 Physical examination 
Physical examination abnormalities will be listed as part of the cardiovascular or 
non-cardiovascular medical history (c.f. 2.3.6 and 2.3.7) as appropriate. 
 
2.3.10 Concomitant treatment 
For drugs entered on the concomitant treatment log pages (CRF page 125 – 129) 
with a date first used before or on the start date of study medication and a date last 
used that is either empty or after the start date of study medication, or for drugs for 
which the field CT.BEFORE_START contains “Y” (i.e. when the investigator has 
indicated on a DCF that the treatment concerned was used at baseline although the 
date first used on the CRF is incomplete), the following will be tabulated: 
- N (%) on a beta-blocker. 
- N (%) on an ACE-inhibitor. 
- N (%) on a diuretic. 
- Etc. 
- N (%) using anti-anginal medication categorised as none / one / two or more, 
counting only drugs registered for symptomatic relief of angina as anti-anginal 
medication. 
Cardiovascular and non-cardiovascular treatments will be tabulated separately. 
Tabulations will be sorted by frequency of use. 
3 COMPLIANCE WITH FOLLOW UP 
3.1 Person-time of follow up realised 
The ORACLE® database field V_SYS_VISIT_DATES.PLANDT contains for each 
patient the planned date of the end-of-study visit as calculated in accordance with 
the ACTION study document Close-Out Procedures: Guideline for Investigators 
and CRAs (version 2 dated 14 February 2003). 
Follow up for clinical events after the planned date of the end-of-study visit will be 
ignored in time-to-event analyses. 
The total number of person-years of intended follow up will be calculated by 
treatment arm by summation of the following quantities: 
1. For patients who died on or before the planned date of the end-of-study visit: 
sum of years elapsed between start date of study medication and date of death. 
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2. For patients who were seen for the end-of-study visit on or after the planned 
date: sum of years elapsed between start date of study medication and planned 
date of end-of-study visit. 
3. For patients who had the last out-patient clinic visit in the time interval 42 days 
– 1 day (both days included) before the planned date of the end-of-study visit: 
sum of years elapsed between start date of study medication and actual date of 
last visit. 
4. For patients who were last seen or contacted earlier than 42 days before the 
planned date of the end-of-study visit: sum of years elapsed between start date 
of study medication and planned date of end-of-study visit. 
Note that these categories concern mutually exclusive groups of patients. Calcula-
tions will be done in days, which will be converted to years by dividing the number 
of days by 365·25. 
Patients belonging to category 3 above (i.e. last out-patient clinic visit 42 days – 1 
day before the planned date of the end-of-study visit) will not be labelled as ‘lost to 
follow up’ in trial reports. 
The total number of person years of intended follow up as calculated above 
will be displayed by treatment arm as shown in Appendix I – table and figure lay-
outs, Figure 1. In the same figure, the following quantities will also be displayed by 
treatment arm: 
- For patients who died: sum of years elapsed between start date of study medica-
tion and date of death (i.e. total follow up as calculated for patients belonging to 
category 1 above). 
- For patients who terminated follow up earlier than planned: sum of years 
elapsed between start date of study medication and actual date last seen or con-
tacted (i.e. total follow up for patients belonging to category 4 above as calcu-
lated by using the actual date last seen or contacted, rather than the planned date 
of the end-of-study visit). 
- For patients who completed study as planned: sum of years of follow up as cal-
culated for category 2 above plus sum of years of follow up as calculated for 
category 3 above. 
The percentage of intended follow up completed will be taken as (follow up for 
patients who died plus follow up for patients who terminated study earlier than 
planned plus follow up for patients who completed follow up as planned) divided 
by intended follow up as defined earlier. 
 
3.2 Time windows for planned follow up visits 
The planned date for each follow up visit or contact is given in years and weeks 
relative to the start date of study medication in Table 1 in section 9.4.2.1 of the pro-
tocol. Relative to the planned visit or contact date based on this table, the following 
time windows will be used as a basis for deciding whether the planned follow up 
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visit or contact concerned has actually been performed (c.f. summary ACTION 
SAP meeting dated April 17-18, 2003): 
- For visit 1 (2-week clinic visit): minus seven days – plus seven days (first and 
last day included). 
- For visit 2 (6-week clinic visit): minus 2 x 7 = 14 days – plus 3 x 7 = 21 days 
(first and last day included). 
- For visits 3 – 26 (interim contacts, half-yearly clinic visits and end-of-study 
visit): minus 6 x 7 = 42 days – plus 7 x 7 = 49 days (first and last day included). 
Data from visits outside these time windows will not be analysed statistically. 
 
3.3 Planned follow up visits / contacts performed 
The actual dates of (extra) visits and contacts in the database and the time windows 
given in section 3.2 will be used to determine whether a valid planned visit or con-
tact is available for each time window concerned. If more than one visit or contact 
took place within a certain time window, the planned visit or contact closest to the 
planned date will be considered valid even if an extra visit closer to the planned 
date is available. In the case only extra visits have taken place within the time win-
dow concerned, the extra visit that is closest to the planned visit or contact date will 
be considered equivalent to a valid planned visit or contact. Note that this implies 
that follow up data may be available for analysis even though the planned visit 
concerned didn’t take place within the time window specified in the protocol, or 
wasn’t done at all. Note also that the end-of-study visit will be considered valid 
when done no later than 49 days after the planned date.  
For each planned visit or contact specified in the protocol, the percentage of 
visits or contacts that took place will be calculated as follows. The numerator is 
equal to the number of patients who had a valid planned visit or contact within the 
time window concerned as given in section 3.2 of this document. This must be di-
vided by the number of patients who were still under follow up on the last day of 
the time window for the visit or contact concerned. The latter is obtained by taking 
the number of patients in the analysis population concerned minus the number of 
patients who had died either before or on the last day of the time window con-
cerned, minus the number of patients who were last seen or contacted either before 
or on the last day of the time window concerned. Results will be tabulated as 
shown in Appendix I – table and figure layouts, Table 4. 
 
3.4 Compliance with study medication 
3.4.1 Study medication continued at each visit 
For each valid planned follow up visit or contact (c.f. 3.3), the following will be 
calculated: 
1. Number of patients who were continued on any dose of study medication at the 
visit or contact concerned (CRF item 7.1, 10.1 or 12.1 – depending on visit 
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number and type (i.e. planned or extra) – ticked as either 30 mg/day or 60 mg/ 
day). 
2. The fraction of patients who were continued on any dose of study medication at 
the visit or contact concerned, using the total number of valid planned visits or 
contacts that were performed as denominator. 
3. Number of patients who were continued on full dose of study medication at the 
visit concerned (CRF item 7.1, 10.1 or 12.1 ticked as 60 mg/day). 
4. The fraction of patients who were continued on full dose of study medication at 
the visit concerned, using the total number of valid planned visits or contacts as 
denominator. 
Results will be tabulated in similar manner as shown in Appendix I – table and fig-
ure layouts, Table 4. 
Continuation of study medication by visit will be displayed by plotting the fol-
lowing fractions for each treatment group and for each planned clinic visit or con-
tact as specified in the protocol: 
1. Fraction of patients still alive after the planned duration of follow up for the 
visit concerned (as obtained from the Kaplan-Meier curve for total mortality). 
2. Fraction of patients still alive after the planned duration of follow up for the 
visit concerned, multiplied by the fraction of patients on any dose of study 
medication for the visit concerned. 
3. Fraction of patients still alive after the planned duration of follow up for the 
visit concerned, multiplied by the fraction of patients on full dose of study 
medication for the visit concerned. 
 
3.4.2 Time compliance 
Time compliance with the study medication regimen (% of time until event or cen-
soring on full dose / % of time until event or censoring on half dose) will be calcu-
lated based on start and stop dates documented on the study medication log pages 
(CRF page 130 – 134), and on the event or censoring dates concerned. Calculations 
must be done separately for the time-to-event analyses described below in the sec-
tions Primary analysis for efficacy (c.f. 4.1) and Primary analysis for safety (c.f. 
4.2) respectively, and for the secondary time to event analyses described in section 
4.3.1. Results will be tabulated for each time-to-event analysis mentioned as shown 
in Appendix I – table and figure layouts, Table 5. 
 
3.4.3 Tablet compliance 
Based on tablet count data documented on the study medication log pages, study 
medication tablet compliance will be calculated as the percentage of predicted tab-
lets that was actually used. 
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4 EVALUATION OF EFFICACY AND SAFETY 
4.1 Primary analysis for efficacy 
The primary analysis for efficacy (c.f. 1.2.1) is a time-to-event analysis specified as 
follows: 
Start date: Date of first study medication intake. 
Event date: Date of the first of the following: death (all causes), acute myo-
cardial infarction (AMI), procedural or accompanying myocardial 
infarction (PMI), refractory angina requiring emergency coronary 
angiography, overt heart failure, debilitating stroke, peripheral 
revascularisation (as diagnosed by the CEC, c.f. 1.2.4). 
Censoring date: Date that the patient was last seen or contacted (patient lost to 
follow up, end-of-study visit took place before planned date), or 
planned date of end-of-study visit. 
The planned date of the end-of-study visit in the database has been calculated as 
described in the ACTION study document Close-Out Procedures: Guideline for 
Investigators and CRAs (version 2 dated 14 February 2003). 
Events occurring after the planned date of the end-of-study visit will not be consid-
ered. 
The primary analysis variable is major cardiovascular event-free survival, defined 
as (date of first study medication intake minus date of event or censoring) in days. 
It follows that in the case the date of the first event is the same as the date of first 
study medication intake, the number of days until first event is equal to zero. 
Using the SAS® version 8 proc LIFETEST or equivalent, Kaplan-Meier 
curves will be plotted that show major cardiovascular event-free survival as a func-
tion of observation time by treatment group. These Kaplan Meier plots will be pre-
sented ‘going up’, i.e. starting at 0% experiencing any of the events concerned at 
the time of start of first study medication intake. Below the horizontal axis the 
number of patients still ‘at risk’ of a first major cardiovascular event will be pre-
sented at each half year (i.e. 365·25/2 days) of follow up for each treatment arm 
(c.f. Appendix I – table and figure layouts, Figure 2) 
The primary statistical analysis testing the null hypothesis that there is no 
treatment difference will be a log-rank test (unadjusted for any covariates) accom-
panied by the estimated hazard ratio and its 95% confidence interval. Hazard ratios 
for nifedipine will be taken relative to placebo. Hence, a hazard ratio less than 1 
will indicate that patients assigned to nifedipine GITS have a decreased risk. 
The primary endpoint is a composite of several events. The occurrence of each 
component event (first event only), the number of patients with any combined 
event, the number of patient years at risk for the combined event and the event rate 
(hazard) per 100 patient years ‘at risk’ will be tabulated by treatment group as 
shown in Appendix I – table and figure layouts, Table 5. The hazard ratio (relative 
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to placebo), its 95% confidence interval and the p-value for the log-rank test will 
be given as shown. Note that these tabulations also list the number of patients 
withdrawn permanently from study medication before the combined endpoint con-
cerned occurred, and the applicable percentage of time ‘at risk’ for this combined 
endpoint that full- or half-dose study medication were prescribed. 
 
4.2 Primary analysis for safety 
The primary analysis for safety (c.f. 1.2.2) is a time-to-event analysis similar to the 
primary analysis for efficacy (c.f. 4.1), but considering only the first of the follow-
ing events: death (all causes), acute myocardial infarction (AMI), procedural or 
accompanying myocardial infarction (PMI), debilitating stroke (as diagnosed by 
the CEC, c.f. 1.2.4). 
The primary variable for safety will be analysed and documented in the same 
manner as the primary analysis variable for efficacy (c.f. 4.1). 
Events occurring after the planned date of the end-of-study visit will not be consid-
ered. 
 
4.3 Secondary Analyses 
4.3.1 Time-to-event analyses 
Secondary time-to-event analyses will be performed in the same manner as de-
scribed for the primary analysis for efficacy (c.f. 4.1) for the following combined 
endpoints: 
1. Death from any cause. 
2. Any major cardiovascular event as diagnosed by the CEC (i.e. the primary end-
point for efficacy minus non-cardiovascular death as diagnosed by the CEC – 
secondary efficacy criterion according to protocol). 
Deaths with cause classified by the CEC as ‘unknown’ will be considered as car-
diovascular. 
3. Death or any cardiovascular event as diagnosed by the CEC or cardiac interven-
tion (i.e. the primary endpoint for efficacy plus coronary angiography, PTCA, 
CABG – secondary efficacy criterion according to protocol). 
4. Any major vascular event or revascularisation (i.e. the primary endpoint for ef-
ficacy minus non-cardiovascular death as diagnosed by the CEC, minus overt 
heart failure; plus PTCA, CABG – additional pre-specified secondary efficacy 
criterion). 
Each of these time-to-event analyses will be tabulated in the same manner as the 
primary analysis variable for efficacy (c.f. 4.1). For tabulation purposes, events 
which occur on the same day must be ordered. For events diagnosed by the CEC 
with the same date, the sort order for determining the event that occurred first may 
Chapter 7 
118 
be found in the CEC database. For time-to-event analyses that also consider the 
procedures coronary angiography, PTCA and CABG, the following rules apply: 
1. If the first event includes any event diagnosed by the CEC (c.f. 1.2.4), the event 
terminating event-free follow up will be taken from the CEC database, using the 
sort order from the CEC database in the case of multiple events diagnosed by 
the CEC on the same day. 
2. If the date of the first event concerns one of the procedures coronary angiogra-
phy, PTCA, or CABG in the absence of an event diagnosed by the CEC on the 
same day, the event terminating event-free follow up will be taken as the proce-
dure concerned (note that coronary angiography is counted as event only in the 
third secondary time-to-event analysis mentioned earlier, while PTCA and 
CABG are counted only in the fourth). 
3. If the date of the first event concerns any two or three of the procedures coro-
nary angiography, PTCA, or CABG in the absence of an event diagnosed by the 
CEC on the same day, the sort order which determines the event terminating 
event-free follow up will be taken as PTCA, CABG, coronary angiography 
(note that coronary angiography is counted as event only in the third secondary 
time-to-event analysis mentioned earlier). 
Events occurring after the planned date of the end-of-study visit will not be consid-
ered. 
 
4.3.2 Analyses for individual events 
The total occurrence of each individual event or procedure mentioned in the previ-
ous section, the number of patients with at least one event, the number of patient 
years at risk of event and the event rate (hazard) per 100 patient years ‘at risk’ will 
be tabulated by treatment group as shown in Appendix I – table and figure layouts, 
Table 6. For each event, the hazard ratio (relative to placebo), its 95% confidence 
interval and the p-value for the log-rank test will be given as shown. Patient years 
at risk will be taken as the sum of the observation time from start of study medica-
tion until the first occurrence of the event concerned, or until censoring because of 
death, planned end of observation or date last seen or contacted. 
For tabulating coronary angiography and PTCA as individual events, the fol-
lowing rule applies: if a PTCA is documented as an SAE and coronary angiography 
is documented in the SAE table on the same date as PTCA, only PTCA will be 
counted. 
Events occurring after the planned date of the end-of-study visit will not be consid-
ered. 
 
4.3.3 NYHA Class 
The principal analysis of NYHA class is based on the following information: 
- Start date of study medication. 
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- Date of occurrence of the first of the following: death (all causes), acute myo-
cardial infarction (AMI), procedural or accompanying myocardial infarction 
(PMI), refractory angina requiring emergency coronary angiography, overt heart 
failure, debilitating stroke, peripheral revascularisation occurred (i.e. the pri-
mary endpoint for efficacy, based on diagnoses made by the CEC, c.f. 1.2.4). 
- Actual date that the patient was last seen or contacted (patient lost to follow up, 
end-of-study visit took place before planned date). 
- Planned date of end-of-study visit. 
- NYHA class values for valid planned follow up visits and for the end-of-study 
visit (c.f. 3.3). 
The analysis will first calculate the length of follow up in days until death or cen-
soring (as used in time-to-event analyses, not counting days after the planned date 
of the end-of-study visit). For patients who had one of the events mentioned earlier, 
this time will then be subdivided into event-free survival time, and survival time 
after first event. Next, event-free survival time will be subdivided into the time 
spent in each of the four NYHA classes. This will be done as follows. First, the 
start date and the end-date of event-free survival time will be determined. Next, the 
actual dates of available NYHA class values recorded for baseline and for valid 
planned visits (c.f. 3.3) done while the patient was event-free will be determined. 
For patients who were event-free at the end-of-study visit, the end-of-study NYHA 
class value date will be taken as the date the patient was last seen or contacted (for 
end-of-study visits done before the planned date), or as the planned date of the end-
of-study visit (for end-of-study visits done on or after the planned date). The end-
of-study visit NYHA class will be considered missing in the case the end-of-study 
visit was done more than 49 days after the planned date. 
Based on valid planned NYHA class assessments and their actual dates as de-
fined earlier, event-free survival time will be subdivided into the number of days 
spent in each NYHA class, assuming that changes in NYHA class occurred at the 
mid-point between the dates that NYHA class was recorded. In the case there is no 
valid end-of-study NYHA class value, NYHA class will be considered not to have 
changed since the last valid assessment (which may be the baseline assessment). 
Note that this analysis uses only recorded NYHA class values and is not affected 
by missing follow up observations. In the case the baseline NYHA class value is 
missing, the mode (not the mean) of the overall distribution at baseline of available 
assessments will be imputed. 
Having obtained the amount of event-free survival time spent in each NYHA 
class for each patient, and if applicable survival time after first event, the mean 
event-free survival time spent in each NYHA class, and the survival time after first 
event, will be calculated and tabulated for each treatment group. 
An overall significance test for the differences between treatment groups with 
respect to mean time in each NYHA class will be based on the following ranking 
scale: 
1 = Alive, free of any event mentioned earlier, in NYHA class I. 
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2 = Alive, free of any event mentioned earlier, in NYHA class II. 
3 = Alive, free of any event mentioned earlier, in NYHA class III. 
4 = Alive, free of any event mentioned earlier, in NYHA class IV. 
5 = Alive but first event has occurred. 
6 = Died. 
For each patient, the time elapsed between start of study medication and censoring 
will be calculated assuming that no patient died. This time will then be subdivided 
by the time spent in each class of the ranking scale 1 – 6 just given. For the time 
elapsed between start of study medication and first event, this will be done as de-
scribed above for NYHA class. Ranks 5 and 6 on the other hand will be considered 
as ‘absorbing states’. From the results, the weighted average rank will be calculated 
for each patient, using the time spent in each rank as weights. Weighted average 
ranks will be compared between treatment groups using the following model: 
Weighted average rank = c0 + c1·(NYHA class at baseline) + c2·(duration of follow 
up assuming no death) + c3·(indicator of treatment) + random error. 
For each planned visit the availability of NYHA class data will be tabulated by 
treatment group as for other information collected at routine follow up visits. This 
will be done both including and excluding valid planned visits performed subse-
quent to the occurrence of the primary endpoint for efficacy. The following data 
structure will be the basis for displaying the evolution of NYHA class over time for 
each treatment group (imaginary data): 
 
[1] [2] [3] [4] [5] [6] [7] [8] [9] 
 NYHA class (% in patient free of primary efficacy endpoint): Points to plot by month: 
month I II III IV S(t) IV III II 
0 0 70 30 0 1.00 1.00 0.70 0.00 
6 10 62 24 4 0.97 0.93 0.70 0.10 
12 20 55 18 7 0.94 0.88 0.71 0.19 
18 25 44 22 9 0.91 0.83 0.63 0.23 
24 30 42 17 11 0.89 0.79 0.64 0.27 
30 33 40 12 15 0.86 0.73 0.63 0.28 
36 30 38 17 15 0.83 0.71 0.57 0.25 
Etc.         
 
By column, the following is tabulated: 
[1] Planned timing of subsequent clinic visits. 
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[2] – [5] For each planned follow up visit and the end-of-study visit: percentage of 
patients who are free of the primary efficacy endpoint, and who are 
known to be in class NYHA I, II, III or IV respectively. The denominator 
for calculating the percentages is equal to the total number of NYHA 
class assessments available for the valid planned follow up visit con-
cerned (c.f. 3.3) amongst patients who are free of the primary efficacy 
endpoint at the actual date of the visit concerned. 
[6] Kaplan-Meier estimates of major cardiovascular event-free survival for 
the time points corresponding to planned visits. 
[7] For each subsequent follow up visit: estimated fraction of patients who 
are free of the primary efficacy endpoint and who are in either NYHA 
class I, II or III, as obtained by multiplying the entry in column [6] with 
the sum of the entries in column [2] – [4], divided by 100 (for example 
for 12 months: 0·94 x [(20 + 55 + 18)/100] = 0·88). 
[8] Same as in column [7] but now for either NYHA class I or II (for exam-
ple for 12 months: 0·94 x [(20 + 55)/100] = 0·71). 
[9] Same as in column [8] but now for NYHA class I only (for example for 
12 months: 0·94 x (20/100) = 0·19). 
Note that in columns [2] – [5], only actually available NYHA class values are con-
sidered and percentages are taken relative to the total number of patients free of the 
primary efficacy endpoint for whom NYHA class is available. This solves the prob-
lem of missing NYHA class values. 
The points in column [1] and columns [6] – [9] can now be plotted as shown 
below: 
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The Kaplan-Meier estimates of survival will also be plotted in the above figure. 
A secondary analysis for NYHA class will be performed as follows. Suppose 
that valid NYHA class data for planned visits (c.f. 3.3) and hospitalisation data for 
a certain patient have the following form: 
Date(0): Start of study medication, baseline NYHA class = II. 
Date(1): Valid planned out-patient clinic visit, NYHA assessed as class I. 
Date(2): Valid planned out-patient clinic visit, NYHA assessed as class IV. 
Date(3): Admitted to hospital (for any reason). 
Date(4): Discharged from hospital. 
Date(5): Valid planned out-patient clinic visit, NYHA assessed as class I. 
Date(6): End of follow up, end-of-study NYHA (c.f. 4.3.3) assessed as class III. 
This patient contributes [date(6) – date(0)] in days to total survival time, subdi-
vided as follows: 
- From date(0) to ½·[date(1) – date(0)]: no. of days in NYHA class II (assuming 
as before that transitions between NYHA classes occur, on the average, half-
way between assessments). 
- From ½·[date(1) – date(0)] to date(1): no. of days in NYHA class I. 
- From date(1) to ½·[date(2) – date(1)]: no. of days in NYHA class I. 
- From ½·[date(2) – date(1)] to date(2): no. of days in NYHA class IV. 
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- From date(2) to date(3): no. of days in NYHA class IV (assuming that there is 
no change in NYHA class between the last assessment before hospitalisation 
and the date of admission). 
- From date(3) to date(4): no. of days in hospital. 
- From date(4) to date(5): no. of days in NYHA class I (assuming that the patient 
is discharged in the same state as the first NYHA class assessment subsequent to 
discharge). 
- From date(5) to 1/2·[date(6) – date(5)]: no. of days in NYHA class III. 
In the case the end-of-study NYHA class value is missing (i.e. patient died or was 
lost to follow up), the assumption will be made that NYHA class doesn’t change 
after the last assessment, and the last quantity mentioned above will be replaced by: 
- From date(5) to date(6): no. of days in NYHA class I. 
In addition, the following rules apply: 
1. If the baseline NYHA class is missing, impute the mode (not the mean) of the 
overall distribution at baseline of available assessments. 
2. If there are no valid follow up NYHA class assessments before hospitalisation, 
take the NYHA class up to the day of admission as the baseline NYHA class 
value. 
3. If the patient was in hospital at the planned date of the end-of-study visit (or on 
the date last seen or contacted for patients lost to follow up), count only the 
days up to this date. 
4. If there are no follow up NYHA class assessments after discharge from hospital, 
assume that the patient was discharged in the same NYHA class as recorded for 
the last known assessment before hospitalisation (which may be the baseline 
value). 
For tabulation and analysis, the same methods will be used as described earlier in 
this section for the analysis that considers NYHA class only up to the first of the 
events 1 - 6 mentioned in section 1.2.1 of this document. 
 
4.3.4 Vital signs at planned follow up visits 
Available data on vital signs, body weight, body mass index and blood pressure 
classification for valid planned follow up visits (c.f. 3.3) will be tabulated by treat-
ment group for each visit in the same manner as at baseline (c.f. 2.3.8). Data to be 
used include data from end-of-study visits done after the planned date, provided 
that these were done no later than 49 days after the planned date (c.f. 3.2). Changes 
from baseline will not be tabulated but graphs will be provided showing median 
changes from baseline with 95% ranges by treatment group for each planned fol-
low up visit (c.f. Appendix I – table and figure layouts, Figure 3). A standard test of 
the overall difference between treatment groups will be performed. 
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4.3.5 Blood pressure control over time 
For the purpose of assessing blood pressure control over time, available blood 
pressure data for valid planned follow up visits (c.f. 3.3) will be categorised as fol-
lows: 
I = Optimal (SBP < 120 and DBP < 80). 
II = Normal (SBP 120 – 129, DBP 80 – 84). 
III = High normal (SBP 130 – 139, DBP 85 – 89). 
IV = Grade 1 hypertension (SBP 140 – 159, DBP 90 – 99). 
V = Grade 2 hypertension (SBP 160 – 179, DBP 100 – 109). 
VI = Grade 3 hypertension (SBP > 179, DBP > 109). 
When a patient’s systolic and diastolic blood pressures fall into different cate-
gories, the more severe category will apply. Mean time spent in each of the above 
categories will be analysed and displayed in the same manner as described else-
where for NYHA class (c.f. 4.3.3). 
 
4.3.6 Standard laboratory tests and ECG at planned follow up visits 
Available standard laboratory test and ECG data for valid planned follow up visits 
(c.f. 3.3) will be tabulated by treatment group for each visit in the same manner as 
at baseline (c.f. 2.3.3 and 2.3.4). Data to be used include data from end-of-study 
visits done after the planned date provided that these were done no later than 49 
days after the planned date (c.f. 3.2). Changes from baseline will not be tabulated 
but graphs will be provided showing median changes from baseline with 95% 
ranges by treatment group for each planned follow up visit (c.f. Appendix I – table 
and figure layouts, Figure 3). A standard test of the overall difference between 
treatment groups will be performed. 
 
4.3.7 Concomitant medication at planned follow up visits 
Using the actual date of the visit for each valid planned visit (c.f. 3.3) as reference 
date, the following will be tabulated based on data entered on concomitant treat-
ment log pages in the CRF: 
- N (%) on a beta-blocker. 
- N (%) on an ACE-inhibitor. 
- N (%) on a diuretic. 
- Etc. 
- N (%) using anti-anginal medication categorised as none / one / two or more, 
counting only drugs registered for symptomatic relief of angina as anti-anginal 
medication. 
Cardiovascular and non-cardiovascular treatments will be tabulated separately. 
Tabulations will be sorted by frequency of use. 
Concomitant medication at the end of the study will be tabulated in the same 
manner, using as reference date the following as applicable: 
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- For patients who died: date of death. 
- For patients who were lost to follow up or had the end-of-study visit before the 
planned date: date patient last seen or contacted. 
- For patients who had the end-of-study visit on or after the planned date: planned 
date of the end-of-study visit. 
 
4.3.8 Use of anti-anginal drugs over time 
The number of anti-anginal drugs used in addition to study medication (none / one 
/ two or more) will be analysed in the manner as described earlier for categories of 
NYHA class (c.f. 3.3.4). Only drugs registered for symptomatic relief of angina 
will be counted as anti-anginal medication. 
 
4.3.9 Number of days spent in hospital 
For each treatment group, the number of patients ever hospitalised, the total num-
ber of hospitalisations, and mean duration of hospital stay will be tabulated. Days 
in hospital after the planned end of follow up will not be counted. 
 
4.4 Adjusted and subgroup analyses 
4.4.1 Covariate adjustment 
The main covariate-adjusted proportional hazards model planned in the protocol 
for the primary endpoints for efficacy and safety, and for all-cause mortality, will 
be adjusted for the following variables: age, sex, NYHA class, ejection fraction, 
history of MI, history of diabetes, systolic and diastolic blood pressure. Quantita-
tive covariates will be fitted continuously. Binary variables will be fitted by indica-
tor variables coded as 0 = characteristic absent, 1 = characteristic present. Cate-
gorical variables will be represented by (1 – number of categories) binary vari-
ables. All variables mentioned will be included irrespective of the statistical sig-
nificance of the coefficient. From this analysis, the primary feature of interest is the 
hazard ratio for the covariate-adjusted treatment comparison and its 95% confi-
dence interval and p-value. In addition, the proportional hazard model will be dis-
played for each covariate. Model coefficients will be converted into hazard ratios 
and their 95% confidence intervals (based on the standard error of the coefficient); 
for quantitative variables this will be the hazard ratio per a suitable unit of increase 
in the covariate. 
In order to develop a more extensive proportional hazards model predicting 
risk for the primary efficacy and safety outcomes and for mortality for the purpose 
of risk stratification (an analysis pre-specified in point 9, section 11.2 of the proto-
col), the following baseline variables will be considered in addition to those listed 
above: serum creatinine, glucose, cholesterol, uric acid, haematocrit, left-
ventricular hypertrophy, QTc interval, atrial fibrillation or flutter (c.f. CRF page 3), 
history of claudication, history of TIA, history of stroke, previous coronary inter-
vention (CABG, PTCA), previous coronary angiogram (yes with left main stem 
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and/or multi-vessel disease, single vessel disease but not left main stem, no signifi-
cant disease or no angiogram), smoking (current, ex, never), body mass index, 
height, pulse rate, blood pressure, angina attack frequency, angina at rest (as ticked 
on CRF page 12), treated for hypertension, treated for hyperlipidaemia with drugs, 
treated with: beta-blocker, ACE-inhibitor and/or A2 receptor antagonist, long 
and/or short acting nitrate, aspirin and/or other anti-platelet agents, digoxin, anti-
arrhythmic drugs, diuretics, previous treatment with calcium antagonist, number of 
anti-anginal drugs (none, one or two). 
For each outcome, from this large set of potential predictors a subset of sig-
nificant independent predictors will be selected by a forward stepwise selection 
procedure based on proportional hazard models with increasing numbers of covari-
ates that always also include treatment assignment. In this forward stepwise se-
quence, the most significant predictor not in the model so far will be included next 
at each step. At the same time, the need for interaction terms with treatment as-
signment will be considered. Also, certain variables may be combined (i.e. history 
of peripheral artery disease, combining history of claudication, TIA or stroke) or 
replaced by indicators representing categories (i.e. two indicators representing 
three categories of baseline blood pressure). The final model will be such that all 
variables and interaction terms are independently predictive at p<0·05, but the next 
most significant variable not in the model fails to achieve p<0·05. In addition, the 
presence of each variable in the final model must be supported by biological plau-
sibility or relevant findings about risk factors from other studies. 
For each of the three outcomes concerned, the final model will be displayed 
with hazard ratios and their 95% confidence intervals for each covariate. The linear 
predictive function in this final proportional hazards model will then be used as a 
risk score to categorise patients into five levels of risk. The risk score will be calcu-
lated assuming that the patient was assigned to placebo. The five risk categories 
will be chosen such that they contain equal numbers of patients experiencing the 
outcome (both treatment assignments combined). For each of these five risk cate-
gories the following will be tabulated: 
- Number of patients, number of events and number of patient years by treatment 
group. 
- Event rate per 100 patient years by treatment group. 
- Hazard ratio and its 95% confidence interval relative to placebo. 
In addition, a p-value for interaction will be calculated. Results will be displayed as 
shown for age in Figure 4, Appendix I – table and figure layouts. 
 
4.4.2 Subgroup analyses 
Pre-defined subgroup analyses for the primary endpoints for efficacy and safety, 
and for all-cause mortality, will be performed for the following baseline variables 
(as defined in tabulations of baseline characteristics, c.f. 2.3): 
- Age (in tertiles of the age distribution for patients with event). 
- Sex (male / female). 
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- NYHA class (class I / II / III and IV combined). 
- Ejection fraction (in tertiles of the ejection fraction distribution for patients with 
event). 
- History of document AMI (no / yes item 6.4 CRF page 4). 
- History of diabetes (no / yes). 
- On a beta-blocker. 
- On lipid-lowering drug therapy. 
- Use of a calcium-antagonist before entry. 
- On an ACE-inhibitor or an AII-antagonist. 
- On digoxin. 
- Diastolic blood pressure (DBP), in tertiles of the DBP distribution for patients 
with event. 
- Systolic blood pressure (SBP) in tertiles of the SBP distribution for patients 
with event. 
- Blood pressure classification categorised as described in section 2.3.8. 
For each outcome/subgroup variable combination, a statistical test of interaction 
will be performed to test whether there is evidence of heterogeneity in hazard ratios 
between subgroups. For quantitative subgroup variables, these interaction tests will 
take into account the ordering of the subgroup categories. Subgroup analyses will 
be displayed as shown in Appendix I – table and figure layouts, Figure 4 
In addition, subgroup analyses will be performed for the following (regional 
groupings of) countries: 
- Canada. 
- Israel. 
- Netherlands and Belgium. 
- Germany, Austria and Switzerland. 
- Denmark, Finland, Norway and Sweden. 
- France, Spain, Portugal, Italy, Greece. 
- UK, Australia, New Zealand. 
For each region and for each outcome the number of patients, number of events 
and hazard by treatment group, and the hazard ratio with its 95% confidence inter-
val will be tabulated. For each outcome a statistical test of interaction will be per-
formed to see if evidence of heterogeneity in hazard ratios between regions is pre-
sent. 
Subgroup analyses will also be tabulated by country and by centre but due to 
the larger number of categories, many with small numbers, only the numbers of 
patients and events by treatment group will be displayed for each country, and each 
centre. 
 
Chapter 7 
128 
4.5 (Serious) adverse events 
The occurrence of coded (serious) adverse events after start of study medication 
(AEs with an onset date = start date of study medication included) will be tabulated 
by treatment group as follows: 
 
4.5.1 For each system organ class 
- Total number of events belonging to system organ class. 
- Total number of events belonging to system organ class on study medication. 
- Total number of events belonging to system organ class that were reported as 
serious. 
- Total number of events belonging to system organ class on study medication 
that were reported as serious. 
- Number of patients with at least one event belonging to system organ class. 
- Number of patients with at least one event belonging to system organ class on 
study medication. 
- Number of patients with at least one event belonging to system organ class on 
study medication that was reported as serious. 
 
4.5.2 For each code within any given system organ class 
- Total number of occurrences. 
- Total number of occurrences on study medication. 
- Total number of occurrences that were reported as serious. 
- Total number of occurrences on study medication that were reported as serious. 
- Number of patients with at least one occurrence. 
- Number of patients with at least one occurrence on study medication. 
- Number of patients with at least one occurrence on study medication that was 
reported as serious. 
5 PROCEDURES 
5.1 Where the programming will be done 
Baseline comparisons and univariate time-to-event analyses for the primary and 
secondary efficacy and safety criteria (including the analysis for time spent in each 
of four NYHA classes) will be independently programmed at SOCAR Research SA 
and at the Medical Statistics Unit of the London School of Hygiene and Tropical 
Medicine (LSHTM), based on analysis data sets created independently. Analysis 
data sets must be documented as shown in Appendix III – Documentation of analy-
sis data sets for the SAS data set PATINF. Programming at SOCAR will be done in 
such manner that the output (from SAS®: SAS font 10, no more than 75 characters 
per line) can be inserted directly into the integrated clinical report to be prepared 
by SOCAR. Subgroup and covariate-adjusted analyses using Cox regression will 
ACTION Statistical Analysis Plan (SAP) 
129 
be programmed at the LSHTM. Output for final analyses and models must be for-
matted such that direct insertion into the report mentioned earlier is possible. Pro-
gramming and output generation of descriptive follow up data by visit will be done 
only at SOCAR. 
 
5.2 Validation 
For the purpose of validation, data for the first 500 patients randomised will be 
stored separately on CDs that contain identical files. A dummy treatment code will 
be added to allow tabulations by treatment group and statistical analyses comparing 
treatment groups can be tested. 
All summary statistics tabulated will be validated independently. Acceptable 
methods are: 
- Summary statistics obtained by SQL queries performed directly on the 
ORACLE® database. 
- Independent analysis using any standard statistical package (SAS®, STATA®, 
Statistica®, etc.) of datasets obtained by SQL queries performed directly on the 
ORACLE® database. 
- Independent analysis of data sets created within any standard statistical package 
(SAS, STATA, Statistica, etc.). 
All analyses must be fully documented by either a printout of the SQL queries per-
formed directly on the ORACLE® database, or a declaration of variables used from 
the ORACLE® database. 
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APPENDIX I – TABLE AND FIGURE LAYOUTS 
Table 1: Tabulation layout for descriptive statistics 
Table <#>: <Type of data> at <time point> (<all-randomised> or <valid-
for-efficacy>)* 
 
 Nifedipine§ 
N=# ### 
Placebo§ 
N=# ### 
Continuous variables (e.g. age):   
Age (years)   
No. available (% of N in column head) N (%) N (%) 
Mean (sd)   
Lowest   
2.5th percentile   
Median   
97.5th percentile   
Highest   
Age group (years)   
35 – 44 (% of available values)¶ N (%) N (%) 
45 – 54 (% of available values) N (%) N (%) 
55 – 64 (% of available values) N (%) N (%) 
65 – 74 (% of available values) N (%) N (%) 
75 – 84 (% of available values) N (%) N (%) 
Over 84 (% of available values) N (%) N (%) 
Binary variables (e.g. gender)   
No. available (% of N in column head) N (%) N (%) 
Male (% of available values) N (%) N (%) 
Female (% of available values) N (%) N (%) 
Categorical variables (e.g. NYHA class)   
No. available (% of N in column head) N (%) N (%) 
NYHA class I (% of available values) N (%) N (%) 
NYHA class II (% of available values) N (%) N (%) 
NYHA class III (% of available values) N (%) N (%) 
NYHA class V (% of available values) N (%) N (%) 
* The table heading must contain the type of data tabulated (e.g. demographics), the time point (e.g. 
baseline) and – between brackets – the analysis population concerned (either all-randomised or 
valid-for-efficacy). 
§ The column heading must show the number of patients for whom the data tabulated should have 
been available, taking death and loss to follow up into account. 
¶ Percentages by category must be based on the total number of available values = 100. 
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Table 2: Admission protocol violations 
Total number of patients randomised (%) N (100) 
PVs of inclusion criteria:  
Age less than 35 years (CRF 12.2.1) N (%) 
Not in a stable clinical condition and/or no symptomatic an-
gina (CRF 12.2.2) 
N (%) 
Not on anti-anginal treatment, Ca-antagonist not washed 
out, or on Ca-antagonist (CRF 12.2.3)  
N (%) 
Criteria for coronary artery disease not met (CRF 12.2.4) N (%) 
Core lab LV EF less than 35%, or local value and core lab 
value missing (CRF 12.2.5)  
N (%) 
Not ambulatory or no informed consent signed (CRF 
12.2.7) 
N (%) 
Patients with at least one PV of inclusion criteria  N (%) 
PVs of exclusion criteria related to medical history: N (%) 
Recent major CV event or surgery (CRF 12.3.1) N (%) 
PTCA or CABG planned (CRF 12.3.2) N (%) 
Known intolerance to diphydropyridines (CRF 12.3.3) N (%) 
Clinically significant valvular disease (CRF 12.3.4) N (%) 
Severe obstructive airway disease (CRF 12.3.5) N (%) 
Unstable insulin-dependent diabetes (CRF 12.3.6) N (%) 
Gastro-intestinal condition limiting absorption or passage 
(CRF 12.3.7 or 12.3.8) 
N (%) 
Non-CAD condition limiting life expectancy (CRF 12.3.9) N (%) 
Patients with at least one PV related to medical history  N (%) 
PVs of exclusion criteria related to current symptoms or find-
ings: 
 
Clinically significant heart failure (CRF 12.3.10) N (%) 
Orthostatic hypotension or supine SBP lower than or equal 
to 90 mm Hg, or SBP unknown (CRF 12.3.11) 
N (%) 
SBP greater than or equal to 200 mm Hg and/or DBP 
greater than or equal to 105 mm Hg despite treatment, or 
BP unknown (CRF 12.3.12)  
N (%) 
Creatinine above 2 x upper limit of normal, or creatinine 
unknown (CRF 12.3.13) 
N (%) 
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ALAT or ASAT above 3 x upper limit of normal, or ALAT or 
ASAT unknown (CRF 12.3.14) 
N (%) 
Patients with at least one PV related to current symptoms or 
findings 
N (%) 
PVs of exclusion criteria related to current treatment:  
Dose of diuretics above limit (CRF 12.3.15) N (%) 
On ACE-inhibitor plus diuretic for heart failure (CRF 
12.3.16) 
N (%) 
On other incompatible medication (CRF 12.3.17) N (%) 
Patients with at least one PV related to current treatment  N (%) 
PVs of miscellaneous exclusion criteria:  
Anticipated problems with compliance or follow up (CRF 
12.3.18)  
N (%) 
Pregnancy, breast feeding or risk of pregnancy (females 
only, CRF 12.3.19) 
N (%) 
Participation in another trial or study (CRF 12.3.20) N (%) 
Patients with at least one PV related to miscellaneous exclu-
sion criteria 
N (%) 
Other protocol violations:  
Any time window violation (CRF 9.4.1) N (%) 
Valid-for-efficacy population:  
Number of patients with any protocol violation N (%) 
Valid for efficacy population N (%) 
 
ACTION Statistical Analysis Plan (SAP) 
133 
 
Table 3: Patient disposition by country and by centre 
 Nifedipine Placebo 
Total number of patients: all-randomised N (100) N (100) 
Total number of patients: valid-for-efficacy N (100) N (100) 
Australia:   
AUS-001: all-randomised N (%) N (%) 
 valid-for-efficacy N (%) N (%) 
AUS-002: all-randomised N (%) N (%) 
 valid-for-efficacy N (%) N (%) 
Next centre, etc.   
Total Australia: all-randomised N (%) N (%) 
 valid-for-efficacy N (%) N (%) 
Next country, etc.   
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Table 4: Completeness of follow up visits (<all-randomised> or <valid-
for-efficacy>) 
 
 Nifedipine 
NT=# ### 
Placebo 
NT=# ### 
Visit 1 (7 - 21 days)   
Died before or on last day of window (% of N 
in column head) N1 (%) N1 (%) 
Lost to f-up before or on last day of window 
(% of N in column head) N2 (%) N2 (%) 
Under f-up at end of window (% of N in col-
umn head) N3 (%) N3 (%) 
Any visit within window (% of N under f-up at 
end of window) N (%) N (%) 
Cave: N3 must be equal to NT – N1 – N2 
Visit 2 (6 wks – 14, + 21 days)   
Died before or on last day of window (% of N 
in column head) N1 (%) N1 (%) 
Lost to f-up before or on last day of window 
(% of N in column head) N2 (%) N2 (%) 
Under f-up at end of window (% of N in col-
umn head) N3 (%) N3 (%) 
Any visit within window (% of N under f-up at 
end of window) N (%) N (%) 
Cave: N3 must be equal to NT – N1 – N2 
Visit 3 (13 wks – 42, + 49 days)   
Died before or on last day of window (% of N 
in column head) N1 (%) N1 (%) 
Lost to f-up before or on last day of window 
(% of N in column head) N2 (%) N2 (%) 
Under f-up at end of window (% of N in col-
umn head) N3 (%) N3 (%) 
Any visit within window (% of N under f-up at 
end of window) N (%) N (%) 
Cave: N3 must be equal to NT – N1 – N2 
Etc.   
   
f-up, follow up 
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Table 5: Tabulation layout for combined endpoints 
The example below shows the table layout for the primary endpoint for efficacy for 
the all-randomised population. Tables for other combined endpoints differ only as 
regards the individual endpoints considered. 
 
 Nifedipine Placebo  
 Number Event rate* Number 
Event 
rate* HR (95% CI) 
Total patients (all random-
ised) N NNN - N NNN -  
Total patient years ‘at risk’ N NNN - N NNN -  
On full dose study medica-
tion (%) §      
On half dose study medica-
tion (%) §      
No of patients permanently 
withdrawn from study medi-
cation while ‘at risk’ 
N (%)  N (%)   
No of patients with first 
event¶      
Death (all causes) N - N - - 
Acute MI N - N - - 
Procedural MI N - N - - 
Refractory angina N - N - - 
Heart failure N - N - - 
Stroke N - N - - 
Peripheral revascularisation N - N - - 
Any of the above N h N h HR (hl - hu) (p=value)# 
* Number of events per 100 patient years ‘at risk’ for the event concerned. 
§ Percentage of total patient years of follow up. 
¶ As diagnosed by the Critical Events Committee (CEC). 
# p-value from log-rank test without adjustment for co-variates. 
CI, confidence interval; HR, hazard ratio (nifedipine relative to placebo); MI, myocardial infarction. 
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Table 6: Tabulation layout for individual endpoints 
 
 Nifedipine Placebo  
Event Total No. of events 
Pts with 
event (event 
rate*) 
Total No. 
of events 
Pts with 
event (event 
rate*) 
 
Death (all causes) - N (h) - N (h) hr (hl - hu) 
Non-cardiovascular§ - N (h) - N (h) hr (hl - hu) 
Cardio-vascular§ - N (h) - N (h) hr (hl - hu) 
Unknown§ - N (h) - N (h) hr (hl - hu) 
Acute MI§ N N (h) N N (h) hr (hl - hu) 
Procedural MI§ N N (h) N N (h) hr (hl - hu) 
Refractory angina§ N N (h) N N (h) hr (hl - hu) 
Heart failure§ N N (h) N N (h) hr (hl - hu) 
Stroke§ N N (h) N N (h) hr (hl - hu) 
Peripheral revascularisa-
tion§ N N (h) N N (h) hr (hl - hu) 
PTCA N N (h) N N (h) hr (hl - hu) 
CABG N N (h) N N (h) hr (hl - hu) 
Coronary angiography¶ N N (h) N N (h) hr (hl - hu) 
* Number of events per 100 patient years ‘at risk’ for the event concerned. 
§ As classified by the Critical Events Committee (CEC). 
¶ Without PTCA on same day. 
MI, myocardial infarction; PTCA, percutaneous coronary angioplasty; CABG, coronary artery by-
pass grafting. 
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Figure 1: Trial profile 
 
N centres 
(NNN patients) ex-
cluded 
N patients study 
medication not 
started 
N NNN patients al-
located study medi-
cation 
N NNN patients in 
intention-to-treat 
analysis 
N NNN nifedipine 
(intended follow up 
NN NNN.N years) 
P PPP placebo (in-
tended follow up PP 
PPP.P years) 
N NNN completed 
study as planned 
(NN NNN.N years 
of follow up) 
P PPP completed 
study as planned 
(PP PPP.P years of 
follow up) 
NNN terminated 
study earlier than 
planned (NNN.N 
years of follow up) 
PPP terminated 
study earlier than 
planned (PPP.P 
years of follow up) 
NNN died (NNN.N 
years of follow up) 
PPP died (PPP.P 
years of follow up) 
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Figure 2: Display of time to occurrence of clinical outcomes 
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Figure 3: Display of evolution over time of repetitive observations 
E.g. for systolic and diastolic blood pressure and blood pressure control: 
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Time (yrs) 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 
Number of values: 
Nifedipine: nnnn nnnn nnnn  nnnn nnnn nnnn  nnnn nnnn nnnn  nnnn nnnn nnnn 
Placebo: pppp pppp pppp  pppp pppp pppp  pppp pppp pppp  pppp pppp pppp 
% blood pressure controlled (systolic < 140 and diastolic blood pressure < 90): 
Nifedipine nn.n nn.n nn.n  nn.n nn.n nn.n  nn.n nn.n nn.n  nn.n nn.n nn.n 
Placebo pp.p pp.p pp.p  pp.p pp.p pp.p  pp.p pp.p pp.p  pp.p pp.p pp.p 
Systolic (overall p=0.####) 
Diastolic (overall p=0.####) 
Placebo Nifedipine 
p= * * * * * * * * *
p= * * * * * * * * *
Imaginary 
result
Imaginary 
result
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Figure 4: Display of subgroup analyses 
 
 
MI, myocardial infarction. Rates in number of events per 100 patient years of follow up ‘at risk’. P-
values for interaction or trend. 
 
 Number of pa-tients 
Number of 
events (rate)
 Nif / Plac Nif / Plac 
Male NNNN / NNNN N(h) / N(h) 
Female NNNN / NNNN N(h) / N(h) 
Age (years)   
<55 NNNN / NNNN N(h) / N(h) 
55-65 NNNN / NNNN N(h) / N(h) 
>65 NNNN / NNNN N(h) / N(h) 
   
Previous MI NNNN / NNNN N(h) / N(h) 
No previous 
MI NNNN / NNNN N(h) / N(h) 
   
Etc.   
Favours nifedipine              Favours placebo 
1.00.5 2.0 
p=0.# 
p=0.# 
p=0.# 
Imaginary 
result
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APPENDIX II – STANDARD LABORATORY TEST UNITS 
Not incorporated in this thesis. 
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APPENDIX III – DOCUMENTATION OF ANALYSIS DATA SETS 
Analysis Dataset: PATINF 
Description: Patient Information. 
Source Tables (ORACLE): C_DD_DDA, CT, DEATH, HISTORY1, HISTORY2, HISTORY3, MEDREC, PATID, PHYSICAL, 
RANDOM, STUDYLOG, V_SYS_VISIT_DATES, WITHDRAW 
Sorted by: PATID, one record per patient 
 
Variable 
Name Label 
ORACLE Source 
(TABLE.var1, var 2) Type Format Notes 
PATID Unique Patient Identifier RANDOM.patid Num 8. = RANDOM.patid 
SCRNR Screening Number RANDOM.scrnr Num 8. = RANDOM.scrnr 
INIT Patient Initials RANDOM.init Char $3. = RANDOM.init 
CENTNO Centre  RANDOM.centno Char $9. = RANDOM.centno 
COUNTRY Country Derived Char country. Derived from centno. Take letter(s) preceding ‘-‘ to identify 
country 
DOBDT Date of Birth RANDOM.dob_crf Num date9. RANDOM.dob_crf converted to SAS date format. The general 
imputation rule (see Note 1 below) is used for partial dates 
RANDDT Date of Randomisation RANDOM.startdt_crf Num date9. RANDOM.startdt_crf converted to SAS date format. If 
RANDOM.startdt_crf is missing or incomplete then RANDDT is 
missing (no imputation done) 
AGE Age at Baseline Derived Num 8. Age in years on day of randomisation, calculated using randdt 
and dobdt.  
SEX Sex RANDOM.sex Num sex. = PATID.sex 
RACE Race PATID.race Num race. = PATID.race 
RACEOTH Race (other) PATID.race, race_o Char $40. = PATID.race_o for patients where RACE = 4 
EF_DT EF – Date Performed ECHO_2D_ALL.cldt 
PATID.efdt_crf 
Num date9. Last core lab date (ECHO_2D_ALL.cldt) that is on or before the 
start date of study medication (i.e. RANDDT). If no such value 
exists, then EF_DT = PATID.efdt_crf.  
EF_DT must be in SAS date format 
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Variable 
Name Label 
ORACLE Source 
(TABLE.var1, var 2) Type Format Notes 
EF_MTH EF – Method Used PATID.efmeth, efdt_crf Num efmeth. = PATID.efmeth if PATID.efdt_crf (converted to SAS date 
format) is on or before the start date of study medication 
(i.e. RANDDT) 
= missing otherwise 
EF_IO EF – Investigator value 
only  
Derived Num noyes. = 2 (i.e. ‘yes’) if EF_DT = . and EF_MTH is not missing 
= 1 (i.e. ‘no’) otherwise 
EF_B Ejection Fraction (%) at 
Baseline 
ECHO_2D_ALL.ef1, ef2, 
ef3 
PATID.ef 
Num 8.2 If ECHO_2D_ALL.ef1, ef2, ef3 are all present, then EF_B is 
equal to the median of the three values. 
If only two are present, then EF_B is equal to the mean of the 
two values. 
If only one value is present, then EF_B is equal to this value. 
If there are no values, then EF_B = PATID.ef 
Remainder omitted from this thesis 
 
Notes: 
1. Rules for imputing partial dates: The general rule for 
imputing partial dates is described in section 1.6.1 of the 
SAP. If the month for the partial date is missing then it is 
imputed to be ‘06’; if the day is missing it is imputed to 
be ‘15’. For certain variables, additional rules must be 
used to prevent implausible values being imputed; these 
rules are discussed in the individual specifications for 
these variables. 
2. Analysis Populations: Populations currently assigned by 
running program P:/ACTION/SAS/REPORT/2_SET UP 
POPULATIONS.SAS 
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Formats for data set PATINF: 
 
Format Type Values 
country. Character 'AUS’ = ‘Australia’ 
'A' = ‘Austria’ 
'B' = ‘Belgium’ 
'C' = ‘Canada’ 
'DK' = ‘Denmark’ 
'FIN' = ‘Finland’ 
'F' = ‘France’ 
'D' = ‘Germany’ 
'GR' = ‘Greece’ 
'IL' = ‘Israel’ 
'I' = ‘Italy’ 
'NL' = ‘Netherlands’ 
'NZ' = ‘New Zealand’ 
'N' = ‘Norway’ 
'P' = ‘Portugal’ 
'E' = ‘Spain’ 
'S' = ‘Sweden’ 
'CH' = ‘Switzerland’ 
'UK' = ‘United Kingdom’ 
efmeth. Numeric 1 = ‘2D-echocardiography’ 
2 = ‘Radionuclide scanning’ 
3 = ‘Contrast ventriculography’ 
. = ‘Not Done’ 
noyes. Numeric 1 = ‘No’ 
2 = ‘Yes’ 
race. Numeric   1 = ‘White’ 
  2 = ‘Black’ 
  3 = ‘Asian’ 
  4 = ‘Other’ 
99 = ‘Unknown’ 
sex. Numeric 1 = ‘Male’ 
2 = ‘Female’ 
 
Notes: 
1. In SAS, missing numeric values are denoted by ‘.’ (quotes not included) 
e.g. if x = . then x = 1 means “If x is missing, then let x=1” 
2. In SAS, Missing character values are denoted by ‘’ (quotes included) 
e.g. if x = ‘’ then x= ‘one’ means “if x is missing, then let x = ‘one’ ” 
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Chapter 8 
General discussion 
 
 
he section on Trial Conduct Considerations in the ICH Note for Guidance on 
Statistical Principles for Clinical Trials (ICH E9)1 states on page 20: “For the 
purpose of overseeing the quality of the trial the checks involved in trial monitor-
ing may include whether the protocol is being followed, the acceptability of data 
being accrued, the success of planned accrual targets, the appropriateness of the 
design assumptions, success in keeping patients in the trials, etc.”. On page 4, the 
same document defines bias as: “the systematic tendency of any factors associated 
with the design, conduct, analysis and interpretation of the results of clinical trials 
to make the estimate of treatment effect deviate from its true value”. Monitoring 
means to watch, keep track of, or check.2 The purpose of trial monitoring as de-
fined in ICH E9 cannot merely be to watch passively, but surely it must also be to 
prevent errors during trial conduct pro-actively. We prefer therefore the term man-
agement over the term monitoring, and define trial management as all activities 
directed at ensuring appropriate trial conduct while avoiding bias as defined earlier. 
Based on our experience with managing the PICO (Chapter 2) and ACTION 
(Chapter 4) trials, this chapter puts trial management into perspective. In an ideal 
trial investigators make no mistakes with patient selection, follow all patients ac-
cording to protocol, report events as required and complete Case Report Forms 
(CRFs) without error or omission. Ideal patients undergo follow up assessments 
exactly as planned, and take study treatment as instructed. In practice the ideal is 
rarely if ever achieved however and contingencies that compromise the ideal do 
occur. Management of an ongoing trial requires therefore that such contingencies 
are spotted as soon as possible, corrected as appropriate, and prevented from reoc-
curring. Every individual contingency detected requires a trial management deci-
sion as to how it should be handled. In the interest of consistency, these decisions 
must be based on pre-defined policies based on the scientific principles underlying 
randomised clinical trials. 
In this chapter we consider the policies implemented to deal with the most im-
portant contingencies that occurred during the conduct of the two trials mentioned 
earlier. Our purpose is to show that there is an intricate relationship between how a 
trial is managed and the underlying scientific principles. We will distinguish be-
tween validity of comparison and generalisability, and will consider a treatment 
comparison valid “if it is based on comparable groups of persons treated and ob-
served in such a way so as to make treatment assignment the most likely explana-
tion of the result observed”.3 Importantly, validity of comparison “derives from the 
design of the trial and the way it is carried out”.3 Generalisability on the other hand 
T
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has to do with applicability to clinical practice. As such it is “largely a matter of 
judgement”3, and is an issue only when a trial result can be considered valid. The 
chapter ends with a list of recommendations. 
PREREQUISITES FOR TRIAL MANAGEMENT 
Realising the complexities of multi-centre trials 
The proper conduct of a single-centre study or trial requires care and attention to 
detail. This is true a fortiori for medium to large multi-centre trials such as PICO 
and ACTION. Hence, the complexity of managing such trials needs to be appreci-
ated from the outset and nothing can be left to chance. One cannot assume that in-
vestigators interpret a certain medical term, or execute a certain measurement in 
the same way. While managing the ACTION trial, we noted that the same medica-
tion trade name was used in different countries for different drugs. Despite efforts 
to standardise units of measurement, variation between centres remains. The same 
applies to normal ranges for even the most frequently used laboratory tests. In 
ACTION, we started by using local normal ranges when evaluating laboratory tests 
for each participating centre, but found this unmanageable because of frequent 
changes. In the same study, 19 different countries from various geographical and 
linguistic regions were involved. While selecting centres, it is therefore necessary 
not just to consider whether the availability of patients, the facilities and the ex-
perience with performing trials are adequate. One must also ensure that the com-
mand of oral and written English by all research personnel involved is sufficient for 
this to be the official language for all study documents and communication (rec-
ommendation 1). Nonetheless, documents such as the patient information sheet and 
the declaration of informed consent need translation in local languages, and need to 
comply with local regulations. In some countries, a version of the protocol and 
CRF must be provided in the local language in order to obtain approval of local 
ethics committee or other competent authorities. 
 
Protocol and case report form 
No trial can start before complete trial documentation has been approved by all 
parties involved. Within a trial, the protocol has the same role as the law in a con-
stitutional state. A well-developed protocol is therefore a prerequisite for effective 
trial management. In the ICH Note for Guidance on Good Clinical Practice (ICH 
E6), the protocol is defined as “a document that describes the objective(s), design, 
methodology, statistical considerations and organisation of a trial”.4 ICH E6 also 
comprehensively defines the topics that the protocol must cover. Importantly, the 
protocol is not only the basis for investigators and other participants (committee 
members, coordinating centre, etc.) to judge whether they can fulfil the require-
ments for participation, but also for judging whether the conditions are acceptable. 
To mention just two issues as regards the latter: (i) the protocol needs to specify a 
policy that allows, if this is intended, publication regardless of the trial’s outcome; 
and (ii) the protocol is generally also the basis for contracts that set out “any ar-
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rangements on delegation and distribution of tasks and obligations, and, if appro-
priate, on financial matters”.4  
Apart from a well-developed protocol, trial management and investigators 
alike need a workable CRF. ICH E6 defines the CRF as “a printed, optical, or elec-
tronic document designed to record all of the protocol-required information to be 
reported … on each trial subject”.4 One reason that a good CRF is so important is 
that few investigators will consult the protocol each time a patient is seen. The 
CRF should therefore not just be a document on which data can be recorded but 
also a checklist that instructs the investigator what to do when and how. In this re-
gard, the CRF should follow the sequence in which examinations, laboratory tests, 
etc. are normally carried out in clinical practice. To ensure standardisation both 
within and between centres, relevant instructions for carrying out examinations and 
tests should be printed on the opposite pages so that these are visible during CRF 
completion. Relevant instructions are thus always directly available for consulta-
tion by investigators and their staff while collecting the data required without the 
need to flip through the CRF, let alone consult the protocol. We emphasize that 
procedures for generally-known measurements such as blood pressure, or assess-
ment of NYHA class, should also be specified in detail in the CRF in this manner 
(recommendation 2). 
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Figure 1: Organisational structure ACTION study 
ch, chair; M, monitoring; ER, ethical review; Com, committee; med, medication. The random plan 
was prepared at the Medical Statistics Unit of the London School of Hygiene and Tropical Medicine, 
and was made available only for packing purposes to the pharmacy of the sponsor. Pre-specified in-
terim analyses were performed at the Medical Statistics Unit, based on blinded data supplied by the 
coordinating centre (SOCAR Research SA, Nyon, Switzerland). 
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Organisational structure 
A well-defined and workable organisational structure must be in place before the 
first patient is recruited. Roles, responsibilities and lines of communication must be 
known and no protocol can be finalised without delineating these (recommendation 
3). Of particular importance within the organisational structure is the role of the 
funding source. Today, the majority of clinical trials are industry sponsored. PICO 
and ACTION were no exception. Bodenheimer has outlined the many ways in 
which industry sponsoring can affect the trial conduct.5 The organisational struc-
ture of ACTION is reproduced here as Figure 1 (previous page). While this type of 
organisational structure is fairly standard for multi-centre trials, exact definitions of 
tasks and responsibilities may vary considerably. The initiative to perform the 
ACTION trial was taken by the Steering Committee chairman and our institution. 
The sponsor accepted that the study’s credibility would be enhanced by reducing its 
own role to a minimum. The role and responsibility of each component part in the 
ACTION organisational structure as shown in Figure 1 was defined with this in 
mind, the objective being to set up an organisational structure which allows sensi-
ble decision making about all matters relating to trial conduct while at the same 
time retaining independence from the sponsor. Recently, editors of major medical 
journals have stressed the need to retain scientific independence.6 Nonetheless, it 
must be recognised that funding sources, drug companies included, have legitimate 
interests that must be accommodated without jeopardising scientific integrity. 
Sponsoring a trial such as ACTION is useful to the drug company concerned only 
when the trial is conducted in such a manner that regulatory authorities and the sci-
entific community at large will accept the results. This necessitates that the study is 
conducted in agreement with the many rules and regulations that nowadays apply. 
Also, the sponsor must be in a position to comply with its own adverse drug reac-
tion reporting obligations, which vary from country to country. 
 
Database management system 
Apart from a workable protocol, CRF and organisational structure, trial manage-
ment requires a database management system that serves its needs. These go be-
yond concurrent processing of data for interim and final statistical analysis. Equally 
important is its role as a trial management tool (recommendation 4). 
In Chapter 6 we have outlined the design philosophy and essential features of 
the database management system used to support trial management for the 
ACTION study. The amount of paperwork generated by such a study is enormous. 
To handle this efficiently, all ACTION CRFs and supporting documents were regis-
tered in the database upon receipt, scanned and then archived. Because of this, fur-
ther database management could be based entirely on scanned images. Scanning 
also makes it possible to always display the scanned image and corresponding da-
tabase content simultaneously on the user’s computer screen. The content of the 
database is therefore continuously validated each time the database is consulted. 
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As described in Chapter 6, the system also supports all functions that are rele-
vant to data management, such as generation of Data Clarification Forms (DCFs), 
tracking of implausible values, etc. In addition, the needs of trial management are 
supported. Particularly relevant in this regard is the possibility to flexibly imple-
ment tracking functions for listings that support on-site monitoring (see below). 
Data management for the PICO trial was handled by a traditional relational 
database application. In retrospect, it is difficult to imagine how a trial as large as 
ACTION could have been managed without the system described in Chapter 6. 
 
Investigators’ meetings 
All too often, protocols, CRFs and other study documents are finalised without in-
volving the investigators who will actually perform the trial. Both the protocol and 
CRF need a “reality check” before finalisation however, not just by investigators, 
but also by study nurses, coordinating centre staff and those who will be involved 
in on-site monitoring. For smaller trials such as PICO, we recommend organising 
an investigators’ meeting in order to finalise the protocol and the CRF. For large 
trials such as ACTION this is usually impractical and the “reality check” must be 
left to the steering committee. Because of this, steering committees should not just 
consist of opinion-leaders, but also of practicing clinicians with clinical trial ex-
perience who represent the various geographical and linguistic regions involved. 
While conducting both trials described elsewhere in this thesis, regular inves-
tigator meetings were held, which were also attended by study nurses, CRAs, etc. 
We believe that these meetings were needed while the study was ongoing not just 
to get feed back on problems that had occurred or to explain study procedures, but 
also to promote continued interest and motivation, the basis for successful comple-
tion of both PICO and ACTION (recommendation 5). 
 
On-site monitoring 
That drug trials performed for regulatory purposes by the pharmaceutical industry 
need to comply with Good Clinical Practice (GCP) standards,4 and that on-site 
monitoring is required to ensure this, is generally accepted. For studies done out-
side the industry, or non-drug studies, the situation is less clear because of the high 
cost of on-site monitoring. 
On-site monitoring for industry-sponsored trials is the task of Clinical Re-
search Associates (CRAs). CRAs are the main link between the coordinating centre 
and the clinical sites and robustness of the study data depends directly on the qual-
ity of their work. To perform their tasks successfully, CRAs must have the exper-
tise required. Hence, trial management needs to ensure that CRAs are well trained, 
not just in GCP compliance in general, but also in all the procedures and policies 
that have been defined for a particular study. During monitoring visits, investiga-
tors often ask CRAs what to do in certain cases. If an inappropriate reply is given, 
an unwanted situation may occur that could otherwise have been avoided. 
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For the ACTION study, CRA meetings and special training courses were held 
repeatedly. This was necessary because of the trial’s long duration and the high 
turn-over of CRAs. CRAs were also required to attend investigator meetings. Well-
trained CRAs cannot compensate however for inadequate investigators or lack of 
local facilities. When there is no source documentation, verification of entries in 
the CRF is not possible. Centres who are unable to provide CRAs with the facilities 
required to perform their task should not participate in any trial (c.f. recommenda-
tion 1). 
Both the PICO and ACTION trials used classical CRFs printed on triplicate 
NCR paper. PICO investigators were instructed to mail the relevant CRF pages to 
the coordinating centre immediately after the patient was seen for a study visit. At 
the coordinating centre, each CRF was data entered upon receipt and a listing was 
made of missing or implausible items. Also, compliance with the protocol was 
checked. The CRA then took the results of these checks back to the centre during 
the next monitoring visit for clarification with the investigators. In this manner, 
time delays for data checking can be reduced to a minimum. More importantly, this 
approach allows the coordinating centre to notify investigators of any errors made 
without delay (recommendation 6). 
The sponsor of ACTION insisted that its standard on-site monitoring proce-
dures be used. Completed CRF pages were checked on-site by CRAs and the nec-
essary changes and additions were made by the investigator. Only then were CRFs 
sent to the coordinating centre. This caused time delays in data processing and 
checking as receipt of data was dependent on the frequency of monitoring visits. A 
temporary lack of monitoring capacity may cause major delays. 
The tasks of CRAs can be made easier by supplying them with listings of 
CRFs that should have been received, data queries still needing to be resolved, 
documents such as discharge letters to be collected, etc. In fact, managing a study 
of the size and duration of ACTION is almost impossible without the possibility of 
generating such listings from the database (see also Chapter 6). For these listings to 
be useful, concurrent database management is essential. This is one more reason 
why the on-site monitoring frequency should not be allowed to determine the delay 
with which CRFs are received at the coordinating centre. 
On-site Electronic Data Capture (EDC) is changing the way clinical trial data 
is collected. The considerations involved in CRF preparation and handling men-
tioned in this chapter also apply to EDC however. Hence, it remains to be seen 
whether on-site EDC will prove to be a step forward. 
MANAGING RANDOMISATION AND BLINDING 
Randomisation 
That treatment allocation for a given trial was truly random can never be proven by 
statistical analysis. What matters is that a validated procedure, usually a computer 
program, is used to prepare a random plan based on choices that have been made 
about blocking, etc. and that this plan is then used to allocate treatment in such a 
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manner that the assumptions underlying randomisation are not violated. Trial man-
agement has to ensure that this is indeed the case. Essential to procedurally correct 
randomisation is that the investigator cannot know the treatment the patient is go-
ing to receive when the decision to include the patient in the study is taken. In an 
open study using sequentially numbered envelopes that contain randomly allocated 
treatments, this can usually not be guaranteed as it may be difficult to check that an 
investigator doesn’t open the next envelope first, and then starts to look for a suit-
able patient for the treatment allocation contained in the envelope. Open studies 
therefore generally require a central treatment allocation system that allows the 
investigator to obtain a treatment allocation after the patient has been registered. 
Study medication for double blind studies must be packed in such a manner 
that it is impossible to distinguish between treatments. It is important to verify be-
fore the study starts that this was done properly and that, for example, it is not pos-
sible to open coding envelopes without damaging them permanently, or to deter-
mine what is inside by holding them against a light source. The possibility to taste 
tablets needs to be considered also. We know of patients comparing the taste of 
tablets in waiting rooms. However, provided that double blinding of study medica-
tion is guaranteed, there is no need however to set up a central system for allocat-
ing treatment numbers. If blocking was used when preparing the random plan, it is 
only necessary to ensure that treatment numbers are used sequentially in order to 
prevent incompletely used blocks as much as possible.  
 
Blinding of investigators 
Whether investigators need to be blinded is a matter of trial design. It is sometimes 
argued that blinding is not needed for trials with ‘hard endpoints’. Such trials often 
need blinding however in order to ensure validity of comparison for other out-
comes, such as routine blood pressure measurements made by investigators using a 
standard office measuring device. The recent popularity7,8 of the so-called PROBE 
(Prospective Randomised Open Blinded Evaluation) design9 indicates in our opin-
ion that the need for blinding of investigators may be underestimated. In the 
PROBE design, the committee that adjudicates the clinical events of interest is 
blinded to treatment allocation but the local investigator is not. Because of this, the 
decision of an investigator to send a patient to hospital for chest pain for example 
may very well be influenced also by knowing the treatment to which the patient 
was allocated. While the point that open treatment allocation can simplify clinical 
trials considerably9 is well taken, blinding only the adjudication committee to study 
treatment allocation does not ensure validity of comparison based on our under-
standing of the principle involved (recommendation 7). 
For ethical reasons, the investigator or any other treating physician must be 
able to break the code when this is necessary to decide on further treatment. Rather 
than setting up a telephone system to monitor code breaks by investigators, we re-
lied on traditional coding envelopes provided with study medication for both PICO 
and ACTION. Monitoring code breaks was left to on-site monitors and code breaks 
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were infrequent. We did explain extensively during investigator meetings that 
breaking the code is in fact rarely necessary to decide on further treatment when 
study medication is stopped for clinical reasons. We found that this is generally 
understood by investigators with experience in performing clinical trials. 
 
Blinding the study structure 
While there is general agreement about the indications for blinding investigators 
and patients, approaches to blinding the study structure seem to vary considerably. 
In our opinion, managing a double blind study requires that there is no possibility 
for anyone involved in data management or trial operations to access the code. We 
prefer therefore that the random plan is not accessible to coordinating centre staff 
before database lock. However, this has consequences for trial management. One 
consequence is that the coordinating centre is unable to perform interim analyses as 
specified in the protocol. For the ACTION trial, interim analyses were therefore 
performed at another institution by statisticians not otherwise involved in the trial 
(c.f. Figure 1). This institution also prepared the random plan before the study 
started, which was then made available only to the sponsor’s pharmacy responsible 
for packing study medication. When a code break was required by the sponsor in 
order to comply with its adverse drug reaction reporting obligations, the sponsor’s 
drug safety officer had to call the institution responsible for preparing the random 
plan. Because of this, it was possible to track the frequency and purpose of code 
breaks. 
We believe that procedures for maintaining blinding of the study structure are 
more important for safeguarding scientific integrity than is generally realised (rec-
ommendation 8). Scientific integrity requires that only pre-defined interim analyses 
are performed based on explicit stopping rules in order to avoid a trial being 
stopped early for inappropriate reasons, either by investigators, or by sponsors. The 
regulatory authorities have realised this for many years. Instances of a sponsor 
stopping a trial early for commercial reasons have in the past been surrounded by 
publicity and debate.10-12 We know of instances where the investigator was pre-
vented from publishing because the sponsor was unwilling to provide the random 
plan. Conflicts of interest affecting trial conduct are a cause for concern.13 Al-
though preparing the random plan for industry-sponsored drug trials is usually 
done by the sponsor, the latter should preferably not be involved in this. Ideally, 
access to the random plan should be controlled by an independent institution, as 
was the case in the ACTION trial. 
FORMATION OF THE TRIAL COHORT 
Centre-specific considerations 
Timely patient recruitment is a prerequisite for any trial’s success. To ensure the 
deadlines for patient recruitment are met, trial management needs to be up to date 
on a daily basis on the status of patient recruitment in each participating centre. In 
both the PICO and ACTION trials, investigators were required to notify the coor-
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dinating centre immediately by telefax once a patient had given informed consent 
or had started study medication. This allowed continuous monitoring of progress 
and early identification of slow and fast recruiting centres alike. Today, the internet 
may be used for this purpose. 
It is customary to define in the protocol or in the investigator contract, the 
minimum number of patients that each centre is expected to contribute. Blocked 
randomisation and stratification for centre being standard practice, this number is 
usually based on the minimum number of blocks to be used in each centre. Often, 
the maximum number of patients each centre can contribute is also defined. For the 
ACTION trial, the minimum was set in the protocol to 24 (4 blocks of six) and no 
maximum was set. Whether the minimum and maximum should be enforced is 
questionable. One could exclude from the analysis all patients contributed by cen-
tres that did not reach the minimum, and/or stop recruitment in centres when the 
maximum is reached. While neither of these would compromise validity of com-
parison, excluding centres that didn’t reach the minimum is difficult to justify ethi-
cally and scientifically since patients in the centres concerned have been exposed to 
study treatment. Hence, no centre has been excluded from either the PICO or the 
ACTION trial because the number of patients recruited did not reach the block 
size. As far as maxima is concerned, faster recruiting centres compensated for 
slower recruiting ones in both trials, which ensured that the overall recruitment re-
mained on target. This required that faster recruiting centres were re-supplied with 
sufficient study medication and other materials required, such as CRFs, etc. Man-
aging the timely shipment from central stocks of trial supplies was therefore an 
important task in both trials (recommendation 9). 
A consequence of not enforcing centre minima or maxima may be that not all 
blocks are used completely. Centre contribution to each treatment arm will there-
fore tend to deviate from the allocation ratio used during blocked randomisation. 
This may decrease statistical power but should not compromise validity of the trial 
as a whole. When the number of centres is large, the effect of incomplete blocks 
will tend to ‘randomise out’ and treatment groups for all centres combined will be 
very similar in size if the random plan was based on blocks of an equal number of 
allocations to each treatment. 
While deciding on trial cohort membership, the question of what to do when 
trial conduct appears to be unsatisfactory in a certain centre cannot be avoided. Ex-
clusion of centres for such reasons is rarely mentioned in trial reports. An exception 
is the INSIGHT report, which mentions that “254 patients from centres withdrawn 
for misconduct” were excluded from intention-to-treat analysis.14 Nonetheless, we 
find it difficult to believe that unsatisfactory local conduct is as rare as the absence 
of mentioning this in published trial reports suggests. As long as all patients from 
the centres concerned are excluded, validity of comparison in the remainder of the 
trial should not be compromised (recommendation 10). While this is by itself a 
simple and methodologically sound policy, its actual execution is nonetheless com-
plex and requires time, judgement and evidence. The trial coordinating centre 
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and/or the on-site monitors must determine which centres need to be audited, and 
these audits must then be performed with care (recommendation 11). 
The ACTION protocol contained a provision that allowed exclusion of cen-
tres. In a small fraction of centres, five in total, local trial conduct was found to be 
unsatisfactory by an independent auditor. We favour exclusion of centres that fail to 
deliver data of verifiable quality.  
 
Who has actually been allocated treatment? 
While recruitment is ongoing, trial management must first of all identify the pa-
tients that belong to the trial cohort based on an unequivocal operational definition 
of treatment allocation that can be applied in practice. The CONSORT group has 
written extensively about the need to describe clearly how participants were allo-
cated to interventions. CONSORT has published a template for a diagram that is 
today part of many trial reports.15 In the template, the terms ‘randomised’, ‘allo-
cated to intervention’ and ‘received allocated intervention’ are used. 
The distinction between ‘allocated to intervention’ and ‘received allocated in-
tervention’ is essential in an open comparison between, for example, coronary by-
pass surgery and (continued) treatment with drugs. In such situations, ‘allocated to 
intervention’ should be taken as being equivalent to telling the patient which treat-
ment he/she is going to receive.  
Double blind trials such as PICO or ACTION are different from open trials. 
Double blind medication is packed in sequentially numbered containers and the 
actual tablet composition is concealed. Allocating a specific medication number to 
a specific patient does not necessarily mean that the first tablet from the allocated 
study medication pack is actually used. In many situations, a certain amount of 
time may pass between allocation of a study medication pack and actual start of 
treatment. This poses the problem as to what should be done in the case an allo-
cated medication pack remains unused. One solution is to consider the patient in 
question a member of the trial cohort nonetheless. The logical consequence of this 
is that such patients must be followed as planned in the protocol. While we know 
of instances where this solution has been used, we consider it generally unjustifi-
able. Continuing patients who never started study medication in a trial poses ethical 
problems and may influence willingness to undergo follow up assessments. In ac-
cordance with ICH E91 it is our policy to omit from trial cohorts patients who 
failed to start double blind study medication even if a study medication number had 
been allocated. This should not compromise validity of comparison as the circum-
stances that caused this cannot have been influenced by a treatment that was never 
taken. It is our policy therefore to define treatment allocation in a double blind 
study as equivalent to taking the first tablet of study medication as this provides an 
unequivocal definition of trial cohort membership for such trials. 
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Dealing with violations of selection criteria 
Ideally, all patients selected by investigators comply with the selection criteria in 
the protocol. These criteria often define a subgroup of patients free from other ma-
jor clinical conditions or laboratory test abnormalities. The ACTION selection cri-
teria (c.f. Chapter 4, Table 1 on page 43 of this thesis) are a case in point. In total 
20 different reasons for exclusion were defined when the study was designed. Lim-
iting recruitment to eligible patients only based on such complex criteria is rarely 
achievable in practice, in particular when exclusion criteria such as creatinine 
above twice the local upper limit of normal apply. From a trial management per-
spective, this is better replaced by clinically relevant elevation of creatinine as this 
leaves judgement to the investigator (recommendation 12). 
Unless ineligible patients can be detected before study treatment is started 
(which is difficult to implement in large multi-centre trials), trial management must 
determine eligibility status for each patient, and consider the steps to be taken if 
selection criteria have been violated. 
One approach in this regard is to insist that patients who were allocated to 
treatment in violation of the selection criteria are considered members of the trial 
cohort nonetheless, and are hence also accounted for in the analysis. As noted in 
ICH E9, this policy implies “complete follow up of all randomised subjects for 
study outcomes”.1 This may be ethically unjustifiable, and also raises the question 
whether trial managers should advise investigators who started study treatment in 
violation of a selection criterion to withdraw study treatment in the interest of pa-
tient safety. An alternative approach is therefore to exclude ineligible patients from 
the trial cohort, notify the investigator accordingly as soon as the violation is de-
tected, and advise the investigator to stop study medication at the same time.  
There seems to be no agreement in the literature about the approach to be 
taken. The interpretation of the intention-to-treat principle is at issue here also. An 
inclusive interpretation is that ineligible patients in the trial cohort are apparently 
also candidates for the treatment investigated in the opinion of investigators and 
must therefore be included in a true intention-to-treat analysis. In addition, it is ar-
gued that removing ineligible patients could introduce bias, and is therefore inap-
propriate.16 A drawback of including ineligible patients in the trial cohort is that the 
overall result of the study becomes a weighted average of the result in eligible pa-
tients and in patients who were not eligible. Depending on the percentage of ineli-
gible patients and the effect of treatment in this category, the overall result may 
differ substantially from the result that would have been obtained had the trial co-
hort consisted only of eligible patients. Hence, an alternative exclusive interpreta-
tion is that the intention-to-treat principle applies only to eligible patients. Essential 
to this interpretation is the argument that there is no reason why excluding ineligi-
ble patients should compromise validity of comparison for those who were eligible, 
provided that the distinction between ineligible and eligible is made strictly based 
on patient characteristics established before study treatment was started. 
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Although proponents of the exclusive interpretation are vindicated by ICH E9 
– which states that “failure to satisfy major entry criteria (eligibility violations)” is 
one of the “limited number of circumstances that might lead to excluding random-
ised subjects”1 – we note that it is difficult to implement a policy of exclusion that 
is indeed strictly based on patient characteristics that were established before allo-
cation to treatment. An example illustrating this problem could be the following. 
Suppose that a patient in a clinical trial was operated for prostate cancer one year 
after study medication was started, that the discharge letter stated that the patient 
was known to have prostate cancer for two years, and that the presence of this con-
dition was not reported on the baseline CRF by the physician who recruited the 
patient. CRAs may be inclined to ask the investigator to add prostate cancer to the 
patient’s baseline medical history. This added information is however biased be-
cause the presence of prostate cancer at baseline would in this case have never 
come to light, had the patient died suddenly six months after start of study medica-
tion. Obviously, it must be prevented that information which emerges after study 
medication was started influences the decision to exclude a patient from the trial 
cohort. A related issue is that the analysis of comparability at baseline of treatment 
groups as presented for the PICO trial (c.f. Chapter 2, Table 2, page 8), and analy-
ses based on baseline characteristics (c.f. Chapter 5), are also affected by changing 
baseline data because of information that became available after start of follow up. 
A clear policy to prevent exclusion of ineligible patients on inappropriate grounds 
and to ensure validity of comparison for baseline data should be in place (recom-
mendation 13). This is just one example of the notion that maintaining validity of 
comparison in clinical studies is sometimes more important than complete repre-
sentation of all that is known about a particular subject in the database. 
The exclusive interpretation of the intention-to-treat principle mentioned ear-
lier is, in our opinion, scientifically the only tenable one. Nonetheless, for reasons 
just mentioned, we have found it not easy to implement strict policies based on this 
interpretation. The protocol of the PICO trial required the coordinating centre to 
instruct the investigator to stop study medication in the case the investigator com-
mitted a major error of selection. The results section of the PICO trial report (c.f. 
Chapter 2, page 8) describes that 14 patients were excluded for violations of selec-
tion criteria before the medication code was broken. The trial design section of the 
same report states: “While the trial was ongoing, patients were withdrawn when a 
clinically relevant violation of the selection criteria was detected at the co-
ordinating centre. The decision to do so was taken … before the medication code 
was broken.” (c.f. Chapter 2, page 6). Taking such decisions before breaking the 
code in a double blind trial does not ensure validity of comparison however be-
cause excluding the just mentioned case of prostate cancer not reported at baseline 
compromises validity no matter when the code is broken. In the PICO trial, only a 
small number of ineligible patients were started on study medication. We are 
tempted to assume that one reason for this was the immediate notification of the 
investigator combined with an instruction to stop study medication. There was no 
room for argument about this as it was based on the provision in the protocol men-
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tioned earlier and withholding remuneration for patients who don’t comply with 
the selection acted as a deterrent (recommendation 14).  
Because it was impossible to reach consensus on a policy concerning exclu-
sion of ineligible patients from the trial cohort after start of study medication, the 
design of ACTION was based on the inclusive interpretation of intention-to-treat. 
In the protocol, in the design paper (c.f. Chapter 4, page 51) and in the statistical 
analysis plan (SAP, c.f. Chapter 7, section 1.3, page 100) two analysis populations 
are defined, both to be analysed by assigned treatment. The all-randomised popula-
tion consists of all patients who took at least one tablet of study medication irre-
spective of eligibility. The valid-for-efficacy population on the other hand is con-
fined to eligible patients only, and is thus based on the exclusive interpretation of 
intention-to-treat. Because of the different views on the exact meaning of intention-
to-treat, this term was not used in naming analysis populations. The inclusive view 
prevailed however as the ACTION protocol states in section 1.6: “The primary 
analysis will focus on all patients who were randomised (conventional ‘intention-
to-treat’ analysis).” 
The fact that the inclusive interpretation prevailed when the study was de-
signed had considerable consequences for the conduct and management of the AC-
TION trial. The protocol required investigators to follow eligible and ineligible 
patients in the same manner and to maintain patients on study medication unless 
contra-indicated. It was therefore not necessary for trial management to distinguish 
between eligible and ineligible patients while recruitment was ongoing unless pa-
tient safety was compromised. In such instances, investigators were instructed to 
stop study medication while continuing follow up. 
Although eligibility was as such inconsequential for trial conduct, it was none-
theless required to assess eligibility for each ACTION patient as this was the basis 
for defining the analysis populations mentioned earlier. Because of the large num-
ber of patients involved and the complexity of the selection criteria, this was no 
easy task which for several reasons could not be automated. All patients were 
therefore checked for eligibility by a data analyst at the coordinating centre. To 
avoid that minor violations led to exclusion from the valid-for-efficacy population, 
the criteria used for this purpose were less stringent than those mentioned in Chap-
ter 4. For instance the criterion in stable clinical condition for at least one month 
(c.f. inclusion criterion no. 2, Table 1, Chapter 4, page 43) was relaxed by the 
Steering Committee for the purpose of eligibility checking to in stable clinical 
condition for at least 10 days (c.f. Chapter 7, section 1.3.2, page 100). ACTION 
was intended to focus on stable angina, and nifedipine is not indicated for acute 
coronary syndromes. The selection criterion concerned is a reflection of this. None-
theless, one month of stability is as arbitrary as 10 days. This type of arbitrariness 
in clinical trial selection criteria is unavoidable. The result is a ‘grey zone’ in trial 
cohorts between patients who are perfectly eligible and those who are clearly out-
side the clinical spectrum at issue (recommendation 15).  
At the time of writing it is unknown whether the results of ACTION are dif-
ferent between eligible and ineligible patients. What can be said is that the sub-
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group analysis that addresses this question will have little statistical power as only 
6% of patients did not comply with the relaxed inclusion criteria as listed in section 
1.3.2 of Chapter 7 (c.f. page 100). While we remain as a matter of principle com-
mitted to an exclusive interpretation of intention-to-treat combined with immediate 
removal from the trial cohort of patients who were started on study medication in 
violation of the selection criteria, it would not have been possible in retrospect to 
implement such a policy for the ACTION study. That certain selection criteria were 
not always perceived as clinically relevant by investigators didn’t help. Another 
reason was that eligibility checking was a time consuming process, if only because 
the relevant sections of CRFs arrived at the coordinating centre weeks or even 
months after study medication had been started due to the frequency of on-site 
monitoring visits (c.f. On-site monitoring, page 149). 
ENSURING INTEGRITY OF FOLLOW UP INFORMATION 
The importance of defining the time span of follow up 
Ensuring integrity of follow up requires firstly a practical definition of the planned 
time span of follow up. Deciding on the time point when follow up starts is closely 
related to deciding if the patient is a member of the trial cohort. In an open study, 
the moment that the patient is told which treatment he/she is going to receive 
should then also be considered as the start of follow up since everything that hap-
pens thereafter might have been influenced by the patient’s knowledge of future 
treatment. In double blind studies, the logical starting point of follow up is the 
moment when the first dose of study medication is taken. To define this moment 
exactly, we insisted in both PICO and ACTION that the first tablet of study medi-
cation be taken in the presence of the investigator or the study nurse and that the 
clock time that this was done be recorded in the CRF. To illustrate why this is im-
portant for trial management, suppose that study medication was handed out on the 
day of treatment allocation and that the patient was instructed to start study medi-
cation the next morning. If such a patient was found dead the morning after study 
medication was handed out, it may be impossible for trial management to ascertain 
whether the patient had started study medication or not. Ambiguities of this kind 
can only be resolved without potentially compromising validity of comparison by 
considering all patients who were handed out study medication as belonging to the 
trial cohort even when this was never started. 
Another important reason to document the exact time of start of follow up is 
that this allows data managers to determine which information was obtained before 
start of study medication and which information thereafter. To illustrate, suppose 
that the first tablet of study medication was documented in the CRF as having been 
taken at noon on a certain day. An ECG recorded before noon on the same day is 
then indeed a baseline ECG while an ECG recorded after noon is not, as the latter 
may already have been influenced by study treatment. An exact definition of the 
time that study medication was started is therefore a useful tool for management of 
baseline data (recommendation 16).  
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Apart from an unequivocal definition of the start of follow up, all trials require 
an exact and workable definition of its planned end. For clinical outcome trials 
such as ACTION, it is common to follow all patients until an arbitrary ‘common 
stopping date’. However, choosing one common calendar date for this purpose has 
practical drawbacks. Patients still using study medication on the common stopping 
date will continue to do so until they can be seen by the investigator and the need 
for further treatment can be determined. Inevitably, clinical events will occur dur-
ing continuation of study medication beyond the planned end-date. This may po-
tentially lead to a discussion concerning inclusion of such events in the analysis. In 
an attempt to limit the number of such events, one can instruct investigators to see 
all surviving patients for a close-out visit as soon as possible after the common 
stopping date. This however leads to peak work loads for investigators, CRAs and 
data management personnel. To avoid such drawbacks in ACTION, we defined a 
six-month close-out period rather than a common stopping date and determined for 
each patient the planned date of the first regular ACTION out-patient clinic visit 
within this period. We then instructed investigators to consider this visit as the 
close-out visit for the patient concerned and to perform the visit as closely to the 
planned date as possible but not before that date. This approach limited continua-
tion of study medication beyond planned end, and work loads tapered off rather 
than peaked. 
 
Dealing with loss to follow up 
Ensuring complete follow up that allows true intention-to-treat analysis (c.f. Chap-
ter 3) is an important objective. What must be avoided is that time-to-event analy-
ses have to be censored for any reason other than planned end of follow up so as to 
keep censoring non-informative. Similarly, it is necessary to ensure, clinical status 
permitting, that all planned measurements are available when comparing treatment 
groups for outcomes such as exercise capacity, blood pressure or NYHA class at 
specified time points during follow up. Otherwise, validity of comparison may be 
compromised (recommendation 17). In this paragraph, we describe some practical 
problems encountered while executing the PICO and ACTION trials and the poli-
cies implemented to maintain validity of comparison for follow up information. 
For exercise capacity trials such as PICO, full follow up is not generally ac-
cepted standard practice. The primary analysis of such trials is often a per-protocol 
analysis of treatment effect on exercise capacity in patients who actually completed 
the study as planned on study medication – or any pre-defined part of it. In such 
protocols, one often finds criteria for considering a patient who belongs to the trial 
cohort as a ‘drop-out’, usually resulting in exclusion from analysis completely. 
We believe that the very concept of ‘drop-out’ should not exist in any trial and 
that follow up assessments should always be fully completed as planned unless the 
patient is incapable of undergoing assessments for valid clinical reasons (recom-
mendation 18). In Chapter 3 we distinguish between pseudo and true intention-to-
treat analysis. Data that haven’t been collected can’t be analysed. True intention-to-
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treat analyses for PICO as presented in Chapter 2 (c.f. Figure 2 on page 12) and 
Chapter 3 (c.f. Table 3 on page 30) are possible only when the protocol required 
collection of the data needed. These analyses were crucial to the proper understand-
ing of the effect of pimobendan on exercise duration as analysed per-protocol (c.f. 
Chapter 2, Figure 1 on page 11) because they showed that the positive effect of 
pimobendan on exercise duration was not completely negated by its negative effect 
on mortality. 
Alleviating symptoms by treatment often implies an increased risk of morbid-
ity and mortality that is associated with the treatment concerned. This confronts the 
patient with a choice between a shorter life combined with symptomatic improve-
ment and a longer life combined with continuing or even more severe symptoms. 
Because of the risks associated with surgery, hip replacement is an example of such 
a treatment. Whether it is reasonable to even consider the choice can only be shown 
by true intention-to-treat analysis as performed for the PICO trial. Such analyses 
should therefore always be performed for trials that focus on symptoms or para-
clinical measures as primary outcome (c.f. Chapter 3, Figure 1 on page 25). Such 
analyses may also be highly relevant to elucidate treatment effects in trials with 
clinical events or mortality as primary endpoint. In Chapter 3 we have outlined our 
thinking about how effects on symptoms and on clinical events can be analysed 
jointly in clinical outcome trials. The secondary analysis for NYHA class and mor-
tality as described in section 4.3.3 of the ACTION SAP (c.f. Chapter 7, page 121) 
is a case in point. Such an analysis allows for the possibility that treatment reduces 
mean survival time, while increasing at the same time mean survival in NYHA 
class I (i.e. without cardiac symptoms). As in the case of PICO, this would indicate 
that taking the risk of reduced survival due to treatment might nonetheless be rea-
sonable because of a positive effect on symptoms. Such analyses have been pro-
posed a long time ago.17 It is surprising that they haven’t become more popular 
since they might have lead to different conclusions about the clinical value of heart 
failure treatments such as pimobendan.  
Apart from allowing for elucidating trade-offs between positive and negative 
effects of treatment, there is another important reason for collecting true intention-
to-treat data on morbidity and mortality in trials that focus on symptoms or para-
clinical measures as primary outcome. Drug development is a sequential process 
with decision points that can be defined beforehand. Again, the PICO trial is a case 
in point. A compound such as pimobendan will not be approved by the regulatory 
authorities unless data from a large mortality trial are available. The decision to 
perform a new trial should also depend on an appropriate evaluation of the data that 
have already been collected during earlier trials. Evaluation of the effect on mortal-
ity using the combined data from earlier trials by a statistical meta-analytic method 
presupposes that the data on mortality have been collected based on intention-to-
treat in all trials considered.18 When this is not the case, the meta-analysis will not 
be relevant for the expected results from a large mortality trial. 
For a number of reasons, complete follow up is not always easy to achieve 
even when required by the protocol. One reason may be that the protocol itself is 
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not entirely clear in this regard, or is later amended. For example, the initial version 
of the PICO protocol covered only the 24-week efficacy phase (c.f. Chapter 2 Trial 
design, page 6). For this phase follow up was almost complete; only 10 out of 317 
patients didn’t have an exercise test at 24 weeks for reasons that didn’t relate to 
their clinical status (c.f. Chapter 2, Table 3, page 10). As the extended follow up 
phase (c.f. Chapter 2 Trial design, page 6) was added later, patients had to be asked 
consent for continued participation at the end of the efficacy phase. In PICO this 
was without consequence as only one patient was lost to follow up during exten-
sion. Nonetheless, the need to ask informed consent again because of study exten-
sion is better avoided as this can lead to problems (recommendation 19). A case in 
point is a trial for which the published report states that “1588 (13%) of patients 
did not take part in the extension of the trial made necessary by the redefined pri-
mary endpoint (unable, or refused to restart or continue study medication)”.19 This 
in fact creates censoring at the start of extension that may not necessarily be non-
informative. Hence, validity of comparison for the whole trial may be compro-
mised. 
Even when there are no later protocol amendments, problems with follow up 
occur. Patients may move to another city or country, or withdraw informed consent. 
In addition, investigators may equate refusal to continue study medication with 
refusal to comply with follow up (c.f. recommendation 18). To minimise loss to 
follow up for such reasons, several policies were implemented for ACTION. 
Whenever a patient moved, an attempt was made to enlist the help of another phy-
sician in completion of follow up. That refusal to continue study medication is not 
the same as withdrawal of consent was explained at investigator meetings and to 
individual investigators as cases of refusal were reported. We also sent CRAs a 
monthly list of patients currently identified in the database as lost to follow up, and 
asked them to review the cases concerned with investigators during the next moni-
toring visit. Based on this, it was possible to bring several patients back under fol-
low up and in some cases even to restart study medication. This was made possible 
by the protocol, which stipulated that study medication could always be restarted 
after interruption unless a contra-indication had developed. Finally, we encouraged 
investigators to invite patients who previously did not want to come back regularly 
for planned follow up visits for the end-of-study visit. If this was possible and in-
cluded a review of the clinical history combined with SAE reporting for the pur-
pose of ACTION endpoint detection, we considered such patients no longer as lost 
to follow up. 
Despite all such efforts, loss to follow up can never be completely avoided as 
patients always have the right to withdraw informed consent. In a trial with total 
mortality as the primary evaluation criterion, loss to follow up for this endpoint can 
sometimes be limited because, for instance, a national registry can be accessed to 
ascertain the vital status of patients who withdrew consent. While loss to follow up 
can, and should be limited in this manner as much as possible in a mortality trial, 
this is not an option in a trial with a combined endpoint such as ACTION. The rea-
son is that non-fatal events that terminate event-free follow up can usually not be 
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ascertained in this manner. For the ACTION trial, loss to follow up was therefore 
defined as the inability of the investigator to ensure further SAE reporting for the 
purpose of detection of study endpoints, even if it was possible to ascertain vital 
status at the planned end of follow up for the patient concerned. Because of this, it 
seems unavoidable that trials with a primary endpoint that combines fatal and non-
fatal events should generally have a somewhat higher loss to follow up rate than 
mortality-only trials. 
How should loss to follow up be accounted for in analysis and reporting? Our 
approach is not to accept loss to follow up as a reason for excluding the patient en-
tirely from the trial cohort under any circumstance. As said earlier, there is no place 
for ‘drop-outs’ in this regard. Rather, the approach should be to always include all 
patients with less-than-complete follow up in time-to-event analyses, using the date 
that the patient was lost to follow up as censoring date. This is the approach that is 
outlined in the SAP for the ACTION trial (c.f. Chapter 7, section 4 starting on page 
115). This de facto equates termination of follow up earlier than planned with fol-
low up as planned, and assumes that censoring earlier than planned is non-
informative. In a randomised trial, this assumption always holds under the null-
hypothesis of ‘no difference between treatments’. If the treatments compared are 
different however, non-informativeness of early censoring cannot be assumed even 
when treatment allocation was randomised. We note in passing that loss to follow 
up will also affect analyses for outcomes that are assessed repeatedly at certain pre-
specified time points, such as NYHA class, blood pressure, etc. For such outcomes, 
our general approach is to include patients who were lost to follow up in the analy-
sis with the data that have actually been collected, and to impute missing values 
based on a reasonable rule (c.f. the methods described in Chapter 2 for imputing 
missing exercise duration values).  
 
Simultaneous participation in other studies 
A problem rarely considered in trial reports is participation of patients in more than 
one study at the same time. Ancillary or ‘side-arm’ studies are a feature of many 
large trials as this may render participation more attractive to investigators with 
specific scientific interests. Whether such ancillary studies can be justified is an-
other matter however.  
In general, a distinction must be made between including a patient simultane-
ously in two different studies on the same day and including a patient already par-
ticipating in one study in a second study at a later date. An example that illustrates 
the problems that can be caused by including a patient in two studies on the same 
day is as follows. Suppose that a group of investigators participating in a study 
such as ACTION decides to set up a study that requires baseline and follow up 
coronary angiography in 500 patients. If this was done as an ancillary study to 
ACTION, its overall results will be affected. Complications of angiography in the 
ancillary study become clinical events in the ACTION study that must be counted. 
While this would not compromise validity of comparison of ACTION as such, 
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generalisability may be affected because patients who undergo repeated angiogra-
phy for no other reason than participation in the ancillary study will be treated dif-
ferently. Provided that the main trial was sufficiently large, the question whether 
generalisability was affected by simultaneous participation in an ancillary study 
can be addressed by standard subgroup analysis because participation in the ancil-
lary study is a baseline characteristic in the main study. This type of double partici-
pation therefore has a methodological solution at least in principle.  
Including a patient who is already participating in one study in a second study 
later is infinitely more problematic. For the second study, participation in the first 
study is irrelevant for validity of comparison as this is just a baseline characteristic. 
Within the first study there is a problem however, as patients entered in the second 
study cannot be excluded without affecting validity of comparison. Considering 
patients who are included in the second study as ‘lost-to-follow-up’ is no option 
either, as this introduces potentially inappropriate censoring. 
Based on these considerations, participation in another trial or study was an 
exclusion criterion in the ACTION study (c.f. Chapter 4, Table 1 on page 43). The 
protocol also contained a provision that while participating in ACTION, patients 
were not allowed to participate in any other trial, ancillary or side-arm study unless 
this other trial or study had been approved by the Steering Committee beforehand. 
The purpose of this was to prevent participation in any other study that would inter-
fere with either the practicality of ACTION, or the eventual interpretation of its 
results. The rationale for this was repeatedly explained in detail at ACTION inves-
tigator meetings. In fact, several ancillary studies compatible with the main 
ACTION study were approved by the Steering Committee. 
Notwithstanding this, at least 20 patients were included in other trials after in-
clusion in ACTION. One reason appeared to be that some investigators failed to 
see the problem, as was evidenced by explanations such as “there is no scientific 
reason why patients can’t participate in another trial or study at the same time”, or 
“this patient wasn’t taking ACTION study medication anymore in any case” or “it 
wasn’t me who did it, a colleague of mine entered the patient concerned during an 
admission to our coronary care unit without telling me”. While 20 cases may seem 
an insignificant number, it must be taken into account that this concerns only the 
cases that we were able to detect. It cannot be excluded therefore that participation 
in other trials may have been more prevalent than we were able to assess (recom-
mendation 20). 
Participation in two trials at the same time is not possible for ethical and legal 
reasons. Hence, we were forced to define a policy for dealing with this even though 
the number of cases concerned in ACTION was small. As soon as we became 
aware of a case of inclusion in another study, the investigator was requested to re-
move the patient from the other study if possible. The only exception was a newly 
diagnosed cancer for which treatment was not available other than within a trial 
comparing several cancer treatments. If the investigator didn’t agree to remove the 
patient from the other study, the latter was withdrawn from ACTION until the other 
study was completed. Thereafter we insisted that ACTION be resumed, including 
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restarting study medication unless contra-indicated. If this was not possible, we 
were left with no other option than to consider the patient as lost to follow up as of 
the moment of inclusion in the other study. As far as we know, less than 10 patients 
were lost to follow up for this reason. 
ASSESSMENT OF OUTCOME 
In clinical trials, effect estimation is based on comparing pre-specified outcomes 
between treatment groups by appropriate statistical methods. Valid assessment of 
the outcomes that will be analysed must therefore be ensured while the study is 
ongoing. 
In Chapter 3 we distinguished four hierarchical levels of outcome information 
(c.f. Chapter 3, Figure 1 on page 25). Levels 1 – 3 concern clinical events that may 
occur at any time point during follow up. Level 4 outcomes on the other hand con-
cerns observations that can be repeated over time in the same patient, such as blood 
pressure, NYHA class etc. The distinction between timed clinical events and obser-
vations that can be repeated is important in this context too. Effect estimates for 
clinical events will be diluted when, given validity of comparison, there is random 
misclassification.20 Lack of precision because of random error in observations that 
can be repeated has the same effect. Reducing misclassification and random error 
in measurements is therefore an important concern. Standardisation is the key con-
cept in this regard. In addition, generalisability of trial results must be kept in mind. 
A valid effect estimate for a certain outcome is of little scientific value unless the 
outcome concerned was obtained by a validated and generally-accepted method. 
 
Timed events 
There are several approaches to clinical outcome detection. One is to rely com-
pletely on the investigators to classify outcomes, based on uniform definitions in 
the protocol. Another approach, used in the majority of trials, is to rely on event 
adjudication by a special committee. While the names of the members can usually 
be found in the appendix of a trial report, the actual methods and procedures used 
are rarely described in detail. In this regard a distinction must be made between an 
adjudication procedure that is driven by the diagnosis of the investigator, and a pro-
cedure which is not. This distinction is important because of the potentially differ-
ent event rates that may result. To illustrate the distinction, suppose that details of 
hospitalisations are only sent to the adjudication committee when the investigator’s 
diagnosis was acute myocardial infarction. While this ensures that all cases of hos-
pitalised infarction counted in the analysis fulfil the criteria that the committee 
used, the total number can only be less than the number diagnosed by investigators. 
This was observed in the TRIM trial, one of the few trials that published details on 
the adjudication procedure.21 Hospitalised infarcts that were missed by investiga-
tors can be detected by sending to the adjudication committee details on all hospi-
talisations, and having the committee determine by standard criteria if acute myo-
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cardial infarction occurred during hospitalisation. Such a procedure is not driven by 
the investigator’s diagnosis. 
For the ACTION trial, a Critical Events Committee (CEC) was formed to ad-
judicate events in a manner that was investigator diagnosis-independent as much as 
possible. Briefly, the procedure was as follows. Standard forms for reporting SAEs 
were used to allow the sponsor to comply with its reporting obligations of adverse 
drug reactions. In order to limit the number of forms that investigators had to com-
plete, the same SAE form was also used to document clinical events and proce-
dures that were ACTION study endpoints. This by itself caused a major trial man-
agement problem (recommendation 21). Essentially the same SAE form is used by 
most if not all industry-sponsored drug trials. Hence, investigators are used to 
completing such forms whenever an adverse experience or event is noted that ful-
fils the standard criteria for seriousness. That in the case of ACTION completion of 
the same SAE report form was required also to document ACTION endpoints 
therefore needed to be explained in detail not just to investigators, but also to the 
CRAs and to personnel of the sponsor’s drug safety department.  
In ACTION, data on SAE reports was also the starting point for event adjudi-
cation. Unless it was certain that an event did not require adjudication by the CEC 
(for example removal of a wart under local anaesthesia), a so-called Request for 
Additional Information (RAI) was generated by means of a special database man-
agement module. This document requested the investigator to supply standard 
items of information and documentation (discharge letters, laboratory reports, 
ECGs, etc.) as required by the CEC. The information supplied by the investigator 
was scanned and entered in the ACTION database management system (c.f. Chap-
ter 6). This allowed the automatic generation of documentation that was sent to the 
CEC for adjudication based on standard diagnostic criteria.  
ACTION is a large study with a relatively long follow up in patients who all 
have coronary disease. Hence, the total number of SAEs to be expected is large and 
investigator diagnosis-independent adjudication becomes a major task. Whether 
this results in a higher event rate is another matter however. For example, in a pre-
liminary analysis there were 656 investigator-diagnosed episodes of acute or pro-
cedural myocardial infarction. Of these, 80% (527 out of 656) were confirmed by 
the CEC. In addition, the CEC diagnosed 108 cases of infarction not diagnosed as 
such by the investigator concerned. Thus, the total number of episodes diagnosed 
as infarction by the CEC was 527 plus 108 or 635, which is similar to the total 
number of infarcts diagnosed by the investigator. Based on this, the need for a pro-
cedure as used in ACTION may be questioned. It must be stressed however that 
myocardial infarction is a clearly delineated diagnosis on which few cardiologists 
will err. Other diagnoses of interest in ACTION, such as refractory angina requir-
ing emergency coronary angiography without progression to myocardial infarction, 
or overt heart failure requiring hospitalisation (or occurred during hospitalisation) 
which led to start of, or change in, heart failure treatment (c.f. Chapters 4 and 7), 
can in our opinion only be diagnosed reliably by a procedure that is essentially in-
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vestigator diagnosis-independent, and is based on clearly defined standard diagnos-
tic criteria that are applied by a committee of experienced cardiologists. 
Many recent trials, ACTION included, use a combined primary endpoint and 
one could argue the relevance of adjudicating further events after termination of 
primary endpoint-free follow up. Such an argument ignores the fact that there may 
be other combined endpoints, with different component clinical events. For exam-
ple, a patient who had a peripheral revascularisation procedure is not ‘at risk’ any-
more for the primary efficacy endpoint of ACTION, but is still ‘at risk’ of the com-
bined safety endpoint death, myocardial infarction and stroke. Hence, adjudication 
of further events after peripheral revascularisation is required. This is not the only 
point however. The total number of each individual event will generally also need 
to be reported. Consistency requires that this is done based on the same criteria that 
were used for diagnosing the first component event of a combined endpoint. 
 
Other observations and measurements 
Repeatable assessments such as exercise capacity, blood pressure or NYHA class 
must by definition be left to the investigator, who generally must be blinded for 
treatment allocation to ensure validity of comparison unless a special measurement 
method is used (such as a random-zero blood pressure measuring device). There 
are a variety of ways to measure exercise duration or blood pressure however, and 
investigators will differ concerning the exact interpretation of the NYHA classifica-
tion. The generally accepted solution to ensure precision and generalisability is to 
standardise the methods of investigation across centres as much as possible and to 
perform the trial only in those centres that are familiar with the standard chosen. A 
case in point is exercise testing in the PICO trial. Only centres routinely using bi-
cycle ergometry were invited to participate. The ergometry protocol to be used was 
extensively discussed with the investigators before the trial started and is summa-
rised in Table 1 of Chapter 2 (page 5). The CRF developed for the PICO trial con-
tained detailed step-by-step instructions for exercise testing based on these discus-
sions (c.f. recommendation 2). 
Sometimes it is possible to ensure validity of comparison, achieve better stan-
dardisation and presumably also improved precision, by re-analysing locally made 
recordings at a central facility by uniformly applied standards. Examples are cen-
tral analysis 24-hour ECGs (as done in PICO, c.f. Chapter 2), and central assess-
ment of ejection fraction (as done in ACTION for the baseline ejection fraction, c.f. 
Chapter 4). Central coding of abnormalities in standard 12-lead ECGs has been 
used in many studies. The same is true for central quantitative analysis of coronary 
angiograms, as used for example in the MAAS trial22 that was coordinated by our 
institution.  
An issue related to standardisation is choosing which assessments to use in the 
analysis when comparing treatment groups for the evolution over time of outcomes 
such as NYHA classification, blood pressure, etc. Just as it is necessary to define 
the end-date of follow up in such a manner that censoring in time-to-event analyses 
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is non-informative (c.f. The importance of defining the time span of follow up, page 
158), it is necessary to use only planned assessments of blood pressure, etc. Using 
non-planned assessments may compromise validity of comparison because effects 
of study medication on any of the outcomes to be compared may induce extra visits 
to the investigator. To ensure validity of comparison for repeated follow up obser-
vations at pre-specified time points, the ACTION SAP specifies the assessments to 
be used in detail (c.f. Chapter 7, sections 3.2 and 3.3 on page 113). The purpose is 
to favour the use of observations obtained at planned rather than at extra visits. A 
minor but nonetheless important comment in this regard is that investigators must 
be instructed to always calculate the planned date of a follow up visit relative to 
start of study medication, rather than the previous visit. This avoids that time win-
dows allowed around planned visit dates accumulate, or are influenced by study 
medication. 
ANALYSIS AND REPORTING 
Analysis and reporting starts when the database has been declared ‘clean’ and is 
locked so that no further changes or additions are possible. It is a trial management 
task to plan in detail for all activities related to database lock. Event adjudication 
must be complete. All data queries must have been resolved. For those still out-
standing, a decision must be taken if database lock must wait until the data con-
cerned has been clarified. Coding of medical terms must be complete and accuracy 
of data entry must have been validated. For a double blind study, the study medica-
tion code should only be added after database lock. Otherwise validity of compari-
son may be compromised during data cleaning. 
Even when analysis and reporting is not amongst its tasks and responsibilities, 
trial management must be aware of what analysis and reporting will require. Any 
group of investigators will want to publish the results as soon as the trial has been 
completed. The statistical analyses to be done, and how the trial will be reported, 
derive from its objective and design, not from its results. A well developed and de-
tailed statistical analysis plan should therefore be available well before database 
lock and can play a major role in finalising the database. Trial management can 
make use of analysis programming before database lock to recheck that there is no 
unexplained missing or inconsistent data, that there are no implausible values in the 
database which have been overlooked, etc. 
The ACTION SAP is reproduced in Chapter 7, starting on page 93. This docu-
ment contains detailed specifications of most analyses to be done and the variables 
to be used, and determines how ACTION will be reported. It is the Steering Com-
mittee’s role to decide how this will be done and Steering Committee input while 
preparing a SAP must therefore be ensured. 
Influenced by the CONSORT statement, trial reporting in major journals fol-
lows nowadays more or less the same general pattern. CONSORT provides little 
guidance however as to how results should be tabulated and considerable variation 
in this regard remains.23 In the same issue of a major journal one may find two 
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similar studies published back-to-back,9,14 using a different way of reporting essen-
tially the same combined endpoint. 
Treatment effects for chronic disease trials are nowadays almost uniformly re-
ported as hazard ratios even if this term is not mentioned. Few trials however also 
report the absolute underlying hazards (Wing et al.24 provide a recent example), 
thus making it impossible for instance to calculate meaningful numbers-needed-to-
treat.25 The ACTION SAP specifies that this will be done. 
Not all trials using combined endpoints report endpoint-free survival or which 
individual endpoint occurred first.23 For ACTION both will be reported, as well as 
the total number of each individual event. That there are patients for whom the 
ACTION adjudication committee diagnosed refractory angina, acute myocardial 
infarction, stroke, heart failure and cardiac death in sequence reflects clinical real-
ity. This reality will be fairly represented in the way ACTION will be analysed and 
reported. 
Analyses of mean event-free survival subdivided by time spent in each NYHA 
class are currently not part of standard trial reporting, but will be reported for 
ACTION (c.f. Chapter 7, section 4.3.3, page 118).  
While the ACTION SAP specifies the customary univariate subgroup analyses 
that are a standard feature of trial reports (c.f. Chapter 7, section 4.4.2, page 126), 
an analysis stratified by absolute risk at baseline based on a multi-attribute risk 
score is also included (c.f. Chapter 7, section 4.4.1, page 124). We know of just one 
report of a major trial in cardiovascular medicine that has included this in the 
past.26 Risk stratification is important because a treatment that has a positive effect 
at high risk may have no effect, or even a negative effect, at low risk.26,27 
Ideas such as these are best developed while the trial is still ongoing so that 
trial management can ensure that the necessary data are represented appropriately 
in the data sets upon which the analysis will be based. 
RECOMMENDATIONS 
1. Multi-centre trials that span several linguistic areas should be conducted in 
English and centre selection for such trials must take this into account. For in-
dustry sponsored studies, centres should be selected based on quality consid-
erations (facilities required, compliance with GCP, availability and accessibil-
ity of source date, etc.) only, and should not be influenced by marketing. 
2. Case Report Forms (CRFs) should be formulated in an unambiguous and clear 
manner, and should follow normal clinical procedures. Relevant instructions 
for carrying out examinations and tests should be printed on the opposite 
pages so that these are visible during CRF completion. 
3. Trial management requires an unequivocal mandate based on tasks, responsi-
bilities and lines of communication defined in the protocol. 
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4. Database management systems should be set up in such a manner that study 
management tools, such as listings for CRAs and investigators of outstanding 
study documents, dates of visits to be performed, etc. are also supported. 
5. Regular meetings attended by all research staff involved should be a standard 
feature of multi-centre trials, in particular for trials which take several years to 
complete. 
6. The completed CRF for each visit should be checked at the coordinating cen-
tre with the shortest possible delay so that investigators can be notified 
promptly errors in trial conduct. This should not be the task of on-site moni-
tors (CRAs). 
7. The need for double blinding must also be considered when the primary objec-
tive of a trial concerns ‘hard endpoints’. Validity of comparison for clinical di-
agnoses requires that investigators are blinded even when adjudication of 
events is done by a committee that is blinded to treatment allocation. The 
same applies to outcomes such as routine blood pressure measurements. 
8. Access to the study medication code should be limited to the statistician who 
performs interim analyses. Access to the code for adverse drug reaction report-
ing purposes should limited as much as possible and be monitored centrally. 
9. Faster recruiting centres should be allowed to make up for slower recruiting 
ones and no limit should be imposed on the maximum number of patients that 
each centre can recruit. Trial supply management should take this into ac-
count. 
10. All patients from centres where irregularities in trial conduct were observed 
should be removed from the trial. 
11. Auditing of centres while a trial is ongoing is essential. 
12. Selection criteria should either be enforced verbatim, or should refer to condi-
tions that are present in the opinion of the investigator. 
13. No additions should be made to sections of the case report form that concern 
baseline characteristics based on information that becomes available after start 
of follow up. Updates to baseline characteristics for this reason should be 
made on a separate CRF page and be kept separately in the database. Updated 
information should not be used in statistical analyses that use baseline charac-
teristics, and should not be a ground for exclusion from intention-to-treat ana-
lysis. 
14. In the case investigators are remunerated on a per-case basis, withholding re-
muneration for patients who were started on study medication in violation of 
the selection criteria should be considered. 
15. A policy must be defined for handling ineligible patients who were nonethe-
less allocated study treatment. This policy must define whether such patients 
are a member of the trial cohort, will be followed-up in the same manner as 
eligible patients and will be maintained on study treatment. 
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16. In a double blind trial, the first dose of study medication should be taken in the 
presence of the investigator or study nurse. The exact date and clock time of 
ingestion should be documented in the case report form. In an open trial, the 
moment that the patient is informed about the treatment allocated should be 
similarly documented. Actual ingestion of the first dose of study medication 
(double blind trial), or actual communication of treatment allocated (open 
trial) should define trial cohort membership. The exact times mentioned earlier 
define the moment that follow up starts. 
17. Validity of comparison for outcomes requires that the maximum duration of 
follow up for clinical events or the timing of repeated assessments to be used 
in treatment comparisons, does not depend on treatment allocated. 
18. There is no justification for allowing ‘drop-outs’ during follow up. Clinical 
status permitting, patients who belong to the trial cohort should undergo all 
planned assessments irrespective of withdrawal of study medication. Refusal 
to continue study medication need not imply withdrawal of consent. The rea-
sons for missing assessments should be recorded and information on clinical 
events should be collected based on intention-to-treat. This policy should ap-
ply also to trials that focus primarily on the evolution of symptoms or para-
clinical measures while study medication is being administered. 
19. Unless this contingency is excluded at the outset, the protocol should state that 
treatment and follow up may be prolonged for specified reasons (such as a 
lower endpoint rate than expected) and the need to ask for informed consent 
for this should be avoided. Hence, patients should be informed about possible 
extension during the initial informed consent procedure. 
20. Patients cannot participate in two trials at the same time unless this is ap-
proved in advance by the steering committees involved. 
21. To avoid confusion among investigators, standard forms that are used also in 
other trials (e.g. serious adverse event reports) should be used only for their 
intended purpose. 
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Chapter 9 
Summary / Samenvatting 
Summary 
In a clinical trial, patient groups assigned to different treatments are compared to 
assess the effects of a new treatment or to evaluate the difference between existing 
treatments. To avoid systematic distortion by other factors, patients are randomly 
allocated to the treatments compared. Both patients and treating physicians are also 
blinded for treatment allocation when required by the trial’s objective. All patients 
are followed using standardised methods of observation. 
As such, a clinical trial is a procedural concept. Whether randomisation (and 
blinding when used) was done correctly cannot be answered by statistical analysis. 
Neither is it possible to correct for missed or unreliable patient observations. 
Hence, published trial results can only be trusted when the trial was conducted us-
ing appropriate methods and procedures. This requires appropriate trial manage-
ment from beginning to end. Using examples of procedures implemented for one 
completed and one ongoing study, this thesis aims to put trial management into 
perspective. 
By way of example of a completed study, the main results publication of the 
PICO (PImobendan in COngestive heart failure) trial is reproduced as Chapter 2. 
Pimobendan is a positive inotropic agent that might potentially benefit patients 
with chronic heart failure. PICO was a randomised, double blind, placebo con-
trolled trial to compare two different dosages of pimobendan and placebo. The 317 
patients involved were followed for at least 24 weeks. The effects of pimobendan 
were evaluated by exercise capacity and clinical outcome. Both dosages of pimo-
bendan improved exercise duration by a similar amount as observed in earlier tri-
als, but mortality was higher in patients receiving pimobendan. 
A treatment that increases mortality may nonetheless be clinically useful if it 
improves well-being to such an extent that the increased mortality risk is accept-
able. By a special analysis of exercise capacity data that took mortality into account 
also, it could be shown that the positive effect of pimobendan was not completely 
negated by the higher mortality risk. This analysis was possible because, based on 
the protocol, trial management implemented a policy of continued data collection 
on exercise testing and clinical follow up for patients who had stopped PICO study 
medication earlier than planned (a non-standard design feature for this type of 
trial).  
The thinking on which the analysis of PICO exercise data was based is further 
developed in a publication on combined endpoints reproduced as Chapter 3. The 
use of combined endpoints has become widespread. Combining all-cause mortality 
with selected non-fatal events is useful because event-free survival can be ad-
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dressed in this manner. Further examples are given as to how data on outcomes 
such as exercise capacity can be combined with data on mortality. 
As an example of an ongoing trial, the publication on the design of the 
ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) 
study is reproduced as Chapter 4. Its purpose is to assess the effect of long-acting 
nifedipine (a calcium channel blocker) on major cardiovascular event-free survival 
in patients with stable angina pectoris. Data on baseline characteristics are given in 
a publication reproduced as Chapter 5. 
Although follow up is relatively long (4 – 6 years), ACTION is not a particu-
larly difficult trial for the investigators because only routine clinical follow up is 
required. Managing ACTION is however a highly complex task as almost 7,000 
patients from just under 300 centres in 19 countries are participating. The ACTION 
database management system is described in Chapter 6. All documents containing 
patient data (case report forms, laboratory test reports, electrocardiograms, data 
clarification forms, etc.) are logged, scanned and archived when received at the 
coordinating centre. Data entry and cleaning is done using scanned images. A novel 
feature is that scanned image and database content always appear simultaneously 
on the computer screen. In addition, the system supports the special tracking func-
tions and management tools needed to successfully complete this study to high 
quality standards. 
The approved ACTION statistical analysis plan is reproduced as Chapter 7. 
This plan describes in detail the variables to be used, the statistical analyses to be 
done and how the results will be tabulated. Standard statistical methods for clinical 
outcome trials will be used but several of the pre-specified analyses are not com-
monly reported (mean survival subdivided by symptomatic state, stratification by 
absolute risk at baseline based on a multi-attribute risk score). 
The general discussion (Chapter 8) describes how the most important prob-
lems trial management encountered during the execution of the PICO and ACTION 
trials were solved. Each problem required a solution based on the scientific princi-
ples underlying clinical trials that could also be implemented practically. The chap-
ter ends with a list of recommendations for handling selected aspects of trial con-
duct, chosen because there is no general agreement in the literature concerning the 
approach to be followed (i.e. who actually belongs to the trial cohort), because of 
their particular importance for scientific integrity (i.e. how to deal with loss to fol-
low up), or because we found them to be controversial (i.e. simultaneous participa-
tion in several trials). 
Perfection may be difficult to achieve and may be even utopia. Because of 
their impact on patient treatment and health care costs, methodological diligence 
and an eye for detail is a must when it comes to the design and conduct of clinical 
trials. 
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Samenvatting 
Teneinde na te gaan wat het effect is van een behandeling, of om verschillen tussen 
behandelingen te evalueren, worden in een experimenteel klinisch onderzoek (kli-
nische trial) groepen patienten met elkaar vergeleken die zijn toegewezen aan ver-
schillende behandelingen. Om systematische verstoring door andere factoren te 
voorkomen wordt de behandeling van iedere patient door het toeval aangewezen 
(randomisatie). Wanneer de doelstelling van de trial dit vereist worden zowel de 
behandelend arts als de patient onkundig gelaten ten aanzien van de toegewezen 
behandeling (dubbele blindering). Alle aan de trial deelnemende patienten worden 
bestudeerd met behulp van gestandaardiseerde methoden voor klinisch onderzoek. 
Als zodanig is een klinische trial een procedureel concept. Of randomisatie (en 
dubbele blindering indien van toepassing) correct is uitgevoerd kan niet door 
statistische analyse van de bevindingen worden vastgesteld. Ook is het niet moge-
lijk om te corrigeren voor afwezige of onbetrouwbare observaties. Gepubliceerde 
resultaten van klinische trials zijn daarom alleen betrouwbaar wanneer het onder-
zoek van begin tot eind effectief werd geleid en correct werd uitgevoerd. Doel van 
dit proefschrift is het leiden van de uitvoering van trials te plaatsen in het 
perspectief van de grondslagen ervan. Daarbij wordt gebruik gemaakt van voor-
beelden uit de praktijk afkomstig van één inmiddels afgerond, en één nog aan de 
gang zijnd onderoek. 
Als voorbeeld van een afgerond onderzoek worden in hoofdstuk 2 de eerder 
gepubliceerde resulaten van de PICO (PImobendan in COngestive heart failure) 
studie beschreven. Voor patienten met chronisch hartfalen is pimobendan een 
mogelijk heilzaam positief inotropicum. In een gerandomiseerde, dubbel-blinde 
trial werden twee verschillende pimobendan doseringen vergeleken met placebo. In 
totaal werden 317 patienten gedurende tenminste 24 weken geobserveerd. De 
werkzaamheid van pimobendan werd geëvalueerd aan de hand van inspannings-
proeven en het klinisch beloop. Beide pimobendan doseringen hadden een positief 
effect op de inspanningstolerantie vergelijkbaar met eerdere bevindingen. De 
sterfte was echter hoger bij patienten behandeld met pimobendan. 
Een behandeling die de sterfte verhoogt kan desondanks van waarde zijn als 
deze het welbevinden van de patient in dusdanige mate verbetert dat het hogere 
sterfte risico acceptabel is. Middels een speciale analyse van de inspanningsproef-
bevindingen die tevens rekening houdt met sterfte, kon worden aangetoond dat het 
positieve effect van pimobendan op de inspanningstolerantie niet geheel teniet 
werd gedaan door de hogere sterfte. Deze analyse was mogelijk omdat de onder-
zoeksleiding, zoals voorzien in het onderzoeksprotocol, er op toe zag dat de in het 
onderzoeksplan opgenomen inspanningsproeven en de observatie van het klinisch 
beloop werden gecompleteerd óók bij patienten die de onderzoeksmedicatie voor-
tijdig moesten staken (niet standaard voor dit type trial). 
De gedachtengang waarop de analyse van de PICO inspanningstolerantie-
gegevens is gebaseerd wordt verder ontwikkeld in een publikatie over ‘gecombi-
neerde eindpunten’ (hoofdstuk 3). Kinische trials maken tegenwoordig veelal 
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gebruik van gecombineerde eindpunten. Het combineren van totale strefte en gese-
lecteerde ziektegebeurtenissen in één eindpunt is zinvol omdat dit evaluatie van 
overleving vrij van de betreffende ziektegebeurtenissen mogelijk maakt. Meerdere 
voorbeelden betreffende het combineren van gegevens verkregen uit observaties 
zoals inspanningsproeven, en gegevens over sterfte, worden beschreven. 
Als voorbeeld van een nog niet afgerond onderzoek is de publikatie over de 
opzet van de ACTION (A Coronary disease Trial Investigating Outcome with Nife-
dipine GITS) studie opgenomen als hoofdstuk 4. Doel van dit onderzoek is het 
bepalen van het effect van een langwerkende formulering van de calciumantagonist 
nifedipine op de overleving zonder belangrijke cardiovasculaire ziektegebeur-
tenissen van patienten met stabiele angina pectors. Gegevens over de kenmerken 
van de patientenpopulatie bij toelating tot het onderzoek worden beschreven in een 
publikatie opgenomen als hoofstuk 5. 
Alhoewel dit onderzoek wordt gekenmerkt door een relatief lange observatie-
duur (4 – 6 jaar) is ACTION niet bijzonder veeleisend voor de deelnemende onder-
zoekers omdat uitsluitend routine observaties nodig zijn. Het leiding geven aan de 
uitvoering ervan is daarentegen zeer complex vanwege het grote aantal betrokken 
patienten (bijna 7,000) en centra (bijna 300 in 19 landen). Het ACTION databe-
heerssysteem wordt beschreven in hoofdstuk 6. Ontvangst op het coördinatiecen-
trum van patient-documentatie (standaard formulieren met gegevens, uitslagen van 
laboratoriumonderzoek, electrocardiogrammen, wijzigingsformulieren, etc.) wordt 
geregistreerd in het databestand. Vervolgens wordt ieder document gescand en 
opgeslagen in het databestand, en tenslotte gearchiveerd. Gescande documenten 
dienen als basis voor het invoeren en opschonen van gegevens. Vernieuwend is de 
wijze waarop gescande documenten en gevens aanwezig in het databestand auto-
matisch tegelijkertijd op het computerscherm van de gebruiker worden weergege-
ven. Het systeem maakt het tevens mogelijk de zoekfuncties te implementeren die 
de onderzoeksleiding nodig heeft om aan de hoge kwaliteitseisen die worden 
gesteld te kunnen voldoen, en om dit onderzoek met succes te kunnen afronden.  
Het goedgekeurde ACTION statistische analyse plan is opgenomen als hoofd-
stuk 7. In dit op voorhand vastgestelde plan worden de gegevens die zullen worden 
geanalyseerd, de te gebruiken statistische methoden en de wijze waarop de 
resultaten zullen worden weergegeven in detail beschreven. Standaard statistische 
methoden voor het analyseren van het klinische beloop in trials zullen worden 
gebruikt. Verscheidene beschreven analyses zijn echter niet algemeen gebruikelijk 
(gemiddelde totale overlevingsduur onderverdeeld naar symptomatische toestand, 
stratificatie voor het absolute risico bij toelating tot het onderzoek aan de hand van 
een op meerdere kenmerken gebaseerde risico score). 
In de algemene discussie (hoofdstuk 8) wordt beschreven hoe de belangrijkste 
problemen waarmee de onderzoeksleiding zich tijdens de uitvoering van PICO en 
ACTION geconfronteerd zag, werden opgelost. Voor ieder probleem moest een 
praktisch uitvoerbare oplossing worden gevonden die recht doet aan de weten-
schappelijke basis van klinische trials. Dit hoofdstuk wordt afgesloten met een 
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reeks aanbevelingen hoe de beschreven problemen op te lossen of the voorkomen. 
Daarbij werden keuzes gemaakt, hetzij gebaseerd op de overweging dat in de lite-
ratuur geen eenstemmingheid bestaat over de aanbevolen aanpak van een bepaald 
probleem (zoals de vraag welke patienten feitelijk deel uitmaken van het onder-
zoekscohort), hetzij omdat het probleem van bijzonder belang is voor de betrouw-
baarheid van een klinische trial (zoals de aanpak van incomplete observatie van het 
ziektebeloop), hetzij omdat het desbetreffend probleem controversieël bleek te zijn 
(zoals deelname door dezelfde patient aan meerdere klinische trials tegelijkertijd). 
Perfectie is moeilijk te bereiken en is veelal een utopie. Resultaten van kli-
nische trials hebben belangrijke gevolgen voor de behandeling van patienten en 
bepalen mede de kosten van de gezondheidszorg. Oog voor detail en aandacht voor 
methodologie zijn daarom noodzakelijk bij het opzetten en uitvoeren van klinische 
trials. 
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